

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/EP2004/011577

International filing date: 14 October 2004 (14.10.2004)

Document type: Certified copy of priority document

Document details: Country/Office: DE
Number: 103 48 407.8
Filing date: 17 October 2003 (17.10.2003)

Date of receipt at the International Bureau: 19 January 2005 (19.01.2005)


Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

BUNDESREPUBLIK DEUTSCHLAND

PCT/EP04/11577



Prioritätsbescheinigung über die Einreichung einer Patentanmeldung

Aktenzeichen: 103 48 407.8

Anmeldetag: 17. Oktober 2003

Anmelder/Inhaber: Prof. Martin Widschwendter, Mieming/AT
Erstanmelder: Epigenomics AG, 10435 Berlin/DE

Bezeichnung: Prognostic and Diagnostic Markers for cell
proliferative disorders of the breast tissues

IPC: E 03 B 11/16

Die angehefteten Stücke sind eine richtige und genaue Wiedergabe der ursprünglichen Unterlagen dieser Patentanmeldung.

München, den 29. Dezember 2004
Deutsches Patent- und Markenamt
Der Präsident
Im Auftrag

Kehla



Prognostic and Diagnostic Markers for cell proliferative disorders of the breast tissues

The present invention relates to prognostic and diagnostic markers for cell proliferative disorders of the breast tissues. The present invention therefore provides methods and nucleic acids for the analysis of biological samples for features associated with the development of breast cell proliferative disorders.

Background of the invention

This patent application relates to diagnosis and prognosis of breast cancer. Today involvement of axillary lymph nodes and tumour size are the most important prognostic factors in breast cancer. Although the presence or absence of metastatic involvement in the axillary lymph nodes is the most powerful prognostic factor available for patients with primary breast cancer, it is only an indirect measure reflecting the tumours' tendency to spread. In approximately one-third of women with breast cancer and negative lymph nodes the disease recurs, while about one-third of patients with positive lymph nodes are free of recurrence ten years after loco-regional therapy. These data highlight the need for more sensitive and specific prognostic indicators, ideally reflecting the presence or absence of tumour-specific alterations in the bloodstream that may eventually even after years lead to metastasis. It is now widely accepted that adjuvant systemic therapy substantially improves disease-free and overall survival in both pre- and postmenopausal women up to the age of 70 years with lymph node-negative or lymph node-positive breast cancer (Early Breast Cancer Trialists' Collaborative Group Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet, 351: 1451-1467, 1998.2, 3). It is also generally accepted that patients with poor prognostic features benefit the most from adjuvant therapy, whereas some patients with good prognostic features may be overtreated (Goldhirsch et al.: Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J. Clin. Oncol., 19: 3817-3827, 2001.). Moreover many other factors have been investigated for their potential to predict disease outcome, but in general they have only limited predictive value. Recently, interesting prognostic parameters including gene-expression profiles, cell cycle regulating

proteins and occult cytokeratin-positive metastatic cells in the bone marrow have been added to the list of prognostic factors, but their prognostic relevance needs to be further evaluated.

Changes in the status of DNA methylation, known as epigenetic alterations, are one of the most common molecular alterations in human neoplasia, including breast cancer (Widschwendter and Jones: DNA methylation and breast carcinogenesis. *Oncogene*, 21: 5462-5482, 2002). Cytosine methylation occurs after DNA synthesis by enzymatic transfer of a methyl group from the methyl donor S-adenosylmethionine to the carbon-5 position of cytosine. Cytosines are methylated in the human genome mostly when located 5' to a guanosine. Regions with a high G:C content are so-called CpG islands. It has been increasingly recognized over the past four to five years that the CpG islands of a large number of genes, which are mostly unmethylated in normal tissue, are methylated to varying degrees in human cancers, thus representing tumor-specific alterations. The presence of abnormally high DNA concentrations in the serum of patients with various malignant diseases was described several years ago. The discovery that cell-free DNA can be shed into the bloodstream has generated great interest. Numerous studies have demonstrated tumor-specific alterations in DNA recovered from plasma or serum of patients with various malignancies, a finding that has potential for molecular diagnosis and prognosis. The nucleic acid markers described in plasma and serum include oncogene mutations, microsatellite alterations, gene rearrangements and epigenetic alterations, such as aberrant promoter hypermethylation (Anker et al.: Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. *Cancer Metastasis Rev.*, 18: 65-73, 1999). During recent years some studies have reported cell-free DNA in serum/plasma of breast cancer patients at diagnosis (for example: Silva et al.: Presence of tumor DNA in plasma of breast cancer patients: clinicopathological correlations. *Cancer Res.*, 59: 3251-3256, 1999) and in some cases persistence after primary therapy (for example: Silva et al.: Persistence of tumor DNA in plasma of breast cancer patients after mastectomy. *Ann. Surg. Oncol.*, 9: 71-76, 2002). Nevertheless an increasing number of studies have reported the presence of methylated DNA in serum/plasma of patients with various types of malignancies, including breast cancer, and the absence of methylated DNA in normal control patients (for example: Wong et al.: Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. *Cancer Res.*, 59: 71-73, 1999). So far, only few studies have addressed the prognostic value of these epigenetic alterations in patients' bloodstream (Kawakami et al.: Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. *J. Natl. Cancer Inst.*, 92: 1805-1811, 2000; Lecomte et al.: Detection of free-circulating

tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. *Int. J. Cancer*, 100: 542-548, 2002).

It will be appreciated by those skilled in the art that there exists a continuing need to improve methods of early detection, classification and treatment of breast cancers. In this application prognostic and diagnostic DNA methylation-based markers for breast cancer are disclosed.

5-methylcytosine positions cannot be identified by sequencing since 5-methylcytosine has the same base pairing behavior as cytosine. Moreover, the epigenetic information carried by 5-methylcytosine is completely lost during PCR amplification. Currently the most frequently used method for analysing DNA for 5-methylcytosine is based upon the specific reaction of bisulfite with cytosine which, upon subsequent alkaline hydrolysis, is converted to uracil which corresponds to thymidine in its base pairing behaviour. However, 5-methylcytosine remains unmodified under these conditions. Consequently, the original DNA is converted in such a manner that methylcytosine, which originally could not be distinguished from cytosine by its hybridisation behaviour, can now be detected as the only remaining cytosine using "normal" molecular biological techniques, for example, by amplification and hybridisation or sequencing. All of these techniques are based on base pairing which can now be fully exploited. In terms of sensitivity, the prior art is defined by a method which encloses the DNA to be analysed in an agarose matrix, thus preventing the diffusion and renaturation of the DNA (bisulfite only reacts with single-stranded DNA), and which replaces all precipitation and purification steps with fast dialysis (Olek A, Oswald J, Walter J. A modified and improved method for bisulphite based cytosine methylation analysis. *Nucleic Acids Res.* 1996 Dec 15;24(24):5064-6). Using this method, it is possible to analyse individual cells, which illustrates the potential of the method. However, currently only individual regions of a length of up to approximately 3000 base pairs are analysed, a global analysis of cells for thousands of possible methylation events is not possible. However, this method cannot reliably analyse very small fragments from small sample quantities either. These are lost through the matrix in spite of the diffusion protection.

An overview of the further known methods of detecting 5-methylcytosine may be gathered from the following review article: Fraga and Esteller: DNA Methylation: A Profile of Methods and Applications. *Biotechniques* 33:632-649, Sept. 2002.

To date, barring few exceptions (e.g., Zeschnigk M, Lich C, Buiting K, Doerfler W, Horsthemke B. A single-tube PCR test for the diagnosis of Angelman and Prader-Willi syndrome based on allelic methylation differences at the SNRPN locus. *Eur J Hum Genet.* 1997 Mar-Apr;5(2):94-8) the bisulfite technique is only used in research. Always, however, short, specific fragments of a known gene are amplified subsequent to a bisulfite treatment and either completely sequenced (Olek A, Walter J. The pre-implantation ontogeny of the H19 methylation imprint. *Nat Genet.* 1997 Nov;17(3):275-6) or individual cytosine positions are detected by a primer extension reaction (Gonzalgo ML, Jones PA. Rapid quantitation of methylation differences at specific sites using methylation-sensitive single nucleotide primer extension (Ms-SNuPE). *Nucleic Acids Res.* 1997 Jun 15;25(12):2529-31, WO 95/00669) or by enzymatic digestion (Xiong Z, Laird PW. COBRA: a sensitive and quantitative DNA methylation assay. *Nucleic Acids Res.* 1997 Jun 15;25(12):2532-4). In addition, detection by hybridisation has also been described (Olek et al., WO 99/28498).

Further publications dealing with the use of the bisulfite technique for methylation detection in individual genes are: Grigg G, Clark S. Sequencing 5-methylcytosine residues in genomic DNA. *Bioessays.* 1994 Jun;16(6):431-6, 431; Zeschnigk M, Schmitz B, Dittrich B, Buiting K, Horsthemke B, Doerfler W. Imprinted segments in the human genome: different DNA methylation patterns in the Prader-Willi/Angelman syndrome region as determined by the genomic sequencing method. *Hum Mol Genet.* 1997 Mar;6(3):387-95; Feil R, Charlton J, Bird AP, Walter J, Reik W. Methylation analysis on individual chromosomes: improved protocol for bisulphite genomic sequencing. *Nucleic Acids Res.* 1994 Feb 25;22(4):695-6; Martin V, Ribieras S, Song-Wang X, Rio MC, Dante R. Genomic sequencing indicates a correlation between DNA hypomethylation in the 5' region of the pS2 gene and its expression in human breast cancer cell lines. *Gene.* 1995 May 19;157(1-2):261-4; WO 97/46705, WO 95/15373, and WO 97/45560.

An overview of the Prior Art in oligomer array manufacturing can be gathered from a special edition of *Nature Genetics* (*Nature Genetics Supplement*, Volume 21, January 1999), published in January 1999, and from the literature cited therein.

Fluorescently labelled probes are often used for the scanning of immobilised DNA arrays. The simple attachment of Cy3 and Cy5 dyes to the 5'-OH of the specific probe are particularly suitable for fluorescence labels. The detection of the fluorescence of the hybridised probes

may be carried out, for example via a confocal microscope. Cy3 and Cy5 dyes, besides many others, are commercially available.

Matrix Assisted Laser Desorption Ionisation Mass Spectrometry (MALDI-TOF) is a very efficient development for the analysis of biomolecules (Karas M, Hillenkamp F. Laser desorption ionisation of proteins with molecular masses exceeding 10,000 daltons. *Anal Chem.* 1988 Oct 15;60(20):2299-301). An analyte is embedded in a light-absorbing matrix. The matrix is evaporated by a short laser pulse thus transporting the analyte molecule into the vapour phase in an unfragmented manner. The analyte is ionised by collisions with matrix molecules. An applied voltage accelerates the ions into a field-free flight tube. Due to their different masses, the ions are accelerated at different rates. Smaller ions reach the detector sooner than bigger ones.

MALDI-TOF spectrometry is excellently suited to the analysis of peptides and proteins. The analysis of nucleic acids is somewhat more difficult (Gut I G, Beck S. DNA and Matrix Assisted Laser Desorption Ionisation Mass Spectrometry. *Current Innovations and Future Trends.* 1995, 1; 147-57). The sensitivity to nucleic acids is approximately 100 times worse than to peptides and decreases disproportionately with increasing fragment size. For nucleic acids having a multiply negatively charged backbone, the ionisation process via the matrix is considerably less efficient. In MALDI-TOF spectrometry, the selection of the matrix plays an eminently important role. For the desorption of peptides, several very efficient matrixes have been found which produce a very fine crystallisation. There are now several responsive matrixes for DNA, however, the difference in sensitivity has not been reduced. The difference in sensitivity can be reduced by chemically modifying the DNA in such a manner that it becomes more similar to a peptide. Phosphorothioate nucleic acids in which the usual phosphates of the backbone are substituted with thiophosphates can be converted into a charge-neutral DNA using simple alkylation chemistry (Gut IG, Beck S. A procedure for selective DNA alkylation and detection by mass spectrometry. *Nucleic Acids Res.* 1995 Apr 25;23(8):1367-73). The coupling of a charge tag to this modified DNA results in an increase in sensitivity to the same level as that found for peptides. A further advantage of charge tagging is the increased stability of the analysis against impurities which make the detection of unmodified substrates considerably more difficult.

Genomic DNA is obtained from DNA of cell, tissue or other test samples using standard methods. This standard methodology is found in references such as Fritsch and Maniatis eds., Molecular Cloning: A Laboratory Manual, 1989.

Description

The present invention provides methods and nucleic acids for the analysis of biological samples for features associated with the development of breast cell proliferative disorders. The invention is characterised in that the nucleic acid of at least one member of the group of genes according to Table 1 is/are contacted with a reagent or series of reagents capable of distinguishing between methylated and non methylated CpG dinucleotides within the genomic sequence of interest. The present invention makes available a method for ascertaining genetic and/or epigenetic parameters of genomic DNA. The method is for use for the determining the prognosis of breast cell proliferative disorders. The invention presents improvements over the state of the art in that by means of the methods and compounds described herein a person skilled in the art may carry out a sensitive and specific detection assay of cellular matter comprising cancerous breast tissue. This is particularly useful as it allows the analysis of samples of body fluids which may contain only a minimal amount of cell proliferative disorder cellular matter, and enables the detection of said cells and the identification of the organ from which they originated (in this case breast). To date there are no known clinically utilisable means for the detection of breast cancer using genetic methylation markers to analyse bodily fluid samples, such as blood, lymphatic fluids, nipple aspirate and plasma. The generated information is useful in the selection of a treatment of the patient. If a positive prognosis is determined a further treatment might be redundant, while in a case of a poor prognosis a stronger treatment might be necessary.

Furthermore, the method enables the analysis of cytosine methylations and single nucleotide polymorphisms.

The genes that form the basis of the present invention are preferably to be used to form a "gene panel", i.e. a collection comprising the particular genetic sequences of the present invention and/or their respective informative methylation sites. The formation of gene panels allows for a quick and specific analysis of specific aspects of breast cancer. The gene panel(s) as described and employed in this invention can be used with surprisingly high efficiency for

the diagnosis, treatment and monitoring of and the analysis of a predisposition to breast cell proliferative disorders.

In addition, the use of multiple CpG sites from a diverse array of genes allows for a relatively high degree of sensitivity and specificity in comparison to single gene diagnostic and detection tools. Of the genes known to be specifically methylated in breast cancer, the particular combination of the genes according to the invention provides for a particularly sensitive and specific means for the identification of cell proliferative disorders of breast tissues.

The object of the invention is most preferably achieved by means of the analysis of the methylation patterns of one or a combination of genes taken from the group taken from the group ESR1, APC, HSD174B4, HIC1 and RASSF1A (see, for example, Table 1) and/or their regulatory regions. The invention is characterised in that the nucleic acid of one or a combination of genes taken from the group ESR1, APC, HSD174B4, HIC1 and RASSF1A are contacted with a reagent or series of reagents capable of distinguishing between methylated and non methylated CpG dinucleotides within the genomic sequence of interest.

The object of the invention can also be achieved by the analysis of the CpG methylation of one or a plurality of any subset of the group of genes ESR1, APC, HSD174B4, HIC1 and RASSF1A, in particular the following subsets are preferred:

- RASSF1A and APC,
- RASSF1A, and
- APC

The present invention makes available a method for ascertaining genetic and/or epigenetic parameters of genomic DNA. The method is for use in the improved diagnosis, treatment and monitoring of breast cell proliferative disorders.

The disclosed invention further provides a method for determining the phenotype of a subject with a breast cell proliferative disorder comprising

- a) obtaining a biological sample containing genomic DNA from said subject,
- b) analysing the methylation pattern of one or more target nucleic acids comprising one or a combination of the genes taken from the group consisting of ESR1, APC, HSD174B4, HIC1

and RASSF1A and/or their regulatory regions by contacting at least one of said target nucleic acids in the biological sample obtained from said subject with at least one reagent, or series of reagents that distinguishes between methylated and non-methylated CpG dinucleotides, and

c) determining the phenotype of the individual by comparison to two known phenotypes, a first phenotype characterised by hypermethylation of the target nucleic acid and poor prognosis as relative to a second phenotype characterised by hypomethylation of the analysed target nucleic acid and better prognosis

The DNA may be obtained from any form of biological sample including but not limited to cell lines, histological slides, biopsies, tissue embedded in paraffin, breast tissues, blood, plasma, lymphatic fluid, lymphatic tissue, duct cells, ductal lavage fluid, nipple aspiration fluid and combinations thereof. Genomic DNA must then be isolated from the sample using any means standard in the art. The isolated DNA is treated with at least one reagent, or series of reagents that distinguishes between methylated and non-methylated CpG dinucleotides. This may be carried out by any means standard in the art including the use of restriction endonucleases. However, it is preferably carried out with bisulfite (sulfite, disulfite) and subsequent alkaline hydrolysis which results in a conversion of non-methylated cytosine nucleobases to uracil or to another base which is dissimilar to cytosine in terms of base pairing behaviour. If bisulfite solution is used for the reaction, then an addition takes place at the non-methylated cytosine bases. Moreover, a denaturing reagent or solvent as well as a radical interceptor must be present. A subsequent alkaline hydrolysis then gives rise to the conversion of non-methylated cytosine nucleobases to uracil. The converted DNA is then used for the detection of methylated cytosines. The methylation status of one or more of the genes ESR1, APC, HSD17B4, HIC1 and RASSF1A and/or their regulatory regions is then analysed. This analysis may be carried out by any means standard in the art including the above described techniques. In the final step of the method the methylation pattern of the DNA obtained from the subject is compared to that of two known phenotypes. The first phenotype is characterised by hypermethylation or methylation of the target nucleic acid and poor prognosis as relative to a second phenotype characterised by hypomethylation or no methylation of the analysed target nucleic acid and better prognosis. It is particularly preferred that the genes APC and RASSF1A are analysed. By determining which of the two phenotypes the subject belongs to it is possible to determine a suitable treatment to her breast cell proliferative disorder.

The method according to the invention may be used for the analysis of a wide variety of cell proliferative disorders of the breast tissues including, but not limited to, ductal carcinoma *in situ*, lobular carcinoma, colloid carcinoma, tubular carcinoma, medullary carcinoma, metaplastic carcinoma, intraductal carcinoma *in situ*, lobular carcinoma *in situ* and papillary carcinoma *in situ*.

Furthermore, the method enables the analysis of cytosine methylations and single nucleotide polymorphisms within said genes.

The object of the invention is achieved by means of the analysis of the methylation patterns of one or more of the genes ESR1, APC, HSD17B4, HIC1 and RASSF1A and/or their regulatory regions. In a particularly preferred embodiment the sequences of said genes comprise SEQ ID NOS: 1 to 5 and sequences complementary thereto.

The object of the invention may also be achieved by analysing the methylation patterns of one or more genes taken from the following subsets of said aforementioned group of genes. In one embodiment the object of the invention is achieved by analysis of the methylation patterns of the genes RASSF1A and APC and wherein it is further preferred that the sequence of said genes comprise SEQ ID NOS: 5 and 3, respectively. In a further embodiment the object of the invention is achieved by analysis of the methylation patterns of the gene RASSF1A and/or its regulatory sequences, and wherein it is further preferred that the sequence of said gene comprises SEQ ID NO: 5. The object of the invention may also be achieved by analysis of the methylation pattern of the gene APC and/or its regulatory sequences, and wherein it is further preferred that the sequence of said gene comprises SEQ ID NO: 3.

In a preferred embodiment said method is achieved by contacting said nucleic acid sequences in a biological sample obtained from a subject with at least one reagent or a series of reagents, wherein said reagent or series of reagents, distinguishes between methylated and non methylated CpG dinucleotides within the target nucleic acid.

In a preferred embodiment, the method comprises the following steps:

In the first step of the method the genomic DNA sample must be isolated from sources such as cells or cellular components which contain DNA, sources of DNA comprising, for example, cell lines, histological slides, biopsies, tissue embedded in paraffin, breast tissues, blood,

plasma, lymphatic fluid, lymphatic tissue, duct cells, ductal lavage fluid, nipple aspiration fluid and combinations thereof. Extraction may be by means that are standard to one skilled in the art, these include the use of detergent lysates, sonification and vortexing with glass beads. Once the nucleic acids have been extracted the genomic double stranded DNA is used in the analysis.

In one embodiment the DNA may be cleaved prior to the next step of the method, this may be by any means standard in the state of the art, in particular, but not limited to, with restriction endonucleases.

In the second step of the method, the genomic DNA sample is treated in such a manner that cytosine bases which are unmethylated at the 5'-position are converted to uracil, thymine, or another base which is dissimilar to cytosine in terms of hybridisation behaviour. This will be understood as "pretreatment" or "chemical pretreatment" hereinafter.

The above described treatment of genomic DNA is preferably carried out with bisulfite (sulfite, disulfite) and subsequent alkaline hydrolysis which results in a conversion of non-methylated cytosine nucleobases to uracil or to another base which is dissimilar to cytosine in terms of base pairing behaviour. If bisulfite solution is used for the reaction, then an addition takes place at the non-methylated cytosine bases. Moreover, a denaturating reagent or solvent as well as a radical interceptor must be present. A subsequent alkaline hydrolysis then gives rise to the conversion of non-methylated cytosine nucleobases to uracil. The converted DNA is then used for the detection of methylated cytosines.

Fragments of the pretreated DNA are amplified, using sets of primer oligonucleotides, and a preferably heat-stable, polymerase. Because of statistical and practical considerations, preferably more than six different fragments having a length of 100 - 2000 base pairs are amplified. The amplification of several DNA segments can be carried out simultaneously in one and the same reaction vessel. Usually, the amplification is carried out by means of a polymerase chain reaction (PCR).

The design of such primers is obvious to one skilled in the art. These should include at least two oligonucleotides whose sequences are each reverse complementary or identical to an at least 18 base-pair long segment of the following base sequences specified in the appendix:

SEQ ID NO 6 to 26. Said primer oligonucleotides are preferably characterised in that they do not contain any CpG dinucleotides. In a particularly preferred embodiment of the method, the sequence of said primer oligonucleotides are designed so as to selectively anneal to and amplify, only the breast cell specific DNA of interest, thereby minimising the amplification of background or non relevant DNA. In the context of the present invention, background DNA is taken to mean genomic DNA which does not have a relevant tissue specific methylation pattern, in this case, the relevant tissue being breast tissues.

According to the present invention, it is preferred that at least one primer oligonucleotide is bound to a solid phase during amplification. The different oligonucleotide and/or PNA-oligomer sequences can be arranged on a plane solid phase in the form of a rectangular or hexagonal lattice, the solid phase surface preferably being composed of silicon, glass, polystyrene, aluminium, steel, iron, copper, nickel, silver, or gold, it being possible for other materials such as nitrocellulose or plastics to be used as well.

The fragments obtained by means of the amplification may carry a directly or indirectly detectable label. Preferred are labels in the form of fluorescence labels, radionuclides, or detachable molecule fragments having a typical mass which can be detected in a mass spectrometer, it being preferred that the fragments that are produced have a single positive or negative net charge for better detectability in the mass spectrometer. The detection may be carried out and visualised by means of matrix assisted laser desorption/ionisation mass spectrometry (MALDI) or using electron spray mass spectrometry (ESI).

In the next step the nucleic acid amplifies are analysed in order to determine the methylation status of the genomic DNA prior to treatment.

The post treatment analysis of the nucleic acids may be carried out using alternative methods. Several methods for the methylation status specific analysis of the treated nucleic acids are described below, other alternative methods will be obvious to one skilled in the art.

The analysis may be carried out during the amplification step of the method. In one such embodiment, the methylation status of preselected CpG positions within the genes ESR1, APC, HSD17B4, HIC1 and RASSF1A and/or their regulatory regions may be detected by use of methylation specific primer oligonucleotides. The term "MSP" (Methylation-specific PCR)

refers to the art-recognized methylation assay described by Herman et al. *Proc. Natl. Acad. Sci. USA* 93:9821-9826, 1996, and also disclosed in US Patents No. 5,786,146 and No. 6,265,171. The use of methylation status specific primers for the amplification of bisulphite treated DNA allows the differentiation between methylated and unmethylated nucleic acids. MSP primers pairs contain at least one primer which hybridises to a bisulphite treated CpG dinucleotide. Therefore the sequence of said primers comprises at least one CG, TG or CA dinucleotide. MSP primers specific for non methylated DNA contain a 'T' at the 3' position of the C position in the CpG. According to the present invention, it is therefore preferred that the base sequence of said primers is required to comprise a sequence having a length of at least 10 nucleotides which hybridises to a pretreated nucleic acid sequence according to SEQ ID NOs.: 6 to 26 and sequences complementary thereto wherein the base sequence of said oligomers comprises at least one CG, TG or CA dinucleotide.

In one embodiment of the method the methylation status of the CpG positions may be determined by means of hybridisation analysis. In this embodiment of the method the amplificates obtained in the second step of the method are hybridised to an array or a set of oligonucleotides and/or PNA probes. In this context, the hybridisation takes place in the manner described as follows. The set of probes used during the hybridisation is preferably composed of at least 4 oligonucleotides or PNA-oligomers. In the process, the amplificates serve as probes which hybridise to oligonucleotides previously bonded to a solid phase. The non-hybridised fragments are subsequently removed. Said oligonucleotides contain at least one base sequence having a length of 10 nucleotides which is reverse complementary or identical to a segment of the base sequences specified in the appendix, the segment containing at least one CpG or TpG dinucleotide. In a further preferred embodiment the cytosine of the CpG dinucleotide, or in the case of TpG, the thiamine, is the 5th to 9th nucleotide from the 5'-end of the 10-mer. One oligonucleotide exists for each CpG or TpG dinucleotide.

The non-hybridised amplificates are then removed. In the final step of the method, the hybridised amplificates are detected. In this context, it is preferred that labels attached to the amplificates are identifiable at each position of the solid phase at which an oligonucleotide sequence is located.

In a preferred embodiment of the method the methylation status of the CpG positions may be determined by means of oligonucleotide probes that are hybridised to the treated DNA con-

currently with the PCR amplification primers (wherein said primers may either be methylation specific or standard).

A particularly preferred embodiment of this method is the use of fluorescence-based Real Time Quantitative PCR (Heid et al., *Genome Res.* 6:986-994, 1996) employing a dual-labelled fluorescent oligonucleotide probe (TaqMan™ PCR, using an ABI Prism 7700 Sequence Detection System, Perkin Elmer Applied Biosystems, Foster City, California). The TaqMan™ PCR reaction employs the use of a nonextendible interrogating oligonucleotide, called a TaqMan™ probe, which is designed to hybridise to a GpC-rich sequence located between the forward and reverse amplification primers. The TaqMan™ probe further comprises a fluorescent "reporter moiety" and a "quencher moiety" covalently bound to linker moieties (e.g., phosphoramidites) attached to the nucleotides of the TaqMan™ oligonucleotide. For analysis of methylation within nucleic acids subsequent to bisulphite treatment it is required that the probe be methylation specific, as described in U.S. 6,331,393, also known as the Methyl Light assay. Variations on the TaqMan™ detection methodology that are also suitable for use with the described invention include the use of dual probe technology (Lightcycler™) or fluorescent amplification primers (Sunrise™ technology). Both these techniques may be adapted in a manner suitable for use with bisulphite treated DNA, and moreover for methylation analysis within CpG dinucleotides.

A further suitable method for the use of probe oligonucleotides for the assessment of methylation by analysis of bisulphite treated nucleic acids is the use of blocker oligonucleotides. The use of such oligonucleotides has been described by D. Yu, M. Mukai, Q. Liu, C. Steinman in *BioTechniques* 23(4), 1997, 714-720. Blocking probe oligonucleotides are hybridised to the bisulphite treated nucleic acid concurrently with the PCR primers. PCR amplification of the nucleic acid is terminated at the 5' position of the blocking probe, thereby amplification of a nucleic acid is suppressed wherein the complementary sequence to the blocking probe is present. The probes may be designed to hybridise to the bisulphite treated nucleic acid in a methylation status specific manner. For example, for detection of methylated nucleic acids within a population of unmethylated nucleic acids suppression of the amplification of nucleic acids which are unmethylated at the position in question would be carried out by the use of blocking probes comprising a 'CG' at the position in question, as opposed to a 'CA'.

For PCR methods using blocker oligonucleotides, efficient disruption of polymerase-mediated amplification requires that blocker oligonucleotides not be elongated by the polymerase. Preferably, this is achieved through the use of blockers that are 3'-deoxyoligonucleotides, or oligonucleotides derivatised at the 3' position with other than a "free" hydroxyl group. For example, 3'-O-acetyl oligonucleotides are representative of a preferred class of blocker molecule.

Additionally, polymerase-mediated decomposition of the blocker oligonucleotides should be precluded. Preferably, such preclusion comprises either use of a polymerase lacking 5'-3' exonuclease activity, or use of modified blocker oligonucleotides having, for example, thioate bridges at the 5'-terminii thereof that render the blocker molecule nuclease-resistant. Particular applications may not require such 5' modifications of the blocker. For example, if the blocker- and primer-binding sites overlap, thereby precluding binding of the primer (e.g., with excess blocker), degradation of the blocker oligonucleotide will be substantially precluded. This is because the polymerase will not extend the primer toward, and through (in the 5'-3' direction) the blocker - a process that normally results in degradation of the hybridized blocker oligonucleotide.

A particularly preferred blocker/PCR embodiment, for purposes of the present invention and as implemented herein, comprises the use of peptide nucleic acid (PNA) oligomers as blocking oligonucleotides. Such PNA blocker oligomers are ideally suited, because they are neither decomposed nor extended by the polymerase.

Preferably, therefore, the base sequence of said blocking oligonucleotides is required to comprise a sequence having a length of at least 9 nucleotides which hybridises to a pretreated nucleic acid sequence according to one of SEQ ID NOS: 6 to 26 and sequences complementary thereto, wherein the base sequence of said oligonucleotides comprises at least one CpG, TpG or CpA dinucleotide.

In a further preferred embodiment of the method the determination of the methylation status of the CpG positions is carried out by the use of template directed oligonucleotide extension, such as MS SNuPE as described by Gonzalgo and Jones (Nucleic Acids Res. 25:2529-2531).

In a further embodiment of the method the determination of the methylation status of the CpG positions is enabled by sequencing and subsequent sequence analysis of the amplicate generated in the second step of the method (Sanger F., et al., 1977 PNAS USA 74: 5463-5467).

The method according to the invention may be enabled by any combination of the above means. In a particularly preferred mode of the invention the use of real time detection probes is concurrently combined with MSP and/or blocker oligonucleotides.

A further embodiment of the invention is a method for the analysis of the methylation status of genomic DNA without the need for pretreatment. In the first and second steps of the method the genomic DNA sample must be obtained and isolated from tissue or cellular sources. Such sources may include cell lines, histological slides, biopsies, tissue embedded in paraffin, breast tissues, blood, plasma, lymphatic fluid, lymphatic tissue, duct cells, ductal lavage fluid, nipple aspiration fluid and combinations thereof. Extraction may be by means that are standard to one skilled in the art, these include the use of detergent lysates, sonification and vortexing with glass beads. Once the nucleic acids have been extracted the genomic double stranded DNA is used in the analysis.

In a preferred embodiment the DNA may be cleaved prior to the treatment, this may be by any means standard in the state of the art, in particular with restriction endonucleases. In the third step, the DNA is then digested with one or more methylation sensitive restriction enzymes. The digestion is carried out such that hydrolysis of the DNA at the restriction site is informative of the methylation status of a specific CpG dinucleotide.

In a preferred embodiment the restriction fragments are amplified. In a further preferred embodiment this is carried out using the polymerase chain reaction.

In the final step the amplicates are detected. The detection may be by any means standard in the art, for example, but not limited to, gel electrophoresis analysis, hybridisation analysis, incorporation of detectable tags within the PCR products, DNA array analysis, MALDI or ESI analysis.

The aforementioned method is preferably used for ascertaining genetic and/or epigenetic parameters of genomic DNA.

In order to enable this method, the invention further provides the modified DNA of one or a combination of genes taken from the group ESR1, APC, HSD17B4, HIC1 and RASSF1A as well as oligonucleotides and/or PNA-oligomers for detecting cytosine methylations within said genes. The present invention is based on the discovery that genetic and epigenetic parameters and, in particular, the cytosine methylation patterns of said genomic DNAs are particularly suitable for improved treatment and monitoring of breast cell proliferative disorders.

The nucleic acids according to the present invention can be used for the analysis of genetic and/or epigenetic parameters of genomic DNA.

In another aspect of the present invention, the object of the present invention is achieved using a nucleic acid containing a sequence of at least 18 bases in length of the pretreated genomic DNA according to one of SEQ ID NOS: 6 to 25 and sequences complementary thereto.

The modified nucleic acids could heretofore not be connected with the ascertainment of disease relevant genetic and epigenetic parameters.

The object of the present invention is further achieved by an oligonucleotide or oligomer for the analysis of pretreated DNA, for detecting the genomic cytosine methylation state, said oligonucleotide containing at least one base sequence having a length of at least 10 nucleotides which hybridises to a pretreated genomic DNA according to SEQ ID Nos: 6 to 26. The oligomer probes according to the present invention constitute important and effective tools which, for the first time, make it possible to ascertain specific genetic and epigenetic parameters during the analysis of biological samples for features associated with a patient's response to endocrine treatment. Said oligonucleotides allow the improved treatment and monitoring of breast cell proliferative disorders. The base sequence of the oligomers preferably contains at least one CpG or TpG dinucleotide. The probes may also exist in the form of a PNA (peptide nucleic acid) which has particularly preferred pairing properties. Particularly preferred are oligonucleotides according to the present invention in which the cytosine of the CpG dinucleotide is within the middle third of said oligonucleotide e.g. the 5th - 9th nucleotide from the 5'-end of a 13-mer oligonucleotide; or in the case of PNA-oligomers, it is preferred for the cytosine of the CpG dinucleotide to be the 4th - 6th nucleotide from the 5'-end of the 9-mer.

The oligomers according to the present invention are normally used in so called "sets" which contain at least two oligomers and up to one oligomer for each of the CpG dinucleotides within SEQ ID NOS: 6 to 26.

In the case of the sets of oligonucleotides according to the present invention, it is preferred that at least one oligonucleotide is bound to a solid phase. It is further preferred that all the oligonucleotides of one set are bound to a solid phase.

The present invention further relates to a set of at least 2^n (oligonucleotides and/or PNA-oligomers) used for detecting the cytosine methylation state of genomic DNA, by analysis of said sequence or treated versions of said sequence (of the genes ESR1, APC, HSD174B4, HIC1 and RASSF1A, as detailed in the sequence listing and Table 1) and sequences complementary thereto). These probes enable improved treatment and monitoring of breast cell proliferative disorders.

The set of oligomers may also be used for detecting single nucleotide polymorphisms (SNPs) by analysis of said sequence or treated versions of said sequence of the genes ESR1, APC, HSD174B4, HIC1 and RASSF1A.

It will be obvious to one skilled in the art that the method according to the invention will be improved and supplemented by the incorporation of markers and clinical indicators known in the state of the art and currently used as diagnostic or prognostic markers. More preferably said markers include node status, age, menopausal status, grade, estrogen and progesterone receptors.

The genes that form the basis of the present invention may be used to form a "gene panel", i.e. a collection comprising the particular genetic sequences of the present invention and/or their respective informative methylation sites. The formation of gene panels allows for a quick and specific analysis of specific aspects of breast cancer treatment. The gene panel(s) as described and employed in this invention can be used with surprisingly high efficiency for the treatment of breast cell proliferative disorders by prediction of the outcome of treatment with a therapy comprising one or more drugs which target the estrogen receptor pathway or are involved in estrogen metabolism, production, or secretion. The analysis of each gene of the panel contributes to the evaluation of patient responsiveness, however, in a less preferred embodiment the

patient evaluation may be achieved by analysis of only a single gene. The analysis of a single member of the 'gene panel' would enable a cheap but less accurate means of evaluating patient responsiveness, the analysis of multiple members of the panel would provide a rather more expensive means of carrying out the method, but with a higher accuracy (the technically preferred solution).

According to the present invention, it is preferred that an arrangement of different oligonucleotides and/or PNA-oligomers (a so-called "array") made available by the present invention is present in a manner that it is likewise bound to a solid phase. This array of different oligonucleotide- and/or PNA-oligomer sequences can be characterised in that it is arranged on the solid phase in the form of a rectangular or hexagonal lattice. The solid phase surface is preferably composed of silicon, glass, polystyrene, aluminium, steel, iron, copper, nickel, silver, or gold. However, nitrocellulose as well as plastics such as nylon which can exist in the form of pellets or also as resin matrices are suitable alternatives.

Therefore, a further subject matter of the present invention is a method for manufacturing an array fixed to a carrier material for the improved treatment and monitoring of breast cell proliferative disorders. In said method at least one oligomer according to the present invention is coupled to a solid phase. Methods for manufacturing such arrays are known, for example, from US Patent 5,744,305 by means of solid-phase chemistry and photolabile protecting groups.

A further subject matter of the present invention relates to a DNA chip for the improved treatment and monitoring of breast cell proliferative disorders. The DNA chip contains at least one nucleic acid according to the present invention. DNA chips are known, for example, in US Patent 5,837,832.

Moreover, a subject matter of the present invention is a kit which may be composed, for example, of a bisulfite-containing reagent, a set of primer oligonucleotides containing at least two oligonucleotides whose sequences in each case correspond to or are complementary to a 18 base long segment of the base sequences specified in SEQ ID NOS: 6 to 26 and/or PNA-oligomers as well as instructions for carrying out and evaluating the described method.

In a further preferred embodiment said kit may further comprise standard reagents for performing a CpG position specific methylation analysis wherein said analysis comprises one or more of the following techniques: MS-SNuPE, MSP, Methyl light, Heavy Methyl, and nucleic acid sequencing. However, a kit along the lines of the present invention can also contain only part of the aforementioned components.

Typical reagents (e.g., as might be found in a typical MethyLight®-based kit) for MethyLight® analysis may include, but are not limited to: PCR primers for specific gene (or methylation-altered DNA sequence or CpG island); TaqMan® probes; optimized PCR buffers and deoxynucleotides; and Taq polymerase.

Typical reagents (e.g., as might be found in a typical Ms-SNuPE-based kit) for Ms-SNuPE analysis may include, but are not limited to: PCR primers for specific gene (or methylation-altered DNA sequence or CpG island); optimized PCR buffers and deoxynucleotides; gel extraction kit; positive control primers; Ms-SNuPE primers for specific gene; reaction buffer (for the Ms-SNuPE reaction); and radioactive nucleotides. Additionally, bisulfite conversion reagents may include: DNA denaturation buffer; sulfonation buffer; DNA recovery regents or kit (e.g., precipitation, ultrafiltration, affinity column); desulfonation buffer; and DNA recovery components.

Typical reagents (e.g., as might be found in a typical MSP-based kit) for MSP analysis may include, but are not limited to: methylated and unmethylated PCR primers for specific gene (or methylation-altered DNA sequence or CpG island), optimized PCR buffers and deoxynucleotides, and specific probes.

The oligomers according to the present invention or arrays thereof as well as a kit according to the present invention are intended to be used for the improved treatment and monitoring of breast cell proliferative disorders. According to the present invention, the method is preferably used for the analysis of important genetic and/or epigenetic parameters within genomic DNA, in particular for use in improved treatment and monitoring of breast cell proliferative disorders.

The methods according to the present invention are used, for improved detection, treatment and monitoring of breast cell proliferative disorder.

The present invention moreover relates to the diagnosis and/or prognosis of events which are disadvantageous or relevant to patients or individuals in which important genetic and/or epigenetic parameters within genomic DNA, said parameters obtained by means of the present invention may be compared to another set of genetic and/or epigenetic parameters, the differences serving as the basis for the diagnosis and/or prognosis of events which are disadvantageous or relevant to patients or individuals.

In the context of the present invention the term "hybridisation" is to be understood as a bond of an oligonucleotide to a completely complementary sequence along the lines of the Watson-Crick base pairings in the sample DNA, forming a duplex structure.

In the context of the present invention, "genetic parameters" are mutations and polymorphisms of genomic DNA and sequences further required for their regulation. To be designated as mutations are, in particular, insertions, deletions, point mutations, inversions and polymorphisms and, particularly preferred, SNPs (single nucleotide polymorphisms).

In the context of the present invention the term "methylation state" is taken to mean the degree of methylation present in a nucleic acid of interest, this may be expressed in absolute or relative terms i.e. as a percentage or other numerical value or by comparison to another tissue and therein described as hypermethylated, hypomethylated or as having significantly similar or identical methylation status.

In the context of the present invention the term "regulatory region" of a gene is taken to mean nucleotide sequences which affect the expression of a gene. Said regulatory regions may be located within, proximal or distal to said gene. Said regulatory regions include but are not limited to constitutive promoters, tissue-specific promoters, developmental-specific promoters, inducible promoters and the like. Promoter regulatory elements may also include certain enhancer sequence elements that control transcriptional or translational efficiency of the gene.

In the context of the present invention the term "chemotherapy" is taken to mean the use of drugs or chemical substances to treat cancer. This definition excludes radiation therapy (treatment with high energy rays or particles), hormone therapy (treatment with hormones or hormone analogues (synthetic substitutes) and surgical treatment.

In the context of the present invention, "epigenetic parameters" are, in particular, cytosine methylations and further modifications of DNA bases of genomic DNA and sequences further required for their regulation. Further epigenetic parameters include, for example, the acetylation of histones which, cannot be directly analysed using the described method but which, in turn, correlates with the DNA methylation.

In the following, the present invention will be explained in greater detail on the basis of the sequences, figures and examples without being limited thereto.

Figure 1 shows the Kaplan-Meier estimated overall survival curves for the gene APC, for a set of 86 breast cancer patients. The dotted line (upper curve) shows unmethylated samples whereas the unbroken line (lower curve) shows methylated samples. The x-axis shows the number of years, and the Y-axis shows the proportion of the group.

Figure 2 shows the Kaplan-Meier estimated overall survival curves for the gene RASSF1A, for a set of 86 breast cancer patients. The dotted line (upper curve) shows unmethylated samples whereas the unbroken line (lower curve) shows methylated samples. The x-axis shows the number of years, and the Y-axis shows the proportion of the group.

Figure 3 shows the combined Kaplan-Meier estimated overall survival curves for the genes APC and/or RASSF1A, for a set of 86 breast cancer patients. The dotted line (upper curve) shows unmethylated samples whereas the unbroken line (lower curve) shows methylated samples. The x-axis shows the number of years, and the Y-axis shows the proportion of the group.

SEQ ID NOs: 1 to 5 represent 5' and/or regulatory regions and/or CpG rich regions of the genes according to Table 1. These sequences are derived from Genbank and will be taken to include all minor variations of the sequence material which are currently unforeseen, for example, but not limited to, minor deletions and SNPs.

SEQ ID NOs: 6 to 26 exhibit the pretreated sequence of DNA derived from the genomic sequence according to Table 1. These sequences will be taken to include all minor variations of

the sequence material which are currently unforeseen, for example, but not limited to, minor deletions and SNPs.

Examples

Using MethylLight, a high-throughput DNA methylation assay, the inventors analysed 39 genes in a gene evaluation set, consisting of ten sera from metastasised patients, 26 patients with primary breast cancer and ten control patients. In order to determine the prognostic value of genes identified within the gene evaluation set, the inventors finally analysed pretreatment sera of 24 patients having had no adjuvant treatment (training set) to determine their prognostic value. An independent test set consisting of 62 patients was then used to test the validity of genes and combinations of genes, which in the training set were found to be good prognostic markers.

In the gene evaluation set the inventors identified five genes (ESR1, APC, HSD17B4, HIC1 and RASSF1A). In the training set, patients with methylated serum DNA for RASSF1A and/or APC had the worst prognosis ($p < 0.001$). This finding was confirmed by analysing serum samples from the independent test set ($p = 0.007$). When analysing all 86 investigated patients, multivariate analysis showed methylated RASSF1A and/or APC serum DNA to be independently associated with poor outcome, with a relative risk for death of 5.7. DNA methylation of particular genes in pretherapeutic sera of breast cancer patients, especially of RASSF1A/APC, is more powerful than standard prognostic parameters.

The gene evaluation set consisted of patients with recurrent disease ($n=10$; sera obtained at diagnosis of metastasis in the bone, lung, brain or liver) and pretherapeutic sera of recently diagnosed primary breast cancer patients ($n=26$; age range: 36.1 yrs to 83.9 yrs. (mean: 59.3 yrs.); two, 18 and six patients had pT1, pT2 and pT3 cancers, respectively; 15, ten and one patients had lymph node-negative, - positive and unknown disease, respectively) and normal controls ($n=10$; age range: 20.5 to 71.5 yrs. (mean: 44.6 yrs.); all underwent a core biopsy and were confirmed to have benign disease of the breast).

To assess prognostic significance the inventors used pretherapeutic sera in independent training ($n=24$) and test ($n=62$) sets consisting of patients who did not receive any adjuvant treatment after surgery.

Systemic adjuvant therapy was either not necessary or the patients were not eligible or refused any further treatment. The primary surgical procedure included breast-conserving lumpectomy or modified radical mastectomy and axillary lymph node dissection. Median age of the study population was 60 years (range, 28 to 86 yrs.). After a median follow-up of 3.7 yrs. (range: one month to 12.2 yrs.) 17 of the 86 patients (20 %) had died. Distribution of aberrant serum DNA methylation of the 86 patients and association with clinical and histopathological characteristics are shown in Table 2.

Patients' blood samples were drawn prior to therapeutic intervention. The blood was centrifuged at 2000 g for 10 min at room temperature, and 1 mL aliquots of serum samples were stored at -30°C. Genomic DNA from serum samples was isolated using the High Pure Viral Nucleic Acid Kit (Roche Diagnostics, Mannheim, Germany) according to the manufacturer's protocol with some modifications for multiple loading of the DNA extraction columns to gain a sufficient amount of DNA. Thus, 4 x 200 μ l of a serum sample were each mixed with 200 μ l of working solution (binding buffer supplemented with polyA carrier RNA) and 50 μ l proteinase K [18 mg/ml] and incubated for 10 minutes at 72°C. After adding 100 μ l isopropanol the solution was mixed, loaded onto the extraction column and centrifuged for 1 minute at 8000g. The flow-through was pipetted back into the same column reservoir and centrifuged a second time. This procedure was repeated four times for each serum sample. After these "pooling steps" the DNA isolation was processed as described in the manufacturer's protocol. For DNA elution 55 μ l of AE-buffer (Qiagen, CA, USA) were added, incubated for 20 min at 45°C and centrifuged for three minutes at 12.000g. For both, normal sera and cancer sera analysis the same amount of serum for DNA extraction was used.

Sodium bisulfite conversion of genomic DNA was performed as described previously (Eads et al.: MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res., 28: E32, 2000).

Sodium bisulfite-treated genomic DNA was analysed by means of the MethyLight, a fluorescence-based, real-time PCR assay, as described previously (Eads et al 2000, see above, Eads et al.: Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res., 61: 3410-3418, 2001). Briefly, two sets of primers and probes, designed specifically for bisulfite-converted DNA, were used: a methylated set for the gene of interest and a reference set, β -

actin (*ACTB*), to normalise for input DNA. Serum samples of patients with recurrent disease revealed the highest amount of β -actin, whereas no difference between β -actin values from serum samples of patients with primary breast cancer and sera of normal controls was observed. Specificity of the reactions for methylated DNA was confirmed separately using *SssI* (New England Biolabs)-treated human white blood cell DNA (heavily methylated). The percentage of fully methylated molecules at a specific locus was calculated by dividing the *GENE:ACTB* ratio of a sample by the *GENE:ACTB* ratio of *SssI*-treated white blood cell DNA and multiplying by 100. The abbreviation PMR (percentage of fully methylated reference) indicates this measurement. For each MethylLight reaction 10 μ l of bisulfite-treated genomic DNA was used.

A gene was deemed methylated if the PMR value was > 0 . Primer and probes specific for methylated DNA and used for MethylLight reactions are listed in Supplemental Data.

The inventors used Pearson's Chi² or – in the case of low frequencies per cell – Fisher's exact method to test associations between categorically clinicopathological features. The Mann-Whitney-U-Test was used to assess differences between non-parametric distributed variables. Overall survival was calculated from the date of diagnosis of the primary tumour to the date of death or last follow-up. Overall survival curves were calculated with the Kaplan-Meier method. Univariate analysis of overall survival according to clinicopathological factors (histological type, tumour stage, nodal status, grading, menopausal status, hormone receptor status (estrogen and/or progesterone receptor positivity), estrogen and progesterone receptor status) and gene methylation were performed using a two-sided log-rank test.

Multivariate Cox proportional hazards analysis was used to estimate the prognostic effect of methylated genes.

A p value < 0.05 was considered a statistically significant difference. All statistical analyses were performed using SPSS Software 10.0.

The inventors initially investigated 39 genes in the sera of ten patients with metastasised breast cancer for the presence of aberrant methylation. The 33 genes positive in the sera of the metastasised patients were further evaluated in an independent sample set of pretherapeutic sera of 26 patients with primary breast cancer and ten healthy controls. An overview of the

frequency of methylation in the investigated serum samples is given in Table 3. The most appropriate genes for our further analyses were determined to be those that met one of the following criteria: (i) unmethylated in serum samples from healthy controls and > 10% methylated in serum samples from primary breast cancer patients, or (ii) ≤ 10% methylated in serum samples from healthy controls and >20% methylated in serum samples from primary breast cancer patients. A total of five genes, namely ESR1, APC, HSD17B4, HIC1 and RASSF1A, met at least one of these criteria (Table 3).

Pre-treatment serum samples from patients included in the training set were used to evaluate the prognostic value of the methylation status of these five genes. In this training set the inventors identified ESR1, APC or RASSF1A methylation in primary breast cancer patients' sera to be markers of poor prognosis, whereas HSD17B4 reached only borderline significance and aberrant methylation of HIC1 showed no significant results (Table 4). Furthermore, various combinations of the investigated genes were analyzed. Patients were classified as methylation-positive if at least one of the genes included in the combination showed aberrant methylation. Patients with methylated serum DNA for RASSF1A and/or APC had the worst prognosis ($P < 0.001$), even worse than when each gene was analysed individually (Table 4).

The highly significant prognostic value for APC and/or RASSF1A methylation in serum samples from breast cancer patients was confirmed by analysing the test set ($P = 0.007$, log rank test). ESR1 and APC methylation as single genes or the combinations ESR1/RASSF1A and ESR1/APC no longer had prognostic significance (Table 4).

Combined analysis of the training and test sets ($n=86$) showed correlation between ESR1 and RASSF1A ($P = 0.005$) and between ESR1 and APC ($P = 0.031$), whereas no correlation was observed between RASSF1A and APC. In patients with advanced tumours RASSF1A and ESR1 methylation and in patients with progesterone receptor-negative tumours APC methylation was more prevalent in pretherapeutic sera, while no further associations were seen between clinicopathological features and DNA methylation of APC, ESR1 or RASSF1A (Table 5). RASSF1A methylation in pretherapeutic sera was more prevalent in older than in younger patients, whereas age had no effect on DNA methylation of ESR1 or APC.

Univariate analysis of all 86 investigated patients (training set plus test set) revealed prognostic significance for tumour size, lymph node metastases and methylation status of APC,

RASSF1A and the combination of RASSF1A/APC (Table 6; Fig. 1). Due to the fact that ESR1 methylation correlates with APC as well as with RASSF1A methylation, the inventors did not test the triple combination in the univariate or the multivariate analyses of all 86 patients.

The Cox multiple-regression analysis included tumour size, lymph node metastases, age and methylation status of the investigated genes. Beside lymph node status, methylated RASSF1A and/or APC serum DNA was strongly associated with poor outcome, with a relative risk for death of 5.7 (Table 7).

Prognosis in patients with newly diagnosed breast cancer is determined primarily by the presence or absence of metastases in draining axillary lymph nodes. Nevertheless, the life-threatening event in breast cancer is not lymph node metastasis per se, but haematogenous metastases which mainly affect bone, liver, lung and brain. The inventors therefore aimed to develop a prognostic test that is sensitive for haematogenous metastases and could be performed in patients' pretherapeutic serum.

In recent years several studies have reported cell-free tumour-specific DNA in serum/plasma of breast cancer patients at diagnosis. Aberrant methylation of serum/plasma DNA of patients with various types of malignancies, including breast cancer, has been described (see above).

In light of these observations, the inventors examined the methylation status of 39 genes, which, on the one hand, are known to be frequently methylated in breast cancer and other malignancies (Jones and Baylin: The fundamental role of epigenetic events in cancer. *Nat. Rev. Genet.*, 3: 415-428, 2002; Widschwendter and Jones: DNA methylation and breast carcinogenesis. *Oncogene*, 21: 5462-5482, 2002) and, on the other hand, were reported to be abnormally regulated in tumours of patients with poor prognostic breast cancer (van't Veer et al.: Gene expression profiling predicts clinical outcome of breast cancer. *Nature*, 415: 530-536, 2002; van de Vijver et al.: A gene-expression signature as a predictor of survival in breast cancer. *N. Engl. J. Med.*, 347: 1999-2009, 2002) Because levels of circulating DNA in metastasised patients are known to be higher (Leon et al.: Free DNA in the serum of cancer patients and the effect of therapy *Cancer Res.*, 37: 646-650, 1977) and because the loss of genetic heterogeneity of disseminated tumour cells with the emergence of clinically evident metastasis was recently reported (Klein et al.: Genetic heterogeneity of single disseminated

tumour cells in minimal residual cancer. *Lancet*, 360: 683-689, 2002), the inventors firstly investigated these 39 genes in ten sera of metastasised patients to determine the overall prevalence of methylation changes in breast cancer. As a next step the inventors analysed the 33 genes that were positive in the metastasised patients, in the pre-treatment sera of 26 patients with primary breast cancer and in ten benign controls in order to identify the most important genes for further analysis. Eventually the inventors came up with five genes (ESR1, APC, HSD17B4, HIC1 and RASSF1A), which were primarily analysed in a group of 24 patients (training set). To confirm the significance of this result the inventors tested these genes in an independent set of 62 patients (test set). In order to apply the strictest criteria for testing the potential of a prognostic factor, the inventors investigated these markers in women, who had not undergone adjuvant systemic treatment. DNA methylation of APC and RASSF1A in pretherapeutic sera, both frequently methylated and abnormally regulated in human primary breast cancers (Dammann et al.: Hypermethylation of the CpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. *Cancer Res.*, 61: 3105-3109, 2001; Virmani et al.: Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas. *Clin. Cancer Res.*, 7: 1998-2004, 2001), turned out to be a strong independent prognostic parameter. These genes are involved in pathways counteracting metastasis: mediation of intercellular adhesion, stabilisation of the cytoskeleton, regulation of the cell cycle and apoptosis (Fearnhead et al.: The ABC of APC. *Hum. Mol. Genet.*, 10: 721-733, 2001; Dammann et al.: Epigenetic inactivation of the Ras-association domain family 1 (RASSF1A) gene and its function in human carcinogenesis. *Histol. Histopathol.*, 18: 665-677, 2003). Methylated DNA in patients' pretherapeutic serum coding for these two genes reflects poor prognosis. The source of the tumour-specific DNA and its definite role in metastasis remains elusive. Circulating tumour-specific altered genetic information may serve as a surrogate marker for circulating tumour cells that ultimately cause distant metastases. An alternative, but equally attractive, hypothesis is that circulating altered DNA per se may cause de novo development of tumour cells in organs known to harbour breast cancer metastases. This so-called "Hypothesis of Genometastasis" suggests that malignant transformation might develop as a result of transfection of susceptible cells in distant target organs with dominant oncogenes that circulate in the plasma and are derived from the primary tumour. Interestingly, irrespective of the source of DNA in the serum, it is noteworthy that some genes provide prognostic information when methylated in patients' sera, whereas genes like HIC1, which is

methylated in about 40% and 90% of primary and metastasised breast cancer patients, respectively, but in only 10% of healthy individuals, are not at all a prognostic parameter.

Irrespective of the mechanistic role of methylated DNA with regards to metastasis in breast cancer patients, these epigenetic changes in serum have several advantages as indicators of poor prognosis as compared to currently used or studied prognostic parameters: DNA in serum is stable and can be analysed by a high-throughput method like MethylLight. Compared to bone marrow aspiration, a simple blood draw (which can be repeated any time throughout the follow-up period) is sufficient. The more screening mammographies are performed, the more small cancers are treated and after histopathological examination no tumour material will remain to perform RNA- and/or protein-based assays for risk evaluation. This application therefore demonstrates a useful and easy approach for risk assessment of breast cancer patients.

Table 1

Gene	Genomic sequence	Bisulphite sequence
HIC1 NM 006497	1	6, 7, 16 and 17
HSD17B4 NM 000414	2	8, 9, 18 and 19
APC NM 000038	3	10, 11, 20 and 21
ESR1 NM 000125	4	12, 13, 22 and 23
RASSF1A NM 170715	5	14, 15, 24 and 25

Table 2. Characteristics of training and test sets.

Characteristics	Training Set (N=24)	Test Set (N=62)	P Value*
Size of tumour			
T1	62.5	79	
T2	37.5	13	
T3 + T4	0	7	0.024
Histologic type			
Invasive ductal	67	63	
Invasive lobular	8	13	n.s
Others	25	24	

Tumor grade			n.s.
1	46	44	
2	33	39	
3	17	10	
Lymph node metastases			n.s.
No	75	65	
Yes	12.5	11	
Unknown	12.5	24	
Menopausal status			n.s.
Premenopausal	33	16	
Postmenopausal	67	84	
Estrogen-receptor status			n.s.
Positive	54	40	
Negative	42	45	
Progensteron-receptor status			n.s.
Positive	58	45	
Negative	38	40	
Hormone-receptor status			n.s.
Positive	63	50	
Negative	33	36	

*P values for the comparison of numbers of patients were calculated by means of the Chi² test. n.s., not significant; Median age: training set (54.2 years; 37.6-83.2), test set (65.7 years; 28.2-86.2), P = 0.052 ; Follow-up: training set (8.0 years; 1 month to 12.2. years), test set (3.1 years; 1 month to 11. years) P < 0.001.

Tumour grade was unknown in six cases.

Hormone-receptor status was unknown in ten cases.

Tumour size was unknown in one case.

Table 3. Frequency of methylated serum DNA in the gene evaluation set.

Gene	Healthy Controls (N = 10)	Primary Breast Cancer		Recurrent Breast Cancer
		(N = 26)	percent positive	(N = 10)
ESR1	0	27		70
APC	0	23		80
HSD17B4	0	12		30
CDH13	0	8		40
ESR2	0	4		20
MGMT	0	4		10
SYK	0	4		10
HIC1	10	39		90
RASSF1A	10	23		80
GSTP1	10	12		60
MYOD1	20	27		80
CDH1	20	20		90

PTGS2	30	39	100
PGR	30	46	80
CALCA	40	50	60
HLAG	60	69	100
BLT1	60	85	100
ARHI	100	100	100
MLLT7	100	100	100
TFF1	100	100	100
SOCS2	0	0	40
SOCS1	0	0	30
TERT	0	0	30
DAPK1	0	0	30
TIMP3	0	0	20
BRCA1	0	0	20
GSTM3	0	0	20
MT3	0	0	20
TWIST	0	0	10
MLH1	0	0	10
CYP1B1	0	0	10
TITF1	0	0	10
FGF18	0	0	10
CDKN2A	n.d.	n.d.	0
HSPA2	n.d.	n.d.	0
PPP1R13			
B	n.d.	n.d.	0
TP53BP2	n.d.	n.d.	0
REV3L	n.d.	n.d.	0
IGFB2	n.d.	n.d.	0

n.d., not done

Table 4. Univariate analysis of methylation status in *training* and *test sets*.

Genes	Training Set (N=24) P Value	Test Set (N=62) P Value
ESR1	0.018	0.555
APC	0.002	0.307
HSD17B4	0.056	
HIC1	0.796	
RASSF1A	0.042	0.014
RASSF1A/APC	<0.001	0.007
ESR1/APC	0.001	0.951
ESR1/RASSF1A	0.032	0.138

*P values for each variable were calculated by means of the log rank test.

Table 5. Frequency of methylated genes according to clinicopathological features.

Characteristics	No. of Patients	ESR1	APC	RASSF1 A	RASSF1 A and/or APC
		% positive			
Size of tumour					
T1	64	14	11	9	19
T2	17	12	12	19	31
T3 + T4	4	75	25	50	50
Histologic type					
Invasive ductal	55	18	15	11	22
Invasive lobular	10	20	0	30	30
Others	21	10	10	10	20
Tumor grade					
1	38	11	11	13	21
2	32	19	16	16	31
3	10	30	10	11	11
Lymph node metastases					
No	58	12	9	9	18
Yes	10	20	30	20	40
Unknown	18	28	11	22	28
Menopausal status					
Premenopausal	18	28	11	11	22
Postmenopausal	68	13	12	13	22
Estrogen-receptor					
Positive	38	16	11	16	21
Negative	38	16	16	11	27
Progesterone-receptor					
Positive	42	14	5	14	18
Negative	34	18	24	12	33
Hormone-receptor status					
Positive	46	15	9	15	20
Negative	30	17	20	10	31

Tumour grade was unknown in six cases. Hormone-receptor status was unknown in ten cases. Tumour size was unknown in one case. DNA methylation of RASSF1A for one case was missing. Chi² Pearson: Tumour size – ESR1 (P = 0.005); Tumour size – RASSF1A (P = 0.049); Progesterone-receptor – APC (P = 0.036); Median age – RASSF1A methylated (79.0 yrs.; 49.6 to 86.2), RASSF1A unmethylated (59.4 yrs.; 28.2 to 82.3.) P = 0.009

Table 6. Results of univariate analysis.

Variable	No. of Patients Who Died/Total No.	Relative Risk of Death (95% CI)	P Value
Size of tumour			
T1	10/64		0.018
T2	5/17	2.2 (0.6 - 7.8)	

T3 + T4	2/4	5.4 (0.7 - 42.9)	
Histologic type			0.296
Invasive ductal	13/55		
Invasive lobular	1/10	0.4 (0 - 3.1)	
Others	3/21	0.5 (0.1 - 2.1)	
Tumor grade			0.310
1	6/38		
2	9/32	2.1 (0.7 - 6.7)	
3	2/10	1.3 (0.2 - 7.9)	
Lymph node metastases			0.005
No	7/58		
Yes	5/10	7.3 (1.7 - 31.7)	
Unknown	5/18	2.8 (0.8 - 10.3)	
Menopausal status			0.062
Premenopausal	1/18		
Postmenopausal	16/68	5.2 (0.6 - 42.4)	
Estrogen-receptor			0.369
Positive	10/38	1.9 (0.6 - 5.9)	
Negative	6/38		
Progensterone-receptor			0.766
Positive	9/42	1.1 (0.3 - 3.2)	
Negative	7/34		
Hormone-receptor status			0.799
Positive	10/46	1.1 (0.4 - 3.5)	
Negative	6/30		
ESR1 methylation			0.370
Unmethylated	13/72		
Methylated	4/14	1.8 (0.5 - 6.7)	
APC methylation			0.001
Unmethylated	12/76		
Methylated	5/10	5.3 (1.3 - 21.3)	
RASSF1A methylation			0.001
Unmethylated	11/74		
Methylated	6/11	6.9 (1.8 - 26.5)	
RASSF1/APC methylation			<0.001
Unmethylated	7/66		
Methylated	10/19	9.5 (2.9 - 31.4)	

Table 7. Multivariate Analysis.

Variable	Relative Risk of Death (95% CI)	P Value
Size of tumour		
T2 (vs. T1)	2.7 (0.8-9.3)	0.19
T3 + T4 (vs. T1)	2.9 (0.4-20.5)	
Lymph node metastases		
Yes (vs. no lymph node metastases)	3.9 (1.1-13.9)	0.039

Unknown (vs. no lymph node metastases)	5.2 (1.2-22.4)	
Age	1.0 (1.0-1.1)	0.06
RASSF1A and/or APC methylated (vs. unmethylated)	5.7 (1.9-16.9)	0.002

Table 8 Sequences of the primers and probes

HUGO Gene Nomenclature	Forward Primer Sequence	Reverse Primer Sequence	Probe Oligo Sequence
ACTB	TGGTGATGGAGGGTTAGTAA GT	AACCAATAAAACCTACTCCCTTAA	6FAM- ACCAACCCCCAACACACAATAACCAAAACACA- BHQ1
APC	GAACCAAAACGCTCCCCAT	TTATATGTCGGTTACGTGGTTATAT	6FAM- CCCGTGGAAAACCCGGGATTA-BHQ1
ARHI			6FAM- CGCACAAAAACGAAAATACGAAAACGCAA- BHQ1
BLT1	GCGTTGGTTATCGGAAGG	CCCGCATTTTATATTCGACTT	6FAM- 6FAM-GACTCCGCCAACCTCGCCAAAA-BHQ1
BRCA1	GAGAGGTTGGTTAGCGGTAGTT	AAACCGTAATTCCCGCTCG	6FAM- 6FAM-CCGCGCTTTCCGTTACACCGA-BHQ1
CALCA		CCGCCTGGCTATAAATCG	6FAM- 6FAM-ATTCGCCAATACACAACAATAAACG- BHQ1
CDH1	AATTTTAGGTTAGAGGGTTATCGCGT	CCCCAAAACGAAACTAACGAC	6FAM-CGCCCCACCCGACACTCGCAT-BHQ1
CDH13	AATTTCGTTCTGTTTGTGGCT	CTACCCGTACCGAACGATCC	6FAM-AACGCAAAACGGCCCGACA-BHQ1
CDKN2A	TGGAGTTTCGGTTGATTTGGTT	ACAAACGGCCCGAACCTCTT	6FAM-ACCCGACCCCCGAAACCGCG-BHQ1
CYP1B1	GTGCGTTTGACGGGAGTT	AACGGCACCTAACAAAACGAA	6FAM-CGCGGCACACCCAAACCGCTT-BHQ1
DAPK1	TCGTCGTTCTGGTTAGTT	TCCCTCCGAAACGCTATCG	6FAM-CGACCTAACCCCAACCGCCG-BHQ1
ESR1	GGCGTTCTGTTTGGGATTG	GGCGACACCGCGAACCTCTAA,	6FAM-CGACCTAACCGAACCGACGA- BHQ1
ESR2	TTTGAATAATTGTTAGGGCGAAGAGTAGACCCGTCGCAACTCGAAATAA	TCGCGCGTAGAAAACGTT	6FAM-CGACCGTACGCATGCCGC-BHQ1
FGF18	ATCTCCTCCTCCCGCTCTCT	AAC GTC GGT ATT AGT CGC GTT T	6FAM-CCC CGT TCT CGG TCC CTT ACC TCC- BHQ1
GSTM3	GCG CGA ACG CCC TAA CT		6FAM- AAACCTCGCGACCTCGAACCTTATAAAA- BHQ1
GSTP1			6FAM- CAACATCGTCTACCCAACACTCTCCTACG- BHQ1
H1C1		GCGAACGGCTCCATCGTAT	
HLA-G		GGT CGT TAC GTT TCG GGT AGT TTA	
HSD17B4	CAC CCC CAT ATA CGC GCT AA	TCCAACCTTCGCA TACTCAC	6FAM-CCCGCCGGATAACCAATACCA-BHQ1
HSPA2	TATCGTTGAGGTTGACGGG	GGG AGC GGA TTG GGT TTG	6FAM-CCG CGC CCA ATT CCC GAT TCT-BHQ1

AAC'T	CGG GAA GAG TAG GGA ATT TTT AGA GT CACTCTCCGAAAACGAAACG	6FAM-ACG CCC GCT CGC CCA CCT-BHQ1 6FAM-CGCAAACGATAACGCCACCGGA-BHQ-1 6FAM- CCCGCTACCTAAAAATAACGCTTACGCG- BHQ-1 6FAM-AAA CAC ATT CCT ACC AAT CTT CAA AAA ATC CGC-BHQ1 6FAM-AAA CGC GCG ACT TAA CTA ATA ACA ACA AAT AAC GA-BHQ-1 6FAM- CTCCAACACCCGACTACTATACCGCGAAA- BHQ-1 6FAM- ATCATCTCCGAAAATCTCAAATCCCAAATAATAC G-BHQ-1 6FAM-AAA AAT CCT CGA CGC CCT CGA-BHQ-1 6FAM-CCCTCCCAAACGCCA-BHQ-1 6FAM-CTC AAA TAA CGC CGC GAC TCC GC- BHQ-1 6FAM-ACAATTCCGCTAACGACTATCGCGCA- BHQ-1 6FAM-CCG AAA AAC TCA AAA CAC CGC AAA ATC AT-BHQ1 6FAM-CCTTAACCGGCCGAACAAACG-BHQ-1 6FAM-CCCAATCCCTCCACGTAAA-BHQ-1 6FAM- CCCTCCGCCAAAATAACTATACTCACTAC AAA-BHQ-1 6FAM-AACTCGCTCGCCCGAA-BHQ-1 6FAM-CTC GCG TTT ATT TTA ACC CGA CGC CA-BHQ-1 6FAM-CGC TCG TAA CGA TCG AAA CTC CCT CCT-BHQ-1 6FAM-CCAACGCCACCCAAATCGCTAAACGA-BHQ- 1
IGFBP2	CTC GCG CCA AAT AAA TAC GGTTTCGACGTTCTGAGGT	
MGMT		
MLH1	AGGAAGAGGGATAGCGATT	
MLL7	CCT CAC GAT ACC TCC CCT CAA CGA TAA ACG AAC TTC TCC AAA CAA	
MT3		
MYOD1	GAGCGCGGTAGTTAGCG	
PGR	TTATAATTGAGGGGGTTAGTGT CCT CAC CCA CCG ACA TCA TC	
PPPIR13B		
PTGS2	CGGAAGCGTTCGGGAAAG ATTGAGTTCGGGAGTTGGT	
RASSF1A		
REV3L	CGA ACG CAA CCG ACCT GGTGTGAGTTCTGGGTATT	
SOCS1	TCC CTT CCC CGC CATT GGCGCGATATTGGGAG GGATTCGGGTATAAGCGTT	
SOCS2		
SYK		
TERT		
TFI	TAAGGGTACGGGTGTTATTTCGTGA GCGTGGAGGGTTAAGGTGTT	
TFIIP3	CGA AAT AAA CCG AAT CCT CCT TAA	
TTF1		
TP53BP2	ACC CCC TAA CGC GACTTTATC GTAGCGGGCGAACGT	
TWIST	AAACGCAACGAATATAACCAAC	

Claims

1. A method for determining the prognosis of a subject with a cell proliferative disorder of the breast tissues, said method comprising analysing the methylation pattern of a target nucleic acid comprising one or a combination of the genes taken from the group consisting of ESR1, APC, HSD174B4, HIC1 and RASSF1A and/or their regulatory regions by contacting at least one of said target nucleic acids in a biological sample obtained from said subject with at least one reagent, or series of reagents that distinguishes between methylated and non-methylated CpG dinucleotides.
2. A method for selecting a treatment of a cell proliferative disorder of the breast tissues, said method comprising:
 - a) determining the prognosis of a subject according to Claim 1, and
 - b) selecting a suitable treatment according to said prognosis.
3. A method for determining the phenotype of a subject with a breast cell proliferative disorder comprising
 - a) obtaining a biological sample containing genomic DNA from said subject,
 - b) analysing the methylation pattern of one or more target nucleic acids comprising one or a combination of the genes taken from the group consisting of ESR1, APC, HSD174B4, HIC1 and RASSF1A and/or their regulatory regions by contacting at least one of said target nucleic acids in the biological sample obtained from said subject with at least one reagent, or series of reagents that distinguishes between methylated and non-methylated CpG dinucleotides, and
 - c) determining the phenotype of the individual by comparison to two known phenotypes, a first phenotype characterised by hypermethylation of the target nucleic acid and poor prognosis as relative to a second phenotype characterised by hypomethylation of the analysed target nucleic acid and positive prognosis.
4. A method according to claims 1 to 3 wherein said prognosis is the life expectancy of said subject.
5. A method according to any one of claims 1 to 4 wherein said target nucleic acid comprises the gene APC and/or its regulatory regions.

6. A method according to any one of claims 1 to 4 wherein said target nucleic acid comprises the gene RASSF1A and/or its regulatory regions.

7. A method according to any one of claims 1 to 4 wherein said target nucleic acids comprise the genes APC and RASSF1A and/or their regulatory regions.

8. A method according to any one of claims 1 to 7, wherein said target nucleic acid or acids comprise essentially one or more sequences from the group consisting of SEQ ID NOs: 1 to 5 and sequences complementary thereto.

9. A method according to claim 5 wherein the sequence of said target nucleic acid comprises essentially of SEQ ID NO: 3.

10. A method according to claim 6 wherein the sequence of said target nucleic acid comprises essentially of SEQ ID NO: 5.

11. A method according to Claim 7, wherein said target nucleic acid or acids comprise essentially of SEQ ID NOs: 3 and 5.

12. A method according to Claims 1 to 11, wherein said cell proliferative disorder of the breast tissue is selected from the group consisting of ductal carcinoma in situ, lobular carcinoma, colloid carcinoma, tubular carcinoma, medullary carcinoma, metaplastic carcinoma, intraductal carcinoma in situ, lobular carcinoma in situ and papillary carcinoma in situ.

13. A nucleic acid molecule consisting essentially of a sequence at least 18 bases in length according to one of the sequences taken from the group consisting of SEQ ID NOs: 6 to 25 and sequences complementary thereto.

14. An oligomer, in particular an oligonucleotide or peptide nucleic acid (PNA)-oligomer, said oligomer consisting essentially of at least one base sequence having a length of at least 10 nucleotides which hybridises to or is identical to one of the nucleic acid sequences according to SEQ ID NOs: 6 to 25.

15. The oligomer as recited in any one of Claims 13 or 14, wherein the base sequence includes at least one CpG dinucleotide.

16. A set of oligomers, comprising at least two oligomers according to any of claims 13 or 14.

17. A set of oligonucleotides as recited in Claim 16, characterised in that at least one oligonucleotide is bound to a solid phase.

18. A set of at least two oligonucleotides as recited in any of claims 14 or 15, which is used as primer oligonucleotides for the amplification of nucleic acid sequences comprising one of SEQ ID NOs: 6 to 25 and sequences complementary thereto.

19. Use of a set of oligonucleotides comprising at least two of the oligomers according to any of claims 16 to 18 for detecting the cytosine methylation state and/or single nucleotide polymorphisms (SNPs) within the sequences taken from the group SEQ ID NOs: 1 to 5 and sequences complementary thereto.

20. A method for manufacturing an arrangement of different oligomers (array) fixed to a carrier material for predicting the responsiveness of a subject with a cell proliferative disorder of the breast tissues by analysis of the methylation state of any of the CpG dinucleotides of the group SEQ ID NOs 1 to 5 wherein at least one oligomer according to any of the claims 14 or 15 is coupled to a solid phase.

21. An arrangement of different oligomers (array) obtainable according to claim 20.

22. An array of different oligonucleotide- and/or PNA-oligomer sequences as recited in Claim 21, characterised in that said oligonucleotides are arranged on a plane solid phase in the form of a rectangular or hexagonal lattice.

23. The array as recited in any of the Claims 21 or 22, characterised in that the solid phase surface is composed of silicon, glass, polystyrene, aluminium, steel, iron, copper, nickel, silver, or gold.

24. A DNA- and/or PNA-array for predicting breast cell proliferative disorders' response by analysis of the methylation state of any of the CpG dinucleotides of the group SEQ ID NOs: 1 to 5 comprising at least one nucleic acid according to any of the claims 14 to 18.

25. A method according to any one of Claims 1 to 4 comprising the following steps:

- a) obtaining a biological sample containing genomic DNA,
- b) extracting the genomic DNA,
- c) converting cytosine bases in the genomic DNA sample which are unmethylated at the 5-position, to uracil or another base which is dissimilar to cytosine in terms of base pairing behaviour,
- d) amplifying at least one fragment of the pretreated genomic DNA, wherein said fragments comprise one or more sequences selected from the group consisting of SEQ ID NOs: 6 to 25 and sequences complementary thereto, and
- e) determining the methylation status of one or more genomic CpG dinucleotides by analysis of the amplicate nucleic acids.

26. The method as recited in Claim 25, characterised in that Step e) is carried out by means of hybridisation of at least one oligonucleotide according to Claims 14 or 15.

27. The method as recited in Claim 25, characterised in that Step e) is carried out by means of hybridisation of at least one oligonucleotide according to Claims 14 or 15 and extension of said hybridised oligonucleotide(s) by at least one nucleotide base.

28. The method as recited in Claim 25, characterised in that Step e) is carried out by means of sequencing.

29. The method as recited in Claim 25, characterised in that Step d) is carried out using methylation specific primers.

30. The method as recited in Claim 25, further comprising in step d) the use of at least one nucleic acid molecule or peptide nucleic acid molecule comprising in each case a contiguous sequence at least 9 nucleotides in length that is complementary to, or hybridises under moderately stringent or stringent conditions to a sequence selected from the group consisting of SEQ ID NOs: 6 to 25, and complements thereof, wherein said nucleic acid molecule or pep-

tide nucleic acid molecule suppresses amplification of the nucleic acid to which it is hybridised.

31. The method as recited in Claim 25, characterised in that Step e) is carried out by means of a combination of at least two of the methods described in Claims 26 to 30.

32. The method as recited in Claim 25, characterised in that the treatment is carried out by means of a solution of a bisulfite, hydrogen sulfite or disulfite.

33. A method according to any one of Claims 1 to 12 comprising the following steps:

- a) obtaining a biological sample containing genomic DNA,
- b) extracting the genomic DNA,
- c) digesting the genomic DNA comprising one or more of the sequences from the group consisting of SEQ ID NOs: 1 to 5 and sequences complementary thereto with one or more methylation sensitive restriction enzymes, and
- d) determining of the DNA fragments generated in the digest of step c).

34. A method according to claim 33, wherein the DNA digest is amplified prior to step d).

35. The method as recited in any one of Claims 25 to 32 and 34, characterised in that more than six different fragments having a length of 100 - 200 base pairs are amplified.

36. The method as recited in any one of Claims 25 to 32, 34 and 35, characterised in that the amplification of several DNA segments is carried out in one reaction vessel.

37. The method as recited in any one of Claims 25 to 32 and 34 to 36, characterised in that the polymerase is a heat-resistant DNA polymerase.

38. The method as recited in any one of Claims 25 to 32 and 34 to 37, characterised in that the amplification is carried out by means of the polymerase chain reaction (PCR).

39. The method as recited in any one of Claims 25 to 32 and 34 to 38, characterised in that the amplificates carry detectable labels.

40. The method according to Claim 39, wherein said labels are fluorescence labels, radio-nuclides and/or detachable molecule fragments having a typical mass which can be detected in a mass spectrometer.

41. The method as recited in any one of Claims 25 to 32 and 34 to 40, characterised in that the amplificates or fragments of the amplificates are detected in the mass spectrometer.

42. The method as recited in any one of the Claims 40 or 41, characterised in that the produced fragments have a single positive or negative net charge for better detectability in the mass spectrometer.

43. The method as recited in any one of Claims 40 to 42, characterised in that detection is carried out and visualised by means of matrix assisted laser desorption/ionisation mass spectrometry (MALDI) or using electron spray mass spectrometry (ESI).

44. The method as recited in any one of the Claim 1 to 25 or one of the Claims 25 to 43, characterised in that the genomic DNA is obtained from cells or cellular components which contain DNA, sources of DNA comprising, for example, cell lines, histological slides, biopsies, tissue embedded in paraffin, breast tissues, blood, plasma, lymphatic fluid, lymphatic tissue, duct cells, ductal lavage fluid, nipple aspiration fluid and combinations thereof.

45. A kit comprising a bisulfite (= disulfite, hydrogen sulfite) reagent as well as oligonucleotides and/or PNA-oligomers according to any one of the Claims 14 to 15.

46. A kit according to claim 45, further comprising standard reagents for performing a methylation assay from the group consisting of MS-SNuPE, MSP, Methyl light, Heavy Methyl, nucleic acid sequencing and combinations thereof.

47. The use of a method according to any one of claims 1 to 12 and 25 to 44, a nucleic acid according to claim 13, of an oligonucleotide or PNA-oligomer or a set thereof according to any one of claims 14 to 18, of a kit according to Claim 45 or 46, of an array according to any one of claims 21 to 24 or of a method of manufacturing an array according to claim 20 in the prognosis, diagnosis, treatment, characterisation, classification and/or differentiation of breast cell proliferative disorders.

WO 2003 031159

Epigenomics AG
E30120

Abstract

The present invention relates to modified and genomic sequences, to oligonucleotides and/or PNA-oligomers for detecting the cytosine methylation state of genomic DNA, as well as to a method for the prognosis and treatment of a cell proliferative disorder of the breast tissues.

Figure 1




Figure 2





Figure 3



Sequence listing

<110> Epigenomics AG

<120> Prognostic and diagnostic markers for breast cell proliferative disorders.

<160> 25

<210> 1

<211> 3501

<212> DNA

<213> Homo Sapiens

<400> 1

gcggggctgg	cagggggcgct	gccctggcac	agctcggggc	ctggcagcgg	cgggtggggc	60
atcggctaag	agctgccacc	gcccgggga	ggggagccc	gcccggcgg	accgcaggta	120
acggggccg	gggccccg	ggccaggagg	ggaacgggg	cgggggggc	agcagcggc	180
agggggagctc	agggctggc	tccgggct	gcccggat	ttggggggc	cgaggaagag	240
ctgcgagcc	agggctgg	gcccggcac	tcctccg	ctgtctgc	ttggaaaact	300
tttccccaa	tttggggcg	cgagttcc	ggggagaagg	gcccgggga	gccgcggagg	360
gaggcgc	gcccgcgt	gtagggcc	ggccgaggcc	ggacgcgg	ttggggcgcag	420
gcccgggt	ggccgcgc	cggctgt	ccgtcccc	ccggggcgt	gccccctccc	480
tccccctgg	gctgcgt	tccccctcc	cccccac	cttccctgc	cagcctcctg	540
ccccgatata	acgcctccc	cgccggg	ccggcct	cgctctgc	gccacggcag	600
ccgctgc	cgctcccc	cgccggcc	ccccggccc	gaccgagg	tgacagcccc	660
cgccagg	ggcgcagg	cgggcacc	gtccccc	tccgtat	ttcccccaac	720
tggggca	acttccgagg	cgggaggc	tggttc	gctcccttc	tccctactt	780
gttaaagtt	tccgcctg	atgacttt	ctgaagc	catttactt	aaatcggt	840
actgtctcc	aaagggtac	tgcgcctg	cagtttctt	ctcggaa	ccagcacca	900
gccaggtg	ctggggcg	caggccccc	tggctccc	tccacc	ggcgtcacc	960
tcctgc	tctcctgg	cgggcg	ggcctgg	cccactcc	agggcagc	1020
gtccttc	ggtgc	ccgcagg	gatgc	ctcag	gaaaggggaa	1080
gtggaggg	gaagtgc	gctgggg	ggcggcc	gcccgcac	gctctcac	1140
ggccgtgt	tgtcccc	ggaggtgt	ctggc	gatgtgg	acgtggagg	1200
cgccggca	ctccagg	ctgctgt	agtc	ccagc	aaggcctt	1260
tgtgcgac	gtatcat	gtgcaga	ccctt	cgcc	cacaag	1320
cggccag	cgcctac	aagtcc	tgtgt	caac	ctgtc	1380
atgacatgt	gagccgg	gtgtcc	tgtgt	ttc	atctac	1440
tggctgac	cgcagagg	gtgcg	cgccgt	accgg	ccggccg	1500
tggcgcc	gctggcg	gccag	tgc	cgac	ctcg	1560
agaaacgc	caagc	actacc	ccat	cg	ctgtgc	1620
gcggctac	gcctatgg	ggca	ccac	cc	ccatcc	1680
aggcctg	cccgtcccc	ggc	ccat	cc	ccatcc	1740
gccca	cgccgtca	ggc	ccat	cc	ccatcc	1800
ccgcgc	ctgtgcct	ggc	ccat	cc	ccatcc	1860
agaagag	gccccgtc	ggc	ccat	cc	ccatcc	1920
cgccccc	cagccctccc	ggc	ccat	cc	ccatcc	1980
tgccgtcg	gcccggct	ggc	ccat	cc	ccatcc	2040
catttc	cggcagcgg	ggc	ccat	cc	ccatcc	2100
gtctctt	tcgtggat	ggc	ccat	cc	ccatcc	2160
gcccgg	cggctcccc	ggc	ccat	cc	ccatcc	2220
cgcccg	gccccgtc	ggc	ccat	cc	ccatcc	2280
ggcccg	ggccggc	ggc	ccat	cc	ccatcc	2340
gcccggc	ggccggc	ggc	ccat	cc	ccatcc	2400
gcgaggac	cagccgc	ggc	ccat	cc	ccatcc	2460
atggcgag	cgagac	ggc	ccat	cc	ccatcc	2520
tccccag	tgagc	ggc	ccat	cc	ccatcc	2580
tgtacgg	ggccg	ggc	ccat	cc	ccatcc	2640
ttggagg	cggggaca	gtc	ccat	cc	ccatcc	2700
cctacc	cgcgtcg	gaca	ccat	cc	ccatcc	2760
agaagac	ctggctg	ccgc	ccat	cc	ccatcc	2820
agcgtgg	gac	cacat	ccat	cc	ccatcc	

acgcgtgcgg	catgcggttc	acgcgccagt	accgcctcac	ggagcacatg	cgcatccact	2880
cgggcgagaa	gccctacgag	tgccaggtgt	gcggcggcaa	gttcgcacag	caacgcAAC	2940
tcatcagcca	catgaagatg	cacgcgtgg	ggggcgcggc	cggcgcggc	ggggcgtgg	3000
cgggcttggg	ggggctccc	ggcgtcccc	gccccgacgg	caagggcaag	ctcgacttcc	3060
ccgagggcgt	cttgcgtgt	gtcgcctca	cggccgagca	gctgagcctg	aagcagcagg	3120
acaaggcgc	cgcggccgag	ctgctggcgc	agaccacgca	cttcctgcac	gaccccaagg	3180
tggcgttga	gaggctctac	ccgctggcca	agttcacggc	cgagctggc	ctcagcccc	3240
acaaggcgc	cgggtgtctg	agccaggcgc	ctcacctggc	ggccggggcc	gacggccgga	3300
ccatcgaccg	tttctctccc	acctagagcg	cccctcgcca	gcccgcctg	tcgctgtgc	3360
gcggccctgg	cccgcacccc	agggagcggc	ggggcggcgg	cgcaggccc	actgtgccc	3420
ggacaaccgc	agcgtcgcca	cagtggcggc	tccacctctc	ggcggcctca	cctggcctca	3480
ctgcttcgtg	ccttagctcg	g				3501

<210> 2

<211> 2501

<212> DNA

<213> Homo Sapiens

<400> 2

tttccatagt	gtaaatgtt	tcccaacc	ctctggagta	atcctactta	aaaccgtttt	60
cagcacaaaa	ttcaaacatc	taaacatgat	cttgctgct	ttgtctttgt	ggctttaccc	120
tcttcctccc	caaaccctgc	tagtgtttgt	gctgcctgt	atgccttct	ttcttgcag	180
gggtcgccac	tttaggtcct	ggtcccttt	cagaaaggtt	ttctctttc	tccccagcgg	240
ggatagggtc	tgttatttt	gacaccatta	gctcaactac	acacattgg	cacaagtcta	300
ggctgcaccg	ttattgaaag	tttaccatct	gactctgagt	agcttgagga	tcctatcaaa	360
actcaggaga	tgctcagtaa	atgttgattg	aactatgact	gttctcaaca	tacaaacgc	420
agatcattt	ggaacacttg	tcaaaatgtt	tttggccctt	gagattctat	tttgggaggt	480
aagcagtggg	ggtccaggac	tctgcatttt	gacagtcccc	tgatgtttgc	atgtagaagt	540
gcagggattt	ttacactgac	aaatctttac	catccctaag	ggggactttc	cttcccaggg	600
gttatctctg	gaagccccctc	aaggataggg	gcccgcatgt	gttctctag	gtcagaact	660
aaaccaggaa	aacgtttatt	gagtaatga	tgaaacgaca	ggtgaataga	tgaacgcaag	720
gtgtcgagtt	aactattctt	ctacacaagt	cctagcaagt	cccattgtt	ccagccgcag	780
aaatggcccc	tggaaggcaa	gtctccagc	gagtgagtc	actcttaact	acatttccca	840
ggatttcaag	ggagccgcgc	gtctgcgtc	catttctta	ccagaaatcg	gcaagtcaact	900
gaccctcgtc	ccgccccccgc	cattccccgc	ctctccctgt	cccgcaagt	gcgtccagcg	960
gctctgcttg	ttcgtgtgt	tgtcggtgc	ggccttattc	atgggctcac	cgctgagggt	1020
cgacgggcgg	gtggtaactgg	tcacggcgc	gggggcaggt	gagcatgcga	aggttggagg	1080
ccgcggccct	tgctgaggcg	cagctggctg	ctctttcgg	gccggcatac	gcgcgcagcc	1140
gcagctgagg	tcaccccgct	gaggtggtgg	ggaggggaat	gttatttctt	gaggcaccgc	1200
atctcttgcg	gaggaaagag	ccggaaacac	ctggtctctc	aagcaggtac	agcccgttc	1260
tccccagcac	cccggtgtgg	gttcccaag	gtccctgcctg	agaggagagg	ccaggctggg	1320
ctgctgattt	caaaaactgg	tgaaagtct	ccctgaccct	tatctgtggg	catcgattgt	1380
tactcttcct	gcaattaact	ctcttagatc	tttgcctagt	cttttaaagg	actgaaaagc	1440
cgcgaggggc	gggggctgga	attccccc	tgaagcgcag	agatgtcagc	tcctgaaaag	1500
tcattcggtc	gttcagtgtt	tgttccctc	tgtcgtaaga	tttaagttc	gtgagaggac	1560
cttctttaaa	gagggcgct	gataagagcc	cttcccggtt	ggagtttga	tgcttagcaa	1620
gtcacaatct	gttctcgaaa	tccactggag	tcttggcag	ggttgtaaagc	tcaaatgcgc	1680
acaggggtca	gfcgtatgt	ggagaaagaa	aatgggagta	ggatgggcac	atctgaggaa	1740
ctggagagca	gagaattccg	aagtggaccg	gccagtggga	aagtgcctg	tatccagga	1800
gcggcaaaat	gaaaaattgt	tatgtgaaat	agccccattt	tttaaagtac	aaaaaattaa	1860
aacaaaccat	tcataccaa	atagatgctg	tgcagtgaga	tttacattt	gtttctcacc	1920
agtgggtgac	ctctgttaacc	tccaagtgc	gggatcttga	cattatgcac	ctttgattct	1980
ccactggtag	taccttatac	ctggaaaggc	cctaattgt	gaattatgg	agttatata	2040
taaacgttac	aaactggaaat	tctgtcaatt	aattcctatg	tactttcata	tctgtattga	2100
taaagtggct	tcttatgtc	cctttcgaa	aatgtttca	gtgttgatga	atagccaagt	2160
attttatacc	catagctgtc	tggttatctc	tgcattggca	tgattttggg	tgtatgtcata	2220
ccttctaaat	gttttttagga	aaacattttg	tttacactt	gcttttattt	taaataatgt	2280
attttacaac	gcttgggtgtt	ttaaatctt	tttgacagct	cttggataat	tttcatgcag	2340
gagggtccagg	gattacattc	taagacgttt	ttgccatcgc	taaggagact	ttcctttca	2400
ggggctatata	ctgaaaatca	ttcaaggata	gggactgctt	cttttgacac	cattagcata	2460
cttacacatg	gtatgcagta	cattttcac	cagtactcag	t		2501

<210> 3
<211> 2470
<212> DNA
<213> Homo Sapiens

<400> 3

aaagatgatt	aaaagttaa	ttgttcatct	gaagagttga	tttttttatt	cctgtataaa	60
agggtacttt	tagcagtctc	tgctcatctt	gcccatccgg	ctcttttgt	ggttgtgtaa	120
ggttataact	tctgtgtctc	agtaaacttg	tgcatgccca	ttttttctc	tgttactacc	180
ttttctctta	tttggttta	ttattttgat	gtaaaattac	ctgttaattt	tatttgaat	240
gagaaatttt	aaggttcaca	ttattcaaat	tctgtcagat	ccctacctct	gtcatatgg	300
ttataatgtg	ctgggtattt	tcagacctgc	ttattaaaaa	gatgtaaaac	aaaataatga	360
tcactcctgt	ggattttcc	tttattttg	agatgtctcc	tttggctgca	ttacttcctc	420
accccttgcc	cattgatcag	aggaggggtc	ttaactatgg	gtgaacccta	tatcttactg	480
aagaggttat	gttacatgt	tatttcata	atataactta	cattacata	gtacttttat	540
tttagcata	cctttttta	ttaatcctaa	taatatcact	gtaagttatg	ttgaagcaga	600
ttgttaagtgt	tcatttacaa	attgtgaaat	gaattaaaat	gaaagggca	agattaaatc	660
atgaccaggc	ctgaaattaa	cacacaagac	tcaattttt	tcaaccaaag	actttttag	720
gtgatccctg	cctgcaggac	tccccctcct	cctcagatgt	cattggattt	taccaggttt	780
actgtagatt	ctagccgtt	tagaactaac	tagatctaag	atgagtcccc	tgatttcctt	840
ttgttagagtc	ttccaattgc	tgaactccaa	tattgtcgt	actagccagt	gttacaacct	900
gtctgcctta	ttttgtgtaa	ttgatttcat	attacagagg	catttttta	atgtcaagat	960
gtttaagtat	tgcttaagt	caaactactt	aatactttt	agctattaag	taattaagat	1020
aggcaggatt	ttatttggtc	caaatgatt	tgacctaaac	taaaaagaga	atgtggatct	1080
cctgaatctt	acttggtaa	tcttaatata	actcctagca	ttctataatt	cttcctaaag	1140
tcctcttacc	ttgctatctt	ttgtatcttc	tttgcctctc	ctcttccttc	ccagtcataa	1200
taactgcccag	actctgcctc	atttctctt	gacagtctct	actcctaagg	tcatccatc	1260
tcttttaggt	tctttggcc	tcagttttag	cacagcagat	cccaagacca	catacgccat	1320
agcataggct	attatagtca	accttttggaa	taaatgtgat	tgaactttat	tttagtaatt	1380
tttatttacc	atcttcctat	aaaaaggct	taaagtcttc	attnaatgct	ctccttcatg	1440
tccattttgt	taaatgattt	ccttttaatg	acatctttaga	acttcagaac	tatttcacca	1500
tggaggatgt	gtaagattag	ccttttatca	aataaaaagt	gtgaaatgga	atatgtaaatc	1560
tcatttaatcc	attctggctc	taaaattctg	tgactatcag	ataaaaattca	gaaataaaaat	1620
agtattacta	atataaataa	atttttatca	taatttatatt	tcctaagttt	tgccgttaag	1680
aatgggtaaa	atatctttaa	aaccttgaag	aaatttattac	ttgatagaaa	gtttaatccaa	1740
tctgtgagaa	ggcaaattgt	ttcagacaca	actaaatttgc	tctttcttat	tttaatttca	1800
tttatcttga	actaaagactc	cactgttca	tctctttaga	tgctgtact	tgaacaatata	1860
tgttttgaga	ccaaaaacta	gcatattaaac	acaatttctc	ttaaaacgtct	taagagtttt	1920
gtttccttta	cccccttctt	taaaaacaag	cagccactaa	atttttttagt	agtgaatttc	1980
aaaatccctt	ttaaccttat	aggccttcaagg	gtagccaaagg	atggcttgcag	tttcataatga	2040
tcagttgttta	aagcaaggtt	aggcactgaa	gatggagaac	tcaaatttcc	gacaagagct	2100
agaagataat	tccaaatcattc	ttacaaaact	ggaaactgag	gcatctaata	tgaaggtatc	2160
aagactgtga	cttttaatttgc	tagtttattcc	atttttatttc	agtattccct	tttgcataact	2220
tgaggtttaaga	cacttttactt	aaaagtgtat	tttaaattaa	gcaataatata	gtaaacttctt	2280
tcttgcaaaa	gttagcattt	atatttttaaa	ataagatata	ttgaatttcat	tcaatgttata	2340
atataaagaa	aataagtgt	aaactccaaat	ggcttagttt	ttcttagttc	tttttaagat	2400
taaagagaag	agaccaaata	tagcatcact	gtactgaggc	aaggtttct	gtgttagttca	2460
tagaaactag						2470

<210> 4
<211> 7001
<212> DNA
<213> Homo Sapiens

<400> 4

aatgcaatgg	aaaaagagag	attgtaaagc	tagaaggctt	aggaattgcc	tcttgattag	60
gtgtggaaagg	caagggaaaa	tcagccctcg	aagaagacag	tgagatttta	atctgggtgg	120
ctggagagac	agtgtatgt	ggcacagaca	cggggaagtt	gagaggaaca	ccatgtttga	180
aatgggtgac	tcatatttga	acaaggctgc	aatgcccagc	agaccgctgg	aaaagtgggg	240
ctggagacac	attcaacgg	ggagccagat	caatcttac	ccttcac	ctgagagagc	300
cagtaagtca	cggttggaaac	gtgtgtgtcc	agcaggagag	ggttagggagg	gaagccaaaga	360

gagctggag cccgagtcaa	gttttgc	aaggcagaag	aggaaagtgc	gcgtgcaca	420
gtatacttc ccaccatgc	tcaccaagcc	caggacaag	gctcaccaag	atgagtttg	480
aagagaatgc tggagagaaa	gtggtaaga	aaactgcctt	tactgaactt	cttgggctaa	540
cttgattgt aagtctctga	acaatcaaag	cctgtgagga	gacagctaac	cttcttattc	600
ttcctatgtc aatagtgaac	aattgcagat	ccccttcct	ttccttctcc	tttcccctgt	660
tcctctctcc tccctccctg	aatacttgc	ctttttctg	ggactggct	agagcatggg	720
tggccattgt tgacctacag	gaggcaccac	tgtcacaac	aaagggtaaac	agtcttctt	780
tcaatattt atttatatcc	agtatttatt	tcaataactg	actatggaga	gagctctcct	840
gtgctcaaac actgcaatac	tggggctt	tcaaagcaca	aaaacatata	tttgcatgat	900
ggcatcatta acattttat	ggcttctat	ttctttttt	tactggctc	aagagccact	960
cataaatctc tcagaactg	catagtgtcc	caggccaga	gaccggccac	tcctggcatt	1020
gtgatttagag tcatttaata	tccaagggtgg	tgactaatgt	ctggcaacaa	agectccatt	1080
gggtgtcatg tgtcctggg	ccctgagcgt	gggcactcta	ggagcacctc	agtattgcgt	1140
gttagtacta tggccgagag	aatagttgag	aaagtggta	agaggtggat	ccatgtgaac	1200
gccactggga aatgagagac	ctcgttccca	atcacggta	gtcaactcg	aaagcctaaa	1260
atcagttaa aacaaaggta	tctacctta	tcttatgttc	atatcctagg	cttttaataa	1320
tacgtatttt tcacatgttt	acagaaagca	gtcaactgag	ctattcatgg	aaaggtttgt	1380
ggggttgggt aacgaagtgg	aggagtatta	catttcagct	ggaaacacat	cccttagaata	1440
ccaaaacatt tattccaaag	tctggtttcc	tggtcaatc	ggaggcatgg	caatgcctc	1500
gttcagagac tggggctag	ggccagtaag	gcatttgatc	cacatgtatc	ccagaaggct	1560
tttattgtt aattatattc	tttcggaaaa	accacccatg	tcctattttt	taaacttgat	1620
atccatacac ttttgactgg	cattctattt	tagccgtaa	actatgattc	acagcaagcc	1680
tgttttccctt cttgttttggg	gtggcagcag	aaagcatagg	gtactttcca	gcctccaagg	1740
gtaggggcaaa aggggctggg	gtttctcctc	cccagtacag	ctttctctgg	ctgtgccaca	1800
ctgctccctg tgagcagaca	gcaagtctcc	cctcactccc	cactgcccatt	catccagcgc	1860
tgtgcagtag cccagctcg	tgtctggcgg	gaggggctgc	caagtgcct	gcctactgjc	1920
tgcttcccgaa atccctgcca	ttccacgcac	aaacacatcc	acacactctc	tctgcctagt	1980
tcacacactg agccactcg	acatgcgagc	acattccttc	tttccttctc	actctctcg	2040
cccttgactt ctacaagccc	atgaaacatt	tctggaaaga	cgttcttgat	ccagcagggt	2100
aggttggtt tgatttctct	ctctgtagct	ttagcatttt	gagaaagcaa	tttacatttc	2160
tggctagtgt ctgtatccta	gcagggagat	gaggattgct	gttctccatg	ggggatgtg	2220
tgtgtctcct ttttcttca	ggactttag	gattcttgc	gccatttgca	tataatttgg	2280
caggttcaca tttttaaga	gccctatgaa	gtgcttttg	catgtttttt	aaaaaggcat	2340
ttgaaaattt aaagtgtat	ttatggaaat	taaatcatct	gtaaaaaaatt	gttttgaaa	2400
gtaatgattt ctggccataa	agggaaatat	ctgcgtatgc	cctaattgtgt	tttttacccct	2460
ttatttgcgt acaatctata	gtcattaatg	ctaaactcga	ttttggcttc	agctacattt	2520
gcatattgtc caacaatgg	ctattttgt	aagaatttga	taaaatgtat	acttgatata	2580
aaatagtcaa aaatgtact	cttagtaaca	gtaagcttgg	catttagata	gaccatgaac	2640
acttcgtcag atactctgtt	gggtgtttgg	gatacattt	aaaacaaagt	attgtatatt	2700
gtatcagagt ctattaggct	gcagcaagg	aagtttattt	aaaagataaa	actatccaag	2760
attatagacg catgatatac	ttcacctatt	ttttgtctcc	ttaatatgt	tatataata	2820
tatataataata tatacaca	tatatgtgt	tgtgtatgt	cgtgtgcatt	ttaactttt	2880
aattcagttt aaaactttttt	tctatttgc	tttcatctgg	atatttgatt	ctgcataatcc	2940
tagcccaagt gaaccgagaa	gatcgatgtt	tagactaaa	ggatagacat	gcagaaaatgc	3000
attttaaaaaa tctgttagct	ggaccgacc	gacaatgtaa	cataattgcc	aaagctttgg	3060
ttcgtgaccc gaggttatgt	ttggtatgaa	aaggtcata	tttatattca	gttttctgaa	3120
gttttgggtg cataaccaac	ctgtggagg	catgaacacc	catgtgcg	ctaaccaaag	3180
gtttttctga atcatcttc	acatgagaat	tcctaattgg	accaagtaca	gtactgttgt	3240
ccaaacataaa cacacaagtc	aggctgagag	aatctcagaa	gttgtggaa	gggtctatct	3300
actttgggag cattttgcag	aggaagaaac	tgaggtctctg	gcaggttgca	ttctcctgt	3360
ggcaaaaatgc agctttctt	atatgtatac	cctgaatctc	cgcccccttc	ccctcagatg	3420
ccccctgtca gttccccccag	ctgctaaata	tagctgtctg	tggctggctg	cgtatgcac	3480
cgcacacccc attctatctg	ccctatctcg	gttacagtgt	agtcctcccc	agggtcatcc	3540
tatgtacaca ctacgtattt	ctagccaa	aggaggggg	atcaaaacaga	aagagagaca	3600
aacagagata tattggagtc	tggcacgggg	cacataaggc	agcacattag	agaaagccgg	3660
cccctggatc cgctttcgc	gtttatattt	agccca	tccctgggccc	accttttagca	3720
gatcctcg	cgccccccg	ccctggccgt	gaaactcagc	ctctatccag	3780
aagtaaaagta aagttcaggg	aagctgtct	ttgggatcgc	tccaaatcga	gttgcctg	3840
gagtgtatgtt taagccatg	tcagggcaag	gcaacagtcc	ctggccgtcc	tccagcacct	3900
ttgtatgtca tatagagctg	ggagaccgt	acttaaaagt	ggaggccgg	gagcccagga	3960
gctggcgag ggcgttcgtc	ctgggactgc	acttgctccc	gtcgggtcg	ccggcttcac	4020
cggaacccgca ggctcccccgg	gcagggccgg	ggccagagct	cgcgtgtcg	cgggacatgc	4080
gctgcgtcg ctctaacc	ggctgtgt	cttttccag	gtggccccc	ggtttctgag	4140

ccttctgccc	tgcggggaca	cggctctgcac	cctgcccgcg	gccacggacc	atgaccatga	4200
ccctccacac	caaagcatct	gggatggccc	tactgcatca	gatccaaggg	aacgagctgg	4260
agccccctgaa	cgtccgcag	ctcaagatcc	ccctggagcg	gcccctggc	gagggtgtacc	4320
tggacagcag	caagccgc	gtgtacaact	accccggaggg	cgccgcctac	gagttcaacg	4380
cccgccgc	cgccaaacgcg	caggctacg	gtcagaccgg	cctccctac	ggccccgggt	4440
ctgaggctgc	ggcgttcggc	tccaaacggcc	tggggggttt	cccccaactc	aacagcgtgt	4500
ctccgagccc	gctgatgcta	ctgcacccgc	cgccgcagct	gtgcctttc	ctgcagcccc	4560
acggccagca	gttccccctac	tacctggaga	acgagccag	cggtacacag	gtgcgcgagg	4620
ccggccgc	ggcattctac	aggtacccgc	gcccgcggc	cccgtcgggg	tggccgcgc	4680
gcccggcagg	agggagggag	ggagggaggg	agaagggaga	gcctagggag	ctgcgggagc	4740
cgcgggacgc	gcaaaaaacgg	gttgccgc	gggagccgg	ggcgcgcgc	ccagcccggg	4800
gtttctgcgt	gcagccgcg	ctgcgttcag	agtcaagttc	tctgcgggg	cagctaaaaa	4860
aaacgtactc	tccacccact	taccgtccgt	gcaagggagca	gaccggaaag	cccgggcttc	4920
ctaacaaaaac	acactttga	aaaccagaca	aacagcagct	tatttgggg	ggaaaacacc	4980
tccaggcaaa	taaacacggg	gcccgtttag	tcacttggga	aggctctcgct	cttgcattt	5040
aaagttgggg	gtgtttggag	ttagcagagc	tcagcagagt	tttattttatc	cttttaatgt	5100
ttttgtttaa	tgtgtcccc	aaatttcctt	tcatctagac	tatttggattt	gaaatatgtc	5160
agctatgt	atgactttct	gggaagcgat	tcctgtcacc	cgctttcccc	tcctcccccac	5220
ccacagtct	ggggctttag	agagcgattt	ggagttgaat	gggtctgatt	tcggagttag	5280
ctggctgagt	ccgcgttgg	gcggatttgc	ggcatgtgac	ttctgacagc	cgaaaatttt	5340
taggtgtccc	gcaagttaa	aacaagccat	atgaaagcac	aagtgcctaa	aaataatctc	5400
ctgccagccc	agtgacaagc	ctgtcccacc	cggggagaat	gccccggagt	ggcgtgcggg	5460
tcagccaggg	tctgcgcctc	gcagccactg	tggaggagc	gccccgggtc	caggacacag	5520
gagaccactt	tgtgacttca	atggcgaagg	ttgtgtgtcc	tcattttat	ttttttccct	5580
acaagaattt	ttctttctcc	ctctcctctc	cctcccttattt	tctcttgc	agtttctct	5640
tttggttttt	gtttttgtt	ttcctgtatgg	gcctgcagag	ggatttaggt	ggcgttctg	5700
gtgaacacct	tccttaggtgg	ccacaggaca	ggtgtaccce	ggactgggtt	tggaaagcttc	5760
agggcgccac	atggctgggt	cctgaatttag	gcatttccca	actgtacact	ggtatccgga	5820
ctgggtgtccc	tatatttttc	tgccttgtaa	gcccgtggacc	agtttttgg	cagtattctg	5880
tttccaggg	tatttata	agaaggaagg	ggactaaagt	gcagttggc	cccaagaggat	5940
actgaaggc	agattctggg	gttatttgcgt	gtgcacatctc	agccgccttgc	gagaaatttt	6000
gagcatccca	cagccacgc	gatccaagct	gtctttactc	aaaagacaaa	caatgaacaa	6060
aactttaaa	ggttggcata	tttcaaattt	atttacttgc	ttttaatttta	gggttaaaac	6120
agagaaaaaag	gatttttct	gcccacccctt	tttttttttt	atggaaagaa	aaagtacagc	6180
gattaagtct	aattccacac	aatattttaa	actgttgc	gtgaaggaag	gcactggat	6240
gatgtgaatt	ccataaccc	atgtggact	ccagaaacca	ttttttccct	tatttaattt	6300
tcagttctt	tattgcaat	taatgtctgc	gaatttcaat	ggcactaat	gagactgctc	6360
cttggtagat	tatttactgc	cttgctataa	attacaaagt	gAACCTGGTC	aaatacagag	6420
gggatcgcac	cttattccaa	attgttcatc	atcccagtga	taagtggat	cagtgtataa	6480
tgccttatct	tacactttct	gcattacatg	atattcaac	actcttagaa	taataaaaaaa	6540
agagacaagg	aactaaaaaa	ttaaaaaaaaa	aacttgcaca	aatggactc	tgtgtggaaa	6600
ttcagtttta	gaatgatttt	tcctgtgttt	tatttcccg	attatcttc	ctcttttgc	6660
agaattctgc	ctgttattat	ccagcaagga	aaagaagcat	ctatgcacgt	tcttcataatg	6720
gacagatatt	attttagtatt	tttccctct	cagttttct	gcttaatga	ctctgggtat	6780
aaaggaaagg	attgatttggg	ctcttttagg	aaactttaag	tttcttaagt	agtttctcaaa	6840
agttttgggg	ctgaaagcag	tgttttcaaa	ctgcttgc	tgaccagag	gtcatgaac	6900
tcagtttagt	gagtctagaa	tattttttaa	aaggactaa	atggaaagga	atataataga	6960
aaatatcaga	gtgcacatggta	tttcgttaagg	ataagtttttgc	t		7001

<210> 5
 <211> 11001
 <212> DNA
 <213> Homo Sapiens

<400> 5

ccaaagtca	tgttcccaa	ttacctgtgg	acaggtcagg	catattctga	gtcttaatttc	60
actccacagg	cctaatacc	tggagccaga	aagcttccag	gtaaaaagtc	tgaagggggc	120
ctcctcatgt	cattagatgg	actcctgc	ctccagaaga	ttttccacac	cagggaaagat	180
caaagcacca	aggcaattct	tcctggcttc	ttgggacaac	cctaggttt	ggcgttgcgt	240
gtctggaa	cttgc	gttacaatgc	ctatacactc	ctggactgt	tttgcagg	300
ttgtcttca	gcacaattcc	tcctcca	cttactgttag	ctacagccca	tcagtccctgt	360
ctagtgcacaa	ccaagaaact	aagaactatg	tactcacgtt	cacccccc	gagtcatattt	420

ccttcaggac aaagctcagg	gccttgcac tggccctgc	caggagccgc agccgcaggg	480
gctgtcatc atccaacagc	ttccgcaagt acactgtgaa	gggaaagtaa tgatcagaga	540
cagggccagc tgctagccc	ctgcatgctc aggtgcattc	gtatataccc tcacataggg	600
cagggggggg tggaaagccc	accttggccg tgacgctcag	cgcgctaaa gagtgc当地	660
ttgcgggggt catccaccac	caagaactt cgcagcaggg	cctcaatgac ttacatgtcc	720
tttgtgcgtg acagcacatg	caggtgcgg acagcatct	tgggcaggta aaaggaagtg	780
ccgcgcctga cacttgcc	ccgtcctggg cccgc当地	catcctgaa ggagggtggc	840
ttcttgcgg agggcacaga	gacaggcgc accagctca	gctgaacctt gatgaagct	900
gtgtaaagac cgtcctgtt	ctaaagaaat agagaaacca	aacattgata ataggttcca	960
ggtgagatgt cagtctactt	ggggcttaggc tggatgc	caaattactg ctgc当地	1020
cccaagataa cctcagggtt	gaccctctga gtatcaggca	catagctggg tacatgtcc	1080
tccccacgccc cccttcctga	gcagtcact caccagctc	atgaagaggt tgc当地	1140
ctgggcattg tactccttga	tcttctgctc aatctcagct	tgagaaaggt cagggtctc	1200
ccactccaca ggctcgtct	gcaagatggg ccagcatgga	cacaggccc ttgaggaacc	1260
cagggcttct ctgaaaaatg	gcctctgggg cagcttgg	aaactgactg ccttggccc	1320
cctgtccctg atgtacatat	acatagctgg tgcccaccct	gaaccacca ctgc当地	1380
ttttgcattc tctgggtgg	taagggaaag acagaatcat	ttggcttctc tctgctgcct	1440
gcctaggccc tcagcactga	atgtagcctt aagatacca	cagaagcagg ggcaactgaa	1500
ggcacatggc cagggccag	gaacagctga gggactctga	agagggactc tcatat当地	1560
taaaatcagg ctgggtgtgg	tggctcacat ctgcaatccc	agcatttgg gaggctaaagg	1620
taggaggatc acttgatctt	caggagttt agaccagctt	ggcaacata gcaagaccc	1680
atctctacta aaaaaagaaa	aaaaaaaaatt agccagggtt	gttgggtgtc ctgttagtccc	1740
aactgtttag gaggctgagg	tgggaggatc gtttagccc	gggagattgc agctacagta	1800
agctattatc gtgtcactgc	actccagctt gggactgaa	gtgagaccct gttcaaaac	1860
acaaaaaaaca aaaacaggct	gggcacgtt gctcacgcct	gtaattctag cacttgggaa	1920
ggccgaggcg ggtggatcac	ctgaggtcag gagtttggaa	ccagctgac caacatggag	1980
aaaccccgctc tctactaaaa	atacaaaatt agccaggctt	gttggcacat gcctgtatc	2040
ccagctactt aggaggctga	ggcaggagaa ttgtcaaaac	tcgggagggt gagggtgcag	2100
tgaactgaga tcgtccatc	gcactccagc ctggcaaca	agagc当地 tcggctcaaa	2160
aaaaaaaaaa aatcgtaaaa	atcacacctc aattgcacat	tctgatcaca gcacccttagt	2220
tgagttggag tgagggttt	tcctggagaa ggcagccat	tttctcctc tgccccggca	2280
cggggcccattt acccactgca	gggtgagagg agtggagagt	gtgc当地 agtagtccag	2340
ccaccaggtag acagagtagt	acttggagcc agttctccat	gtctcacaca tagtgagaaa	2400
aatcaactgt acatgtatgtt	taaccttgc ccaagctgca	taaaaggcag cttaggcca	2460
ggctccaatc tgccagaggt	acacaggcag ctccctgg	ggtttctgca ctc当地	2520
ctgtctggag atttggccca	aagattttt ttttttga	gacgaagcct cactctgtc	2580
cccaggctgt agtgcagttt	ctggatctt gctcactgca	agttctgcct cttgggttca	2640
agcgattctc ctgcctcaga	ctcccagata gctggacta	ctggc当地 ccacaacaac	2700
acccggctaa tttttgtatt	tttagtagag atgggatttc	caggc当地 ccagggttgt	2760
cttgaactcc tgacctaag	tgatccgcct gccttcacat	ccaaagtgc tgggattaca	2820
ggcgtgaacc atcgatcccg	acccagagat ttttaactcg	accactcaat ccccacatca	2880
tctagggact ggattctgc	cggaagggtt gagtgtggg	caggcagcc agggctctg	2940
accgactttc ttctcccaga	ctcccttggc cccactgcat	cagccttact ttctgttgc	3000
gtcagatagg ccctagttag	aatgc当地 tcacagacac	agctaagctc agcgtgtacc	3060
aatactttgt cccagaagaa	ttcccacaag gttcctgta	aatgatctt gtgc当地	3120
caggagagcc agggcttctcc	ctgactccgc cctggagttc	cctaagcac taaaccatc	3180
tgatggggac aaatggagag	gacagatgag ggagcagggt	ggagc当地 agcagaatgc	3240
tccttaccca gaacccgctg	ctattctgca gccagcaagg	atgtgggtt aagaactaag	3300
gccagggcct tacaggaaaa	aggtaaagg ggagggttgg	gaatttaagc tcattttttt	3360
ccccaaatgt ccaaaggctt	cctggatgga gaagagcact	ggagtaaaaa ccccaatc	3420
aaccttactg gggacagttt	gcaaccttgc cgggttagta	aaaacaaaatg gtgtgggccc	3480
tggaaaatga gggctggagg	ctgtgaataa agcagttggat	gtgtttgttc agtacaccaa	3540
cggaaagaag tacccagatg	ggaggagttac tagggcagg	ggaggactt agaaatgcca	3600
agtgc当地 caagaaggaa	gatcatttt tttgc当地	gacagactt aggaggggca	3660
gctaacttgc ttctgtatg	gctctgagct cctacctaac	cagggtatgtt	3720
cttcccttcc tggatgaccc	aggagccct ggctggatg	cagtgc当地 atttccagcc	3780
cctcccttc tggatgatgaa	cctccctatc ttcaactcaga	aaacagactt ggattagagg	3840
cactgc当地 ccctccagg	attctaaagg aggaagagtt	tcttttctg tttccaaagc	3900
tgccctgctgg aagaggattt	caacagccat cccagtc当地	tgc当地 gaccatggaa	3960
tttcccttcc gcaccatagg	gaccaggccct ccactctacc	actgtccata aaaactgatg	4020
gtttttttt tgagacagag	tctcgctctg tttccaggc	tggaggcag tgggtgc当地	4080
ttggctcatt gcaatctctg	cctccctgggt tcaagcaatt	ctctgcttca gcctcccaag	4140
tagctggat tacaggtgccc	tgccaccaca actggctaat	ttttgttatt tttagtgc当地	4200

acggggtttc accattttgg ccaggctgg ctgtgactcc tgacccatg atccacccac	4260
ctcggttttc caaagtgcgt ggattaaagg tggagccac tgcacctggc ctaaaactga	4320
tgtttttttt ttttttttta acatataact tggacttct cagccctcta ttctttctt	4380
ttttttttt ttttttttga gacagagtct tgctctctca tccaggctgg aatgcagtgg	4440
cccagtctcg actcaactgca acctctgtct tctgggttca agtataactc ctgcctcagc	4500
ctccccagta gctgggattt caggcacaca ccaccatggc cagataattt ttttgtatt	4560
tcagtagaga cggggttttg ctatgtggc ctggcaggtc tcgaacttctt ggcctcaagt	4620
gatctgcctg ccttggcctc caaaaatgtct gagattacag gcatgagtca ccaagcccaag	4680
ccttctttct ttttttttag acagaggctc accctgtcac ccaggttggc gtgcagtggc	4740
acgatcttgg ctcaactgcaa ctttgcctc cgggttgaag tgattcagtc tcccaagtag	4800
ctgggactac agtcacacac caccatgccc ggtaattttt tttatgttta gttagatag	4860
ggtttcacca tggtggccag gttcaagtgc aatcctgtat tgcaaatgtat ccacctgc	4920
tggcctccca aagcattggc attagagggtg tgagccaccg tacttggctt cttttctat	4980
ttttgagaca gagtctcaact ctgtcactca ggctggagtg cagtggcactg atcttggctc	5040
actgcaacct ctgcctccca gttcaagtgc atcctctgc ctcaccctcc caagtagctg	5100
ggattacagg tggcacccctc cgtggcttagc cttcttttc aattggtag ttttgggg	5160
ttttccacc tttccacagt gaaaaatggc tcaggactga ctgacatgaa gacaagccca	5220
ggggtctaca ctcaactcaa ccctgcacc caagctctgg gctaagattt tggcgtctg	5280
agcaccaccc atttttaga gaattttgtaa aattttatac tgaagcatca ctcacaactc	5340
cacttcttt acttaataaa ggatttccgc cccatttctg ccaggcatac tgagcttcac	5400
agtccctgtt tcttttctt ggtgccttagg ctttgccttc tgagctggt ggtcacaccca	5460
atggcatctg gcacacagtt ctccgataat gggataacctt aggagggttcc gagacacctt	5520
acagtccctgg gtttagtaacc tggatctttt tttccacccctc ttttaggcatt ttataatcta	5580
gctttcccccc ttccctgtggg taaagtgcctc ctgaatgcctt atggccaaa acaagacttc	5640
tttcctatct attcccaaattt ctttctccag atccaccctta gaggaaggga acagaatctt	5700
ccacatttcca gcagctgggtg acaggccaga acagggaaga ggtgagggtc cagctggctc	5760
catacaggag tgcagatgga ttttctccat ctttccatggc ttttccatggc ttttccatggc	5820
tacttctcaa ttccctggcga gaggaggcag gagcattcga acgccaat ctttccatggc	5880
tttagtctata gctggataat ccgttccatggc ttttccatggc ttttccatggc ttttccatggc	5940
ccgttccatggc ttttccatggc ttttccatggc ttttccatggc ttttccatggc ttttccatggc	6000
tggatctttt ttttccatggc ttttccatggc ttttccatggc ttttccatggc ttttccatggc	6060
ccacgttagcc aggagggtgg ggcggagctc cagcgaccgc ttttccatggc ttttccatggc	6120
ggcggagctc cagcgaccgc ttttccatggc ttttccatggc ttttccatggc ttttccatggc	6180
tcccgagtctt ctttccatggc ttttccatggc ttttccatggc ttttccatggc ttttccatggc	6240
gaaggcgctt ccgcctcgcc catagccgtt cccgcccgtc ccccaatgcctt ggcgttccgt	6300
agccgccaac caccgccccg cgggtcccg ggcagggtccc cggccaggac cggccggggag	6360
cccgcccg agccgccccg ttttccatggc ttttccatggc ttttccatggc ttttccatggc	6420
cttgcctcat tggggcagga acgcccgggc gggacacgc acgcttcgccc cccaggaatg	6480
acctcatcgc tccggagctc ctttccatggc ttttccatggc ttttccatggc ttttccatggc	6540
gcccgggtcc gggcaagcgc acaagagtgg ctttccatggc ttttccatggc ttttccatggc	6600
cgggaaagtgc gctgtcgccgg agcctgggtc agcctggcc cgggtccgt ttttccatggc	6660
ggagtagttt cggagccggc aatccaggctt ctttccatggc ttttccatggc ttttccatggc	6720
ctctgtggcc cggggaaatc ggcatttgc ttttccatggc ttttccatggc ttttccatggc	6780
ctcgagaatg ctttccatggc ttttccatggc ttttccatggc ttttccatggc ttttccatggc	6840
gctgtcacca ctttccatggc ttttccatggc ttttccatggc ttttccatggc ttttccatggc	6900
caacagtccca ggcagacgag ggcgttccgtc ttttccatggc ttttccatggc ttttccatggc	6960
gagaggctt ggggttccgtc ttttccatggc ttttccatggc ttttccatggc ttttccatggc	7020
ggaagccccca gggagagggtc ggggttccgtc ttttccatggc ttttccatggc ttttccatggc	7080
ggttacctca cactgtctacg cggactctaa ttttccatggc ttttccatggc ttttccatggc	7140
cggttccgtc ttttccatggc ttttccatggc ttttccatggc ttttccatggc ttttccatggc	7200
cggttccgtc ttttccatggc ttttccatggc ttttccatggc ttttccatggc ttttccatggc	7260
ggcctgtca acagttggat ttttccatggc ttttccatggc ttttccatggc ttttccatggc	7320
cttcccccattt ctttccatggc ttttccatggc ttttccatggc ttttccatggc ttttccatggc	7380
tcacccaggc tggagtgcatt ttttccatggc ttttccatggc ttttccatggc ttttccatggc	7440
tcaagcgatt ctttccatggc ttttccatggc ttttccatggc ttttccatggc ttttccatggc	7500
gcccagctaa ttttccatggc ttttccatggc ttttccatggc ttttccatggc ttttccatggc	7560
ctcaaactcc ttttccatggc ttttccatggc ttttccatggc ttttccatggc ttttccatggc	7620
ggcttgcgtcc accgcaccccg ttttccatggc ttttccatggc ttttccatggc ttttccatggc	7680
tacttgaagg aaaaactaaa ctttccatggc ttttccatggc ttttccatggc ttttccatggc	7740
ctactccctt ctttccatggc ttttccatggc ttttccatggc ttttccatggc ttttccatggc	7800
ccctctaccc actccagccaa ctttccatggc ttttccatggc ttttccatggc ttttccatggc	7860
ctcagcgatc ttttccatggc ttttccatggc ttttccatggc ttttccatggc ttttccatggc	7920
cagcatcatt ttttccatggc ttttccatggc ttttccatggc ttttccatggc ttttccatggc	7980

cctacccct	gcagctcctg	ctcagctcct	ttgcagattc	tgactcaact	tccatatctc	8040
acgatgaagt	ctgggctcag	tcctgatcac	tggcctggc	tgtctacatt	catctgcccc	8100
agatccacgg	ctgaaacact	gacctaaacc	ctcagactag	atccctccgtg	ccagtacctt	8160
caactaggatg	tctaaaagac	gttcaagtg	aacatggcca	aaatttaatt	ccctttctt	8220
cagcctact	gctacacttg	cccagcttcc	tcttgcagc	aaaaatggcc	actaggctcc	8280
cagttactgg	agacaaaagc	ccaaacttat	ctttgatttc	tcccttgtct	ctacctctga	8340
taaacatgcc	caaattcatcc	tgcttcttat	ctccatggct	actttatttc	tctttgagaa	8400
cgctgcaatg	tcccagcctt	gttctttttt	ttttttttt	tttttttgag	acagagtctc	8460
actctgtcgc	caaggctgga	gggcagtgcc	acgatctcg	ctcactgcaa	cctccgcctc	8520
ctgtgttcaa	gcaattctcc	cacctcagcc	tcccagtag	ctgggattac	aggcaccgc	8580
caactacgct	ggctcattttt	tttttattttt	tttagtagaca	tgaggttca	ccatgttgc	8640
caggctggc	ttgaactcct	gacctcaggt	gatccacccg	cctccgcctt	ccgaagtgc	8700
gggattacag	gcatgagcca	ccgcgctcgg	cccttgttc	attcttgca	ttctgtcaca	8760
actttgtgt	ccccccagct	gaatttgta	tgtctcttg	taccggatga	gagggtctcc	8820
atgcacacac	agacctggga	cactatccat	ccacaagttc	ctaaataggc	cagagcagtgc	8880
atgctcaacc	cagactccat	gttacaataa	tttggggagt	ttttaaaatt	tactgtatgc	8940
tagggtccac	tcccagcgt	tgattcaaca	ggctctgcgg	gggatccagg	ctagcgggg	9000
ggactgtaaa	agcacccctg	gtgattccag	ctgggtgtcta	cccaggggg	agcaaccttt	9060
gcttgcgtgc	gattttcagg	gtgtcagaag	gactgctggg	tgtgtggctg	cgtgcatatt	9120
tttagcatctg	attcaactggg	tcagaaaagg	gtgtttgcta	aataaagact	caacaaaact	9180
cctgcgttgc	ggggggccac	caaaggttct	aaatttttcc	aggctccctc	ccataggtgg	9240
taatttccct	tcacccctaaa	gttctggag	ggggtcatga	gtgtttgaga	agaggcaagc	9300
ctgggaagat	ggactccgag	gacagtaggc	acaaaccctt	tctcaagaag	ggccaaggca	9360
ttttaaagat	aagaaactta	aatcagcgt	atttttacat	ataagcagcc	acctctgctc	9420
atctgtggcc	cagatacag	tggagtgcga	caagggataa	accattttcg	cgcactcttc	9480
agcgtatggg	cgaaagtaac	ggaccta	ctcggagct	gtcccccgg	acccctctg	9540
ccgcgacttg	acccgcggcg	actgcgtc	cccttggctg	cccctccgc	tctcgtaggc	9600
gwgccggggcc	actactcag	cgcgcaetgc	aggctttgc	gcacgacgc	ccagatgaag	9660
tcgcccacaga	gttcgcacca	cgtgtcg	gcccccccg	cgggctggaa	gcgggtggcca	9720
cgwgccaggga	ccagtcgccc	tgtgggttg	cacgcgggtc	cccgcgcgat	gcgcagcgcg	9780
ttggcacgct	ccagccgggt	gcccgcctc	ccagcgcgc	cagcgggtgc	cagctccgc	9840
agctcaatga	gctcaggctc	ccccgacatg	gcccgggtgg	gcccgtgctt	cgctggctt	9900
gggcgctagc	aagcgcgggc	cgggcgggc	cacaggcgg	gccccgactt	cagcgcctcc	9960
cccaggatcc	agactggcg	gcccggagga	gctgaggaga	gcccgcata	gaaacactgg	10020
gtgcaggggac	tgtggggccc	gaaggcggg	ctggcgcgc	tctcgagag	cccccccccgc	10080
cttgccttc	cttccctct	tcgtcccctc	ctcacacccc	acccggacg	gccacaacga	10140
cgwgccaccgc	aaagcaccac	cgggagatac	ccgtgtttct	ggaggccagc	tttactgtc	10200
tagaggaaga	gggtccccac	atccggccct	ggccctctg	gtccggttt	ctgaagcaac	10260
acacttggcc	tacccactgg	gtggggcagg	aagtctcg	ccttcaactt	gggtgaggag	10320
gagggagatc	ggtcagcagc	tttaccgccc	gctctgtct	ccactgcgg	gactggggct	10380
ccggcagagg	ctggaccgt	atcttgcagg	tcagggggtc	attctgggt	gattcccttg	10440
gcatgggtgg	tcggccctca	gcaactgcag	ccctcatttgc	gctctgtcac	cctgggctgc	10500
caggacacaa	gtcttccat	gttttccca	gtgcttgact	tggca	tgcaggcagg	10560
tgggtattga	ggatggcaat	gcatgtgggg	gatgtggag	tagggcttag	aggtccaagg	10620
ttcttaggata	ccctcacctg	cagaataacc	actcatttgc	gcatcgtgag	cagcgccttgc	10680
aaggcctctgc	actgcagtaa	gcacagcg	gcccgtctgg	agccactg	tctagcacat	10740
ccagcctgta	ggtctcagcc	cacccgggg	aaagtca	aggctcgact	gcccgtggaa	10800
ggtgggggca	ccccacccac	atccatgcct	cctgcaccc	ctccacccctc	cctgcattt	10860
ccacaggcct	tacccctcg	cctgcaccc	caggtcctgc	tctgaggggc	tgaacacatg	10920
ctggagctgg	tgcttggcaa	ttgcctgcca	cttgcctctg	ttttctcgct	ccagccgc	10980
ccagatttct	ggatctagg	a				11001

<210> 6

<211> 3501

<212> DNA

<213> Artificial Sequence

<220>

<223> chemically treated genomic DNA (Homo sapiens)

<400> 6

gcgggggtgg tagggcggtt gttttggat agttcggggt ttggtagcgg cgggtgggt

60

atcggtaag	agtgttatac	gtcgccccg	ggggagttcg	gttcgtcggg	atcgtaggt	120
acgggtcg	gggttcgcg	gtttaggagg	ggaacggggt	cgggcggg	cgatagcgggt	180
aggggagtt	agggttcgt	ttcgggttt	gtcgtcgat	ttgggggtcg	cgaggaaagag	240
ttgcgagtc	agggttggg	gtcggcgat	tttttcgtt	ttgtttgtag	ttggaaaatt	300
tttttaag	tttggggcgg	cggagttcg	ggggagaagg	gttcgggg	gtcgcggagg	360
gaggcgtcg	gtcgcgcgt	gtagggtta	gtcgaggtc	gggacgcgg	tggggcgtag	420
tttcgggt	gggtcgtagt	cggtgtcg	tctgttcgt	tcgggggtt	gtttttttt	480
tttttggg	gttcgtgtt	tttttttt	tttttattt	ttttttgtt	tagtttttt	540
tttcgatata	acgtttttt	cgcgtcggt	tgcgtttcg	cgttttgc	tttacggtag	600
tcgttgttt	cgttttcgc	cggtcg	ttcgggttc	gatcgagggt	tgtatgttt	660
cggtagggc	ggcgttaggg	cgggtatcgc	gtttttttt	ttcgtattat	tttttttaat	720
ttgggttaatt	ttttcgagg	cgggaggcg	tgggtttcg	gtttttttt	tttttattt	780
gttaaagttt	ttcgttttga	atgattttt	ttgaagcgga	tattttattt	aaatcggtt	840
attgttttt	aaagggttat	tgcgttga	tagttttt	ttcggaaagt	tttagtattt	900
gttaggttt	ttggggcgt	tagtcgtt	tggtttttt	tttacggcg	gtcgtttatt	960
ttttgtttt	tttttgggtt	cgggcgggtc	gttttgggtt	tttattttt	agggttagtc	1020
tttttcgtc	ggtgttttag	tcgttaggg	gatgttttcg	tttagtttag	ggaaggggaa	1080
gtggagggg	gaagtgtcg	gttgggtta	ggcggttag	gcgtcg	gtttttattt	1140
ggtcgggtgt	tgttttcgt	ggagagtgt	ttgggttagac	gatgttggat	acgtatggagg	1200
cgttcgggtt	tttttaggt	ttgttgcgt	agtttaataa	ttagcgtatt	aaagggtttt	1260
tgtgcgacgt	gattatcgt	gtgtagaacg	tttttttcg	cgcgtataag	aacgtgttgg	1320
cggtagtag	cgtttatattt	aagtttttgg	tgggtatga	taattttttt	aatttggatt	1380
atgatatgtt	gagtcggc	gtgttcgtt	ttgttgcgtt	tttattttat	atcggtcgtt	1440
ttgttgacgg	cgttagggcg	gtgcgtc	cggtcg	tcgggtt	gagtcgagg	1500
ttggcgtcgt	gttggcgtc	tttagttatt	tttagattt	cgatttcgt	gcgttgcgt	1560
agaaaacgtt	taagcgttac	ggtaagtatt	gttatttgc	ggcgccggc	ggcgccggc	1620
cgccgtacgc	gtttatgg	cggtcgggtc	gggggttgc	ggtcg	tcgggttattt	1680
aggtttgtt	ttcgttttta	gtcgggtttt	cgtcgtcg	tgtcgcgg	tcgttttccg	1740
tttagaggt	cgcgttaat	acgtattcgc	tgcgttgc	cgcgtcgg	ttcgggttccg	1800
tcgtcgtatt	ttgttgcgt	gagcgtcgtt	gtttttttt	ttgtgggtt	gatttggttt	1860
agaagaat	gtcgggttcc	gcggcgttag	acgcgtcg	ggttgcgc	gagttgttt	1920
cgcgttcg	tagttttttt	acgcgtcg	tgcgttta	taaggagt	tttttcgtt	1980
tgtcgtcg	gtcgtcg	tttttttgc	agttggagga	gtcgtatcg	tttttcgatt	2040
tatttcgcgg	cggtagcggt	agttcggtat	tgcgtttt	cggtcg	tttttcgacgt	2100
gtttttttt	tcgttgcgt	aagtcgact	cgggttgg	tagtgcgttgc	gacgggttt	2160
gtcggagcg	cggttttttt	acgcgtcg	gcaagagcg	tggtggggac	gcggtcgtt	2220
cgttcgggg	gtttcgtt	gtttggcgt	cgtcgtcg	ttatttgg	agtttggacg	2280
gttcggcgc	ggggccgcac	ggcgtacgt	ataagagtag	tagcggagg	atcggtat	2340
gcgaggattt	tagtcgtt	ggcgttatt	tgcgttgc	ttatgttgc	tatttggttt	2400
atggcgagtt	cgagagttt	ggtataatt	tgcgttgc	tttacgttgc	gttaagggtt	2460
tttttagttt	tgagtagtt	aacgcgtac	tggaggtt	cgtggagg	gaggaagcgt	2520
tgtacggtag	ggtcgaggcg	gtcgaagtgg	tcgttgggt	cgtcg	ttttttttt	2580
ttggaggcgg	cggggataag	gtcgtcgg	ttcgggtt	tttggagag	ttgttgcgt	2640
tttatcgtt	cgcgtcg	gataagagt	ataaggattt	gttacgttgc	cggtgtac	2700
agaagacgt	ttgttgcatt	cggtttatt	tatgtattat	ttgcggaa	agtttacgt	2760
acgcgtggat	tatgacgcgt	tatgcgt	gtatttgg	tttaagttt	ttcgcgtcg	2820
acgcgtcg	tatgcgtt	acgcgttagt	atcggtttac	ggagtatatg	cgtatattt	2880
cggcgagaa	gttttacgag	tgttaggtt	gcccggta	gttcgtatag	taacgtatt	2940
ttattagtt	tatgaagat	tacgtcg	ggggcgcgg	cggcggc	ggggcggtt	3000
cgggttgg	gggttttcc	ggcgtttcg	gttcgcacgg	taaggta	ttcgatttt	3060
tcgagggcgt	ttttgttgc	gttcgttta	cgtcgtat	gttgcgtt	aagtagtag	3120
ataaggcggt	cgcgtcg	ttgttgcgt	agattacgt	tttttgc	gattttaa	3180
tggcgttgg	gagttttat	tcgttgcgtt	agttacgtt	cgagttgg	tttagtttgc	3240
ataaggcggt	cgttgcgtt	agttaggcg	tttatttgc	tttcgggtt	gacggtcg	3300
ttatcgtat	ttttttttt	attagagcg	ttttcgtt	gttcgtttt	tcgttgcgt	3360
gcggtttgg	ttcgttattt	agggagccgc	ggggccggc	cgtagggtt	attgttgc	3420
ggataatcg	acgcgtcg	tagtggcg	tttattttt	ggcggttta	tttggttt	3480
ttgttgcgt	tttttagtt	g				3501

<210> 7

<211> 3501

<212> DNA

<213> Artificial Sequence

<220>

<223> chemically treated genomic DNA (Homo sapiens)

<400> 7

tcgagtttaag	gtacgaagta	gtgaggtag	gtgaggctgt	cgagaggtag	agtcgttatt	60
gtggcgcacgt	tcgcgttgtt	tcgggtatag	tggttttgc	gcgtctttt	cgtcttttt	120
tgggtgcgg	gtttagggtcg	cgttagtagcg	atagagcggg	ttggcgaggg	gcgtttttagg	180
tggagagaa	acggtcgatg	gttcggctgt	cgggtcgggt	cgttaggtga	gcgttttggg	240
ttagtatttc	ggtcgttttg	tcgggttga	ggtttagttc	ggtcgtgaat	ttggtttagcg	300
ggtagaggtt	tttagcggtt	atttgggtt	cgttagggaa	gtgcgtgggtt	tgcgttagta	360
gttcggctgc	ggtcgttttg	tttgggttt	tttaggtttag	ttgttcggtc	gtgaggcgag	420
ttatagtaaa	gacgttttcg	gggaagtcga	gtttgttttt	gtcgtcgggg	tcggggacgt	480
cggggagttt	tttaagttc	gttagcggtt	cggtcgcgtc	gtcgcgtttt	tttacggcgt	540
gtatttttat	gtgggttgcgt	agggtgcgtt	gttgcgtcga	tttgcgtcgt	tatattttgt	600
attcgttaggg	tttttcgttc	gagtggatgc	gtatgtgttt	cgtgaggcgg	tattggcgcg	660
tgaatcgat	gtcgtacgcg	tcgtacgcga	agggttttag	gttttaggtgg	ttgcgtatgt	720
ggcgcgttat	gtttttacgt	tcgcgtgaatt	tttttcgtta	gtgggtgtat	gggtagggtc	780
gggttagtta	gtgcgttttt	tcgtgttgc	gtagcgtgggt	cgggtttttt	tagtttttgt	840
cgtacgacgc	gtagcggta	ggtcgttagta	gttttttttag	gttattcgg	gttccggcga	900
ttttgttttc	gtcgtttttta	aaaggggtt	ttaggtcggc	gttttttagcg	gttatttcgg	960
tcgtttcgggt	tttgcgtat	agcgtttttt	ttttttttac	gtgagttttt	acgtcgcgt	1020
ttagttgttt	agagttgggg	aagttttgt	cgtacggaa	gtatacgtat	agggtgttat	1080
cgaagtttc	gggttcgtta	tagtttaggt	gcgggtatgg	gtagtttcg	agggtggtcgt	1140
taggcgggtt	ggggttttcg	ttgttatacg	tttttcgtt	gttgcgtttt	tagtcgtcgt	1200
cgtcgtcgtt	cgcgtcgggt	tcgttttaggt	tgttagggta	gcgcggcggc	ggcgttaggt	1260
cgagcggggg	tttttcgggc	gagacggtcg	cgtttttatt	acgtttttcg	tagcgttcgt	1320
tggggagtc	gcgttttcgg	tttagtcgt	cgttatagtt	attaggttc	gttgcgtgtt	1380
ttatatacg	atagaggaga	ttagtcgt	cggggcggtc	gggggttcg	gttgcgtgggt	1440
tgtcggttgc	gtcgcgaat	gggtcggaa	gcgggtcgggt	tttttttagt	ttttggaaagg	1500
gtagcggcg	tagcgtcggt	agggcggag	gcgggttttt	gtaggcggcg	gggtcggcgt	1560
tgggaggtt	tttcggggcgc	ggggtagtt	cgcgttttagt	tagcgtcgt	tttggcgtcg	1620
cggagttcgg	cgggtttttt	ttggataggt	tttaggtata	aagagggag	tagcggcgtt	1680
tcgaggtata	gagtgcggcg	gtcgggtcgg	gttcgcacgc	gtatagttcg	gcgtgtgcg	1740
tgttgcgtc	ggtttttggg	ttcggggcg	gttcgcgggt	aggcggcggc	ggaggttcga	1800
ttggggacgg	gtagtaggtt	ttgatgatcg	gcgtggcggt	tcgttaggtt	cggttcggc	1860
gattataggg	cgcgtatcg	tcgtcgctgt	cgtcgtcggt	tcgttaggtgg	tagtattttgt	1920
cgtggcggtt	gaggcggtt	ttgtatacg	ttacgaggtc	ggggattttgt	aggttagttgg	1980
cggcggttag	tacggcggtt	aggttcgggt	tagtttcgg	gttacggtc	gcggcgtcgt	2040
tcgttttgc	gtcgttagtt	aggcggtcgg	tgtagatgaa	gttttagtatt	aggcggaaata	2100
cggtcgggtt	tattatgtta	tggttttaggt	ttagtaggtt	gttatgtatt	attagggttt	2160
tgaggttaggc	gttgcgttgc	gttagtacgt	tttgcgtcgc	gcggaaagagg	gcgtttttagt	2220
ttacgatgtat	tacgtcgat	aagaagttt	tggtcgttg	gttgcgttagt	tgttagtagta	2280
ttgttttgc	gtggtcgggc	gtttttatcg	tggttagtat	cgtttgtta	gtatattttt	2340
ttgcggggat	atatatcggt	cgggtgagag	tcgtcgccgc	tttgcgtgt	ttgggttttag	2400
ttcgggtattt	tttttttttta	ttttttttt	tttagttga	gcgggggtat	tagtttcgc	2460
gtttgggtat	cggcgaagga	tcgggtgtt	tttggagtgg	gagtttaggt	cgggtcggtc	2520
ggatttaggag	aaggagtagg	aggtgagcgg	tcgtcggtgg	aggggaggtt	agggcgggtt	2580
gtacgtttta	gggtattttgg	ttgggtgtt	gggttttcga	gaagaaaatt	gtttaggcgt	2640
agtgtttttt	ttggagatag	ttattcgatt	taagtaaaat	gtcgtttta	ggaaaagtta	2700
tttagggcgg	agaattttat	ttaagttaggg	agaaaagggag	tcgaggaatt	agcgttttc	2760
gtttcggggag	aagtgttttt	agttggggga	agtgatacgg	aggagggag	cgcggtgttc	2820
gttttggcgt	cgttttggtc	gggggttgg	aatttcgg	cgggttcgg	gcggcggcgt	2880
cgcggggagc	ggaggtagcg	gttgcgtgg	cgggtagagc	gcgaaggcgt	gttgcggcgc	2940
gggggaggcgg	ttatatcggt	gtaggaggtt	gaggttaggaa	gtaggtgggg	gggagggggg	3000
agttacgtat	tttttagggg	agggaggggg	tagcgtttcg	ggcgggtacg	gcgtatagtc	3060
gttgcgggtt	ttgattcggt	tttgcgtttt	attcgcgtt	cgtttcgtt	ttgggtttta	3120
tacgcgcggg	ttcggcgttt	tttttcgcgg	tttttcgtt	ttttttttt	tcggaatttc	3180
gtcgttttaa	atttggggaa	aagttttta	attgtagata	ggcggggagg	agtgcgtcg	3240
tttttaggtt	tcgggtcgta	gtttttttc	gcggttttta	aattcggcgg	taggttcgg	3300
agtgcagttt	tgagtttttt	tgttcgtgt	tcgttcgttc	gatttcgttt	tttttttgg	3360
tcgcgggggtt	tcgcgggtcg	ttatttgcgg	ttcggcgggg	tcgggttttt	tttttcgcgg	3420

cggtggtagt ttttagtcga tgtttattc gtcgttgtta gtttcgagt tgtgttaggg 3480
tagcgtttt gttagttcg 3501

<210> 8
<211> 2501
<212> DNA
<213> Artificial Sequence

<220>
<223> chemically treated genomic DNA (Homo sapiens)

<400> 8

ttttatagt gtaaatgtgt	ttttatttattt tttggagta atttatatta	aaatcgtttt	60
tagtataaaa tttaaatatt	taaatatgtat ttgttggtt	ttgtttttgt ggttttattt	120
ttttttttt taaatttgt	tagtgtttgt gttgttgta	atgtttttt tttttgttag	180
gggtcgttat ttaggtttt	ggttttttt tagaaagttt	ttttttttt tttttaggg	240
ggatagggtt tgtttatttt	gatattatta gtttattttat	atatattgtt tataagttt	300
gttgtatcg ttattgaaag	tttatttattt gatttgagtt	agtttgagga ttttattaaa	360
atttaggaga tggtagtaa	atgttgattt aattatgatt	gttttaataa tataaacgtt	420
agattattta ggaatattt	ttaaaatgtt tttttttt	gagatttttat tttggaggt	480
aagtagtggg ggtttaggt	tttgatttt gatagtttt	tgatgtttgt atgtagaagt	540
gtagggatata ttagattgt	aaatttttat tatttttaag	ggggattttt ttttttaggg	600
tttatttttga aagttttt	aaggataggg gtcgtatgtt	gttagtaatt	660
aaatttttagaa aacgtttt	gagtgaatga tgaaacgata	ggtgaataga tgaacgtaa	720
gtgtcgagtt aattttttt	ttatataagt ttttagtagtt	tttatttttt ttagtcgtat	780
aaatggttt tggaaaggtaa	gttttttagc gagtggagtt	attttaattt atatttttt	840
ggatttttaag ggagtgcgc	gttttgcgtt tattttttt	tttagaaatcg gtaagtttt	900
gattttgcgt tcgttttgcgt	tattttcgt tttttttgt	ttcgttagtcg gcgttttagcg	960
gttttgcgtt ttcgtgtgt	tgtcggttga gtttttattt	atgggtttat cgttgaggtt	1020
cgacgggcgg gttgtattgg	ttatcggcgc gggggtaggt	gagtagtcga aggttggagg	1080
tcgcgtttt tggtaggcg	tagtgggtt ttttttcgg	gtcggatatac gcgctgtatc	1140
gtagttgagg ttatttcgtt	gaggtgggtt ggagggaaat	ggttattttt gaggtatcgt	1200
atttttttgcgtt gaggaaagag	tcggaaatat ttggttttt	aagtaggtat agttcgtttt	1260
tttttagtat ttccgtgtgg	tttttttaag gttttttttt	agaggagagg ttaggttggg	1320
ttgttgattt taaaatttggg	tgaaagttt tttgatttt	tattttgtggg tattcgattgt	1380
tattttttttt gtaatttattt	tttttagatt tttgttttagt	tttttaaagg attgaaaagt	1440
cgcgaggggc gggggtttgg	ttttttttt tgaagcgtat	atcggtttt tttgaaaag	1500
ttattcggtc gtttagtgtt	ttttttttt tgcgtttaa	ttttaagttc gtgagaggt	1560
ttttttttaaa gagggcgttt	gataagagtt tttttcgtt	ggagtttgtt ttttttagtaa	1620
gttataattt gttttcgaaa	tttattttggat tttttgttga	ggtttaagt ttaaatgcgt	1680
atagggggtt ggcgtatgt	ttttttttt ggagaaagaa	aatgggagta ggatgggtt atttgagggaa	1740
ttggagagta gagaatttcg	aatggatcg gtttagtggg	aagtgtttt tatttttagga	1800
gcggtaaaat ggaaaattgt	ttatgtttaat agttttattt	tttaaagtat aaaaaattaa	1860
aataaaattt ttatattat	atagatgtt gtttagtggaa	ttttatattt gttttttttt	1920
agtgggtgtat ttttgcattt	tttaagttgtt gggatttttga	tattatgtat ttttgcattt	1980
ttattttttttt tttttttttt	ttttttttt tttttttttt	ttttttttt tttttttttt	2040
taaacgttat aaatttggat	ttttttttt tttttttttt	ttttttttt tttttttttt	2100
taaagtggtt tttttttttt	ttttttttt tttttttttt	ttttttttt tttttttttt	2160
attttttttttt tttttttttt	ttttttttt tttttttttt	ttttttttt tttttttttt	2220
ttttttttttt tttttttttt	ttttttttt tttttttttt	ttttttttt tttttttttt	2280
attttttttttt tttttttttt	ttttttttt tttttttttt	ttttttttt tttttttttt	2340
gagggtttagg gattatattt	taagacgttt ttgtttagtgc	taaggagatt tttttttttt	2400
ggggtttatat ttggaaaattt	tttaaggata gggattttttt	ttttttttat tatttttttt	2460
ttttatattat gttatgtat	ttttttttt tttttttttt	ttttttttt tttttttttt	2501

<210> 9
<211> 2501
<212> DNA
<213> Artificial Sequence

<220>
<223> chemically treated genomic DNA (Homo sapiens)

<400> 9

<210> 10

<211> 2470

<212> DNA

<213> Artificial Sequence

<220>

<223> chemically treated genomic DNA (Homo sapiens)

<400> 10

aaagatgatt aaaagtttää ttgttattt gaagagtta ttttttatt ttgtataaa	60
agggtatttt tagtagttt tgtttattt gttattcgg tttttttgt ggttgttaa	120
ggttataatt ttgtgtttt agtaaatttg tgtatgtta ttttttttt tgttatttt	180
tttttttttta ttgtttta ttattttgat gtaaaattat ttgttaattt tatttgaat	240
gagaaatttt aaggtttata ttatattaat ttgttagat ttttatttt gttatatggt	300
ttataatgtg ttgggtattt ttagatttgc ttataaaaa gatgtaaaat aaaataatga	360
ttattttgc ggatttttt tttattttg agatgtttt ttgggttgc ttatttttt	420

<210> 11
<211> 2470
<212> DNA
<213> Artificial Sequence

<220>
<223> chemically treated genomic DNA (Homo sapiens)

<400> 11

ataaaaatgg	atataaggag	agtattaaat	gaagatttt	agtttttt	ataggaagat	1080
ggtaaataag	aattattaaat	ataaagtta	attatattt	ttaaaagg	tgattataat	1140
agtttatgtt	atgttatgt	tggtttgg	attgttg	ttaaaattg	ggttaaaa	1200
tatthaaga	gaatggatg	ttttagg	agagattgt	aaagagaa	gaagtagagt	1260
ttggtagtta	ttatgattgg	gaaagaag	gagagataa	gaagatata	aagatagta	1320
ggtaagagga	ttttaggaag	aattatagaa	tgttagg	tatattaaga	ttaattaagt	1380
aagatttagg	agatttat	tttttttta	gtttaggtt	aattattt	gaataaataa	1440
aattttgtt	attnaatta	ttaataagtt	aaaaagtatt	aagtattt	tattnaagta	1500
atatttaat	attnatgtat	taaaaaatg	ttttttaat	atgaaattt	ttatataaaa	1560
taaggttag	aggtttaat	attggtagt	tacgataata	ttggat	gtaattggaa	1620
gattttatta	aaggaaatta	ggggattt	tttagattt	gttagttt	taacggttag	1680
aatttatagt	aaatttggta	taatttaatg	atatttgagg	aggaagggg	gtttttagg	1740
tagggattat	ttataaaaat	tttgggt	aaaaaattg	gttttgg	ttaatttt	1800
gtttgggtat	gattnaattt	ttgtttttt	attnaattt	attnataat	ttgttaatg	1860
atatttataa	tttgttttaa	tataattt	atgtatattt	tttaggattt	taaaaaaagg	1920
tatgttaaaa	ataaaaagtat	tatgttaatg	taagttat	tatgaaaata	tatgttaat	1980
ataattttt	tagtaagata	taggttt	ttatgtttaa	gattttttt	ttgattna	2040
ggtaaggggt	gaagaagtaa	tgttagttaa	ggagatattt	aaaaataaaa	ggaaaaaattt	2100
ataggagtga	ttattat	gtttatatt	ttttaataa	gttaggtt	aatatattt	2160
tatattataa	attatatgtat	agaggtagg	attgtataga	attgtat	tgtgaatttt	2220
aaaattttt	attnaataa	aaattaatag	gtaattttat	attnaataa	taaaataaaa	2280
taagagaaaa	gttagtaata	gagaaaaaaa	tgggtatgt	taagttt	gagatata	2340
agttataatt	ttatataatt	attnaagag	tccgtatgg	aagatgag	gagattgtt	2400
aaagtattt	ttattatagg	attnaaaaaa	ttaattttt	agatgat	ataaattttt	2460
aattatttt						2470

<210> 12

<211> 7001

<212> DNA

<213> Artificial Sequence

<220>

<223> chemically treated genomic DNA (Homo sapiens)

<400> 12

aatgtatgg	aaaaagagag	attgttaa	atgtttagt	aggaattt	ttttgattag	60
gtgttgg	aaaggaaaa	ttagttt	cg aagaagat	tgagattt	atttgggtgg	120
ttggagagat	agtatgtt	gttata	cgggaaagtt	gagagaa	ttatgttt	180
aatgtgtat	ttatattt	ataagtt	aatgtt	agatcgtt	aaaagtgggg	240
ttggagat	attnaacg	ggagtt	tagttaat	ttttttt	ttgagagat	300
tagtaagtt	cgttggaa	gtgtgtt	ataggagag	gtttaggg	gaagttaa	360
gagttggag	ttcgagt	gtttt	ttttaa	aggtagaa	aggaaagt	420
gtatattt	ttatattt	ttat	ttttaat	ttttaa	atgat	480
aagagaatgt	tggagagaaa	gtggtaa	aaattt	ttttaat	tttgggtt	540
tttgattgt	aatgtt	ataattaa	tttgtagg	gatgtt	tttttattt	600
ttttatgtt	aatgtat	aattt	ttttttt	ttttttt	ttttttt	660
ttttttt	ttttttt	aatattt	ttttttt	ttttttt	ttttttt	720
tggttatgt	tgat	gagg	tattt	ttttaat	aaaggta	780
ttaatattt	attatattt	atgtt	ttaatattt	attatgg	gagttttt	840
gtgtttaat	atgtat	tgggg	ttttaat	aaaatata	tttgtat	900
ggtattatta	atatttt	gtt	ttttttt	tattt	tttggttt	960
tataaattt	ttagtaat	tat	ttttttt	ttttttt	ttttttt	1020
gtgatttag	ttat	tttaagg	ttttaat	ttttaat	tttggt	1080
gggtgtat	tgtt	tttt	ttttagt	ttttagt	tttgg	1140
gttagtatta	tggc	aat	ttttagt	ttttagt	tttgg	1200
gttattgg	aatgagag	ttcg	ttttagt	ttttagt	tttgg	1260
attagttaa	aataaagg	ttt	ttttagt	ttttagt	tttgg	1320
tacgtat	ttat	ataga	ttttagt	ttttagt	tttgg	1380
gggtttgtt	aacga	aggat	ttttagt	ttttagt	tttgg	1440
ttaaaatatt	tattna	ttt	ttttagt	ttttagt	tttgg	1500
gtttagagat	tgggg	gtt	ttttagt	ttttagt	tttgg	1560
tttattt	tttattt	ttt	ttttagt	ttttagt	tttgg	1620

atttatataat ttttgattgg tattttatgg tagtcgtaag attatgattt atagtaagg	1680
tgtttttttt tttgtttggg gtggtagtag aaagtatagg gtattttta gtttttaagg	1740
gtaggggtaa aggggttggg gttttttttt ttagtataag ttttttttgg ttgtgtata	1800
ttgttttttg tgagtagata gtaagttttt ttttattttt tattgttatt tatttagcgt	1860
tgtgttagtag ttttagtgcg tgggttcgg gagggttggtaaagttttt gtttattgtt	1920
tgttttcga atttttgtt ttttacgtat aaatatattt atatattttt tttgttttagt	1980
ttatataattt agttattcgt atatgcgagt atatttttt tttttttt attttttcgg	2040
ttttgattt ttataagtt atgaaatattt tttggaaaga cgttttgat ttagtagggt	2100
aggtttgtt tgattttttt tttgttagtt ttagtattttt gagaaggtaa tttatttttt	2160
tggtaggtt ttgtattttt gtagggagat gaggattgtt gttttttatg ggggtatgt	2220
tgtgtttttt ttttttttaa ggattttagt gattttttgtt gttatttgttataatttgg	2280
taggtttata ttttttaaga gttttatgaa gtgttttttg tatgtttttt aaaaaggat	2340
ttgaaaattt aaagtgtat ttatggaaat taaatttattt gtaaaaaattt gttttggaaa	2400
gtaatgattt ttggttataa agggaaatat ttgcgatgtt tttatgtt ttttattttt	2460
ttatttggt ataatttata gttattatgt tttttttttt ttttggttt agttatattt	2520
gtatattgtt taataatggt ttattttgtt aagaatttata gttttttttt ttttggatata	2580
aaatagttaa aaatgttaattt ttttagtaata gtaagttttgg tatttagata gattatgaat	2640
atttcgtagt atattttgtt ggggttttgg gatagtaattt aaaaataagt attgatattt	2700
gtatttaggtt ttatttaggtt gtagtaaagg aagttttttt aaaaatataa attatthaag	2760
attatagacg tatgatataat ttttattttt ttttggttttt ttaatatgttataatata	2820
tatataatata tatataatata tataatgtgtg tttgtatgtg cgtgtgtatg ttttattttt	2880
aatttagttt aaaaattttt ttttattttt ttttattttt gatattttttt ttttggatattt	2940
tagtttaagt gaatcgagaa gatcgatgtt taggattttttt ggtttttttt gtagaaatgt	3000
attttaaaaa tttttaggtt ggatttagatc gataatgtaa ttttattttt ttttggatattt	3060
ttcgtgattt gaggttatgt ttggatgtt aaggatattt ttttattttt ttttggatattt	3120
gttttgggtt tataattttat ttgtggaaagg tatgaatattt tatgtgcgtt ttttattttt	3180
gttttttttga attttttttt atatgagaat ttttattttt ttttggatattt ttttggatattt	3240
ttaatataaa tatataagtt aggtttagag aatttttagaa ggtttggaa ggtttttttt	3300
attttggag ttttggtagt aggaagaaat tgaggttttgg ttttggatattt ttttggatattt	3360
ggtaaaatgt agttttttttt atatgtatattt ttgtttttt ttttggatattt	3420
ttttttgtt gttttttttt ttttattttt ttttattttt ttttggatattt ttttggatattt	3480
cgttatattt attttttttt ttttattttt ttttattttt ttttggatattt ttttggatattt	3540
tatgtatata ttacgtattt ttttattttt ttttattttt ttttggatattt ttttggatattt	3600
aatagagata ttttggatattt ttttattttt ttttggatattt ttttggatattt ttttggatattt	3660
tttttggattt cgtttttcgc gttttttttaa gttttttttt ttttggatattt ttttggatattt	3720
gattttcggtt cgtttttcgtt ttttattttt ttttggatattt ttttggatattt ttttggatattt	3780
aagtaaaatgt aagtttttaggg ttttattttt ttttggatattt ttttggatattt ttttggatattt	3840
gagtgtatgtt taagtttaatg ttttattttt ttttggatattt ttttggatattt ttttggatattt	3900
ttgttaatgtt tatgatgttgc ttttattttt ttttggatattt ttttggatattt ttttggatattt	3960
gttggcggag ggcgttcgtt ttttattttt ttttggatattt ttttggatattt ttttggatattt	4020
cggattcgta ggttttccggg gttttttttt ttttggatattt ttttggatattt ttttggatattt	4080
gttgcgtcgt ttttattttt ttttggatattt ttttggatattt ttttggatattt ttttggatattt	4140
ttttttgtt ttttggatattt ttttggatattt ttttggatattt ttttggatattt ttttggatattt	4200
ttttttatattt ttttggatattt ttttggatattt ttttggatattt ttttggatattt ttttggatattt	4260
agtttttggaa tcgttgcgtt ttttggatattt ttttggatattt ttttggatattt ttttggatattt	4320
tggatgtatgtt taagttcgatc ttttggatattt ttttggatattt ttttggatattt ttttggatattt	4380
tcgcggcgtt cgttaacgcgtt ttttggatattt ttttggatattt ttttggatattt ttttggatattt	4440
tttgagggttgc ggcgttcgtt ttttggatattt ttttggatattt ttttggatattt ttttggatattt	4500
tttcgaggatc gtttgcgtt ttttggatattt ttttggatattt ttttggatattt ttttggatattt	4560
acgggttagtta ggtttttttt ttttggatattt ttttggatattt ttttggatattt ttttggatattt	4620
tcgggttcgtc ggtttttttt ttttggatattt ttttggatattt ttttggatattt ttttggatattt	4680
gttcggtagg agggagggag ttttggatattt ttttggatattt ttttggatattt ttttggatattt	4740
cgcgggacgc gcgattcgatc ttttggatattt ttttggatattt ttttggatattt ttttggatattt	4800
ggttttcggtt gtagttcgatc ttttggatattt ttttggatattt ttttggatattt ttttggatattt	4860
aaacgtatattt ttttggatattt ttttggatattt ttttggatattt ttttggatattt ttttggatattt	4920
ttaataaaat atacgttggatc ttttggatattt ttttggatattt ttttggatattt ttttggatattt	4980
tttaggtaaa taaatacggatc ttttggatattt ttttggatattt ttttggatattt ttttggatattt	5040
aaagttgggg gttttttttt ttttggatattt ttttggatattt ttttggatattt ttttggatattt	5100
ttttgtttaa ttttggatattt ttttggatattt ttttggatattt ttttggatattt ttttggatattt	5160
agttatgtatgtt gggaaaggatc ttttggatattt ttttggatattt ttttggatattt ttttggatattt	5220
tttacgtttt ggggtttttt ttttggatattt ttttggatattt ttttggatattt ttttggatattt	5280
tttgggtttagt tcgcgttggatc ttttggatattt ttttggatattt ttttggatattt ttttggatattt	5340
taggtgtttc gcgagttttaa aataaggatc ttttggatattt ttttggatattt ttttggatattt	5400

ttgttagttt	agtgataagt	ttgttttattt	cggggagaat	gtttcgaggt	ggcgtgcggg	5460
ttagttaggg	tttgcgtttc	gtagttattt	ttgaaggagc	gcggtcggtt	taggatata	5520
gagattattt	tgtgattttt	atggcgaagg	ttgtgtgtt	ttattttaat	ttttttttt	5580
ataagaattt	ttttttttt	ttttttttt	ttttttattt	ttttttgttt	agttttttt	5640
tttgtttttt	gtttttgtt	tttttgcattt	gtttgttagag	ggatttaggtg	ggcgtttttg	5700
gtgaatattt	ttttaggtgg	ttataggata	ggtgtattt	ggatgggtt	ttgaagttt	5760
aggcgttatt	atggttgggt	tttgaattt	gtatttttt	attgtatatt	gttattcgg	5820
ttgggttttt	tatattttt	tgttttgtt	gtcgtggatt	agttttgtt	tagtatttt	5880
tttttaggaa	tatttatagt	agaaggaaagg	ggattaaagt	gtatgtttgt	tttagaggat	5940
attgaagggt	agattttggg	ggtatttt	gtgtattttt	agtcgtttt	gagaattta	6000
gagttatttt	tagttacgtt	gattttttt	gtttttattt	aaaagataaa	taatgaataa	6060
aatttttaaa	ggttggtata	ttttaaattt	attttattt	tttttaattt	gggttaaaat	6120
agagaaaaag	gatttttttt	gttttatttt	ttttttttt	atggaaagaat	aaagtatagc	6180
gattaagttt	aattttatata	aatattttaa	attgtttgtt	gtgaaggaaag	gtattgttat	6240
gatgtgaatt	ttataattttt	atgatggatt	tttagaaattt	ttttttttt	tatttaattt	6300
ttagtttttt	tattgttaat	taatgtttgtt	gaatttttaat	gggttattt	gagattgttt	6360
tttggtagat	tattttattgt	tttgcatttata	attataaaat	gaatttgggtt	aaatataagag	6420
gggatcgat	tttattttaa	attgtttattt	atttttagtga	taagtggat	tagtgcata	6480
tgttttattt	tatatttttt	gtatttatatg	atattttaaat	atttttagaa	taataaaaaaa	6540
agagataagg	aattttaaaaaa	ttaaaaaaaa	aattttgtata	aatggggattt	tgtgtgaaa	6600
tttagttttt	gaatgtttt	tttgcattttt	tatttttcgg	attatttttt	ttttttgttt	6660
agaattttgt	ttgttatttt	tttagtgcatt	aaagaagttat	ttatgtatgt	ttttttatatg	6720
gatagatatt	atttagtatt	ttttttttt	tagttttttt	gtttaaatgt	ttttgggtat	6780
aaagggaaagg	attgattggg	tttttttagg	aaatttttaag	tttttttaatgt	agtttttaaa	6840
agttttgggg	ttgaaagtt	ttgtttttaa	ttgtttgtt	tgattttagag	gtttatgaaat	6900
ttagtttagt	gagtttagaa	tatattttaa	aaggattttaa	atggaaaggg	atataataga	6960
aaatatttata	gtgtatggta	tttcgttattt	ataagttttt	t		7001

<210> 13

<211> 7001

<212> DNA

<213> Artificial Sequence

<220>

<223> chemically treated genomic DNA (Homo sapiens)

<400> 13

ataaaaatcta	tttttacgaa	atattatgt	ttttgatatt	tttttattata	ttttttttta	60
tttttagttt	tttaaaaaat	attttagatt	tattaaattg	agtttatgt	tttttggtt	120
atgataagta	gttgaaaat	attgttttta	gtttaaaat	tttgagaat	tatthaagaa	180
atttaaagtt	ttttaaaaaga	gtttaattaa	ttttttttt	tatatttata	gttatttaag	240
tagaaaaatt	gagaggggaa	aaatattaaa	taatatttgt	ttatatgaag	aatttgtata	300
gatgttttt	ttttttgtt	gataataata	ggtagaattt	taataaaaga	ggaaagataa	360
ttcgggaaat	aaaatatagg	aaaattatt	ttaaaatttga	attttataat	agagtttat	420
tttgttaagt	tttttttttta	attttaagt	tttttgtttt	tttttttatt	attttaagag	480
tggttgaata	ttatgtat	tagaaagtgt	aagataggt	atattatatt	gatattattt	540
attattggta	tgtgaataaa	ttttgaataa	gatgcgattt	tttttgtatt	tgatttagtt	600
tattttgtaa	ttttagttaa	ggtagtaaat	aatttattaa	ggagtagttt	tattagtt	660
tattgaaatt	tagtagtatt	aatttgtat	aaaagaattt	aaaattaaat	agggaagaaaa	720
atggttttt	gagtttatta	taagggtat	gaatttataat	tatattatgt	ttttttttta	780
tattaagtag	ttttaaatgt	tgtgtggat	tagatttaat	cgttgtattt	tgtttttta	840
tttaaaaaaaa	aaaaggtggg	tagaagaaaat	ttttttttt	tgttttaatt	ttaaattaaa	900
ataagtaaaa	ttaatttga	atatgttaat	ttttaaaagt	tttgtttatt	gttgttttt	960
tgagtaaaga	tagtttggat	ttgcgtggtt	gtgggatgtt	ttaaattttt	ttaaggcggt	1020
tgaagatgt	tattgaat	ttttagaatt	tgttttttag	tattttttgg	ggttaaattt	1080
tattttagtt	ttttttttt	tgttataat	attttggaa	atagaatatt	gaataaaaat	1140
tggtttacgg	tttataagg	agaaagat	aggatattt	gttcggat	tagtgtat	1200
ttgggaaaatg	ttaattttag	gatttagtt	tgtggcgtt	tgaagtttt	aaatttagt	1260
cggggtat	ttgttttgt	gttatttagg	aaggtgttta	ttagaagcgt	ttatthaatt	1320
ttttttagg	tttatttagg	aaataaaaaa	taaaaaataa	aaggagaaaat	tggtaagag	1380
aaaatgggag	ggagaggaga	gggagaaaaga	ataattttt	tagggaaaaaa	aattaaaatg	1440
aggatataata	atttcgtt	ttgaagttat	aaagtggttt	tttgtgttt	ggatcggtcg	1500

cgaaaaaaaaaaaaat	ataggggttgcg	cgaggcgtag	attttgggttgcg	attcgta	ttttcgaaaa	1560
tat	gggtgggata	gggtgttat	tgggtggta	ggagattt	ttaagtatt	1620
tgtgttttta	tatggttgt	tttaaaatcg	cgggatattt	ataaatttc	ggttggtaga	1680
agttatatgt	tagtaattcg	tttagcgcg	gatttagtt	gttaatttcg	aaatttagatt	1740
tat	tttaatcg	tttaaaagttt	taggacgtgg	ggtggggagg	agggaaagc	1800
gggtgatagg	aatcg	tttaaaagttt	ttttagatgt	tgatataat	ttaattaaat	1860
agtttagatg	aaagaaatt	tggggagat	attaaataaa	aatattaaaa	ggataaataa	1920
aattttgtt	agttttgtt	at	ttttaattt	taaatgtt	gagcgagatt	1980
ttttaagtg	at	ttttaaaagcg	tttgcgtt	attttttgg	agggtttttt	2040
aattttgtt	ttgttgg	ttttaacgt	tgtttgtt	ggaagtcgg	gttttgcgg	2100
ttgtttttcg	tacggacgg	aagtgggtgg	agagtacgtt	tttttagtt	gttcggcgg	2160
agaatttgat	tttgaacgta	gocgggttgc	tacgtagaat	tttcgggttgc	ggtcgcgcgt	2220
ttcgggtttt	ttgcgcgtat	tttgcgggtcg	cgcgttgc	ggttttgcgt	gttttttagg	2280
ttttttttt	ttttttttt	ttttgtcggg	cgcggcggtt	atttcgacgg	2340	
gcggcgcggg	cgcgggtatt	tgtagaatgt	cggcggtcg	gtttcgcgt	tctgttagtc	2400
gttgggttcg	tttttaggt	at	ttttttttt	ttttttttt	ttttttttt	2460
tagtgcggc	ggcgggtgt	gtatattag	cgggttcg	gatacgtt	tgagtgggg	2520
gaaatttttt	aggtcggttgg	agtcgaacgt	cgtattttta	gattcgggtt	cgtaggggag	2580
gtcgggttga	tcgttagattt	gocgcgttgc	ggcgggtcg	gcgttgaatt	cgtaggcggc	2640
tttttcgggg	tagtgtata	cgcggtttt	gttgggtt	agttatattt	cgttttaggg	2700
tcgttttagg	gggattttga	gttgcggacg	gtttaggggt	tttagttcgt	ttttttttt	2760
ttgatgtagt	agggttattt	tagatgtttt	ggtgtggagg	ttatgggtt	ttgttgcgtt	2820
tcgcgggtag	ggttagatc	gtgttttgc	aggtagaaag	ttttagaaat	cgcggttta	2880
tttggaaaaaa	gagtatagt	cgaggtt	ggcgcacgt	cgtatgtt	gtcgat	2940
gagtttttgt	ttcggtttt	tttgcggagt	tttgcgggtt	gttgaagt	ggcgattcga	3000
cgggagtaag	tgtattttta	ggacgaacgt	tttgcgtt	ttttttttt	ttcggtttt	3060
taatttttaag	tattggttt	tcgagttat	atgtattata	aagggttgg	aggacggta	3120
gggatttgtt	ttttttttt	atattggttt	aaatattatt	tttagtataa	ttcgattttt	3180
agcgatttttta	aagtagtagt	tttttgaatt	ttat	tgtcgtcgtt	tttggataga	3240
gtttagttagt	tacgtttagg	gggcgggggc	gtacgaggat	ttgtttaaagg	ttgtttaggg	3300
aagattgggt	ttaaaataaa	cgcgaaagac	ggatttaggg	gtcggtttt	tttaatgtgt	3360
tgtttttagt	gtttcgtt	agatttcgt	atattttgt	ttttttttt	ttttttttt	3420
ttttttttt	tcgttggta	gaaatacgt	gtgtgtat	aggatgattt	ttttttttt	3480
tatattgtaa	tcgagatagg	gttagatagaa	ttgggtgtgc	gttgtatac	gttagttttt	3540
atagatagt	atatttagt	ggagatggaa	tttgcgtt	tttgcgtt	tttgcgtt	3600
ggagatttag	ggtatata	tttgcgtt	tttgcgtt	tttgcgtt	tttgcgtt	3660
tttaggattt	agttttttt	tttgcgtt	tttgcgtt	tttgcgtt	tttgcgtt	3720
tttttgagat	tttttttagt	tgat	ttttttttt	ttttttttt	ttttttttt	3780
tttttattag	aattttttagt	tgaaggat	tttgcgtt	tttgcgtt	tttgcgtt	3840
gggtgtttat	gttttttata	gggtgtt	gtat	tttgcgtt	tttgcgtt	3900
aatgtgattt	ttttatattt	aatataattt	taggtacga	attaaagttt	ttgttattat	3960
gttatattgt	cggttgg	tgat	ttttttttt	ttttttttt	ttttttttt	4020
tttttagttt	ataattcgat	tttttgcgtt	ttttttttt	ttttttttt	ttttttttt	4080
tttagatgaa	aaataaata	aaaaaagt	ttaattgt	taaaagttt	atatgtatac	4140
gtatataat	atataatata	atgtgtat	atataatata	atataatata	atataatata	4200
aggagataaa	aaatagggt	agtatattt	gcgttataa	ttttttttt	ttttttttt	4260
tgaataaaatt	ttttttgtt	tagttaata	gatttgtata	taatttataa	ttttttttt	4320
taattgtt	tttaaaatatt	taat	tttgacgaa	tgtttatgtt	ttttttttt	4380
gttaagttt	ttgttattaa	gagttat	tttgattt	tttattttt	tttattttt	4440
at	tataaaaata	gattttgtt	ggataat	taatgtgt	tgaagttt	4500
atcgagttt	gtat	ttttagattt	ttttagattt	ttttagattt	ttttagattt	4560
gtgtatcgta	gat	ttttagttt	ttttagttt	ttttagttt	ttttagttt	4620
tagatgattt	aatttttata	aatttattt	ttttagttt	ttttagttt	ttttagttt	4680
gtaaaagta	tttttaggg	ttttttttt	ttttttttt	ttttttttt	ttttttttt	4740
tataaaagaat	tttataagtt	ttgaaagaaa	aaggagat	atataatattt	ttatggagaa	4800
tagtaatttt	tat	ttttttttt	ttttttttt	ttttttttt	ttttttttt	4860
taaaatgtt	aagttataga	gagagaaatt	aaaataagtt	ttttttttt	ttttttttt	4920
gttttttag	aaatgttttta	ttttttttt	ttttttttt	ttttttttt	ttttttttt	4980
ggaaggaat	tgttcgtat	tgccgtt	ttttttttt	ttttttttt	ttttttttt	5040
tggatgttt	tgtgcgtt	atggtaggg	ttcgggaaagt	agtttagt	taggttattt	5100
ggttagtttt	ttcggtagat	acgtatgtt	gttattgtat	agcgttggat	gaatgtttagt	5160
ggggaggtgag	gggagattt	ttgtttttt	atagggagta	gtgtggtata	tttagagaaa	5220
tttgcgtt	ggaggagaaa	ttttttttt	ttttttttt	ttttttttt	ttttttttt	5280

ttttatgttt tttgttgtaa ttttaagtaa gagaaaaat aggttggta gtaattata	5340
tttacggtt aaaatagaat gttagttaa agtgtatgg tattaagttt ataaaata	5400
atatgggtgg tttttcgaa agaatataat ttaataataa aagtttttgg gatataatgt	5460
ggattaaatg ttttattgtt ttttagtttt agttttigaa tagaggtatt gttatgttt	5520
cgattgtatt agggaaattag attttggaaat aaatgtttt gtatttttagg gatgtgttt	5580
tagttgaat gtaatatttt tttatttcgt taattaaatt tataaatttt tttatgaata	5640
gttttagtta ttgtttttttaaataatgtg aaaaatacgt attataaaaa gtttaggata	5700
tgaatataag ataaaggtag atattttgtt tttaaattga ttttaggttt tcgagttgt	5760
ttgatcgta ttggaaacga ggtttttat ttttagtgg cgtttatatg gatttatttt	5820
ttgatattt ttttaattat ttttcgggtt atagtattaa tacgtatata tgaggtgtt	5880
tttagagtgtt tacgtttagg gtttaggat atatgtatatt taatggaggt tttgtgtt	5940
gatattagtt attatttgg atattaaatg attttaatta taatgttagg agtggcgt	6000
ttttggttt gggatattat gtagttttg agagatttt gtaggtttt tgagattagt	6060
ataaaaaaaga aatagaaagt tataaaaatg ttaatgtatgt tattatgtaa atatgttt	6120
ttgtgtttt aaaaaattttt agtattgttag tttttgagta taggaggtt ttttttata	6180
tttagtattga aaataaaatat tggatataaa taaatatgtaa aagaaagat ttttatttt	6240
tgttggtgat agtgggtttt ttttaggtt aataatggttt attatgttt tagattagt	6300
ttagaaaaaaa gtaagagtat ttagggaggg aggagagagg aatagggaa aggagaagga	6360
aaggaaaggg gatttgaat tttttattat ttagatata gaaataagaa gtttagttt	6420
ttttttagt gttttagttt ttttagagatt tataattaa gttagttaa gaagtttagt	6480
aaaggttagt ttttaattttt tttttttt agtattttt tttaaattta ttttggtag	6540
ttttgtttt gggtttgggtt agtattgggtt gggaaagtata tttgttacg tcgattttt	6600
ttttttgtt ttgttaaaaaa ttttattcgg ttttttagt tttttgggtt tttttttat	6660
ttttttttgt tggatataat cgttttagtc gtgattttt gttttttta ggtgaagaag	6720
ggtaaagatt gatttggttt ttgcgttgaat ttttttttta gttttttttt ttttagcgtt	6780
tgttgggtat tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	6840
taatttttc gtgtttgtt ttagtattat tttttttttt gttattttaga taaaattttt	6900
attttttttt tcgagggttg atttttttttt gttttttata ttttaattaa aggttattttt	6960
taagttttttt agtttataaa tttttttttt ttattgtat t	7001

<210> 14

<211> 11001

<212> DNA

<213> Artificial Sequence

<220>

<223> chemically treated genomic DNA (Homo sapiens)

<400> 14

ttaagttaga tttttttaa ttatgttgg ataggttagg tataatttga gtttaatttt	60
attttatagg ttttaatattt tggagttaga aagtttttag gtaaaaaagtt tgaagggggt	120
ttttttatgt tattagatgg atttttgtat ttttagaaga ttttttatat taggaaagat	180
taaagtatta aggttatttt tttttttttt ttgggataat ttttagtttt ggtatgtgt	240
gtttggaaat tttttttttt tttataatgt ttagatattt ttggattttt tttgttaggt	300
ttgtttttta gtataatttt ttttttaatgt ttattgttag ttagatttta ttagttttgt	360
ttagtgataa ttaagaaattt aagaattatg ttttacgtt tttttttta gttttttt	420
tttttaggat aaagtttagg tttttttat tgggttttgg taggagtcgt agtcgttaggg	480
gttggttattt atttaatgtt tttcgtaatgt atattgtaa ggggaagtaa tgattagaga	540
tagggtttagt tttttttttt ttgtatgttt aggtgtatgc gtatataattt ttatataagg	600
taggggtgggg tggaaagttt attttggtcg ttagcttttag cgcgtttaaa ggtgttaat	660
ttgcgggggt tatttattat taagaatttt cgtatgtagg ttttaatgtat tttacgttt	720
tttgcgttgc atagtatatg taggtttttt atagtatttt tgggttagta aagggaaatgt	780
cggcgttta tatttgcgtt tgcgttttttgg tttcgctggg tattttgtaa ggagggtgtt	840
ttttttgtgg agggatata gataggcgtt attagttta gttgaattttt gatgaagttt	900
gtgtaaagat cgtttttgtt ttaaagaaat agagaaatata aattttgtata atagttttt	960
ggtgagatgt tagttttttt ggggttagt tgggtatgtta taaattttt gttgcgttta	1020
ttaagataa ttttagtigt gatttttttga gtattgtta ttagttttttt tttttttttt	1080
tttttacgtt ttttttttga gtagttattt tattttgtttt atgaagaggt tttttttttt	1140
ttgggttattt tttttttttt gttttttttt aattttgtt ttaggtttttt taggtttttt	1200
ttattttata ggttcgtttt gtaagatggg ttagtattgg tttttttttt tttttttttt	1260
tagggttttt ttgaaaaatg gttttttttt tagttttttt gttttttttt aaattttttt	1320
tttgcgtttt atgtatataat tttttttttt tttttttttt gttttttttt tttttttttt	1380

ttttgtatgt	tttgggtgga	taaggaaag	atagaattat	ttggttttt	ttgtgttt	1440
gtttagggtt	tttagtattga	atgtagttt	aaggatatta	tagaagttagg	ggtaattgaa	1500
ggtatatgtt	taggggttag	gaatagttga	gggatttga	agagggattt	ttattnaaag	1560
taaaattagg	ttgggtgtgg	tggtttatat	ttgtatattt	agtattttgg	gagggttaagg	1620
taggaggatt	atttgatttt	taggagttt	agattagttt	ggtaatata	gtaagatttt	1680
attttattta	aaaaaaagaaa	aaaaaaaatt	agtaggtgt	ggtgggtgt	ttgttagttt	1740
aattgtttag	gaggttgagg	tgggaggatc	gttgagttc	gggagattgt	agttatagta	1800
agttatttac	gtgttattgt	attttagttt	gggaaattga	gtgagatttt	gttttaaaat	1860
ataaaaaata	aaaataggtt	gggtacgtt	gttacgttt	gtaatttttag	tattnngga	1920
ggtcgaggcg	ggtggattat	ttgaggttag	gagtttggaa	ttagtttgat	taatatggag	1980
aaatttcggt	tttattaaaa	atataaaatt	agtaggcgt	ggtggtatat	gtttgttaatt	2040
ttagtttattt	aggaggttga	gttaggagaa	ttgtttaaat	tcgggagggt	gagggtttag	2100
tgaatttgaga	tcgtttagtc	gtattnattt	ttggtaata	agagcgaaat	tcggtttaa	2160
aaaaaaaaaa	aatttagtaaa	attatatttt	aattgtatat	tttgattata	gtattnattt	2220
tgagttggag	tgagggtttt	ttttggagaa	ggtagttat	ttttttttt	tgttcggta	2280
cggggttatg	atttattgtt	gggtgagagg	agtggagagt	ggtgtatatt	agtagtttag	2340
ttatttagtgg	atagagtagt	atttggagtt	agttttttat	gttttatata	tagtgagaaa	2400
aattatttgc	atatgtatgtt	taattttat	ttagttgtt	taaaaggttag	tttttaggtt	2460
gttttaattt	tgttagaggt	atataggtag	ttttttgtt	ggttttgtt	tttggtttgc	2520
ttgtttggag	atttggtttta	aagattttt	tttttttga	gacgaagttt	tattnngtgc	2580
tttaggttgt	agtgtatgtgg	ttggattttt	gttattgtt	agttttgtt	tttgggttta	2640
agcgattttt	ttgtttttaga	tttgcagata	gttgggattt	taggcgcgt	ttataataat	2700
attcggttaa	tttttgtatt	tttagtagag	atgggatttt	attatattgg	ttaggttgc	2760
tttgaattttt	tgatttttaag	tgattcgttt	gttttttattt	tttaaagtgt	tgggattata	2820
ggcgtgaatt	atcgattttcg	attnagat	tttaatttgc	attattttt	ttttattttt	2880
tttagggatt	ggatttttgc	cggaagggtt	gagtgtggga	taggttagtt	agggttttga	2940
atcgattttt	ttttttttaga	tttttttgc	tttattgtat	tagtttattt	tttggtttgc	3000
tttagataagg	tttttagttag	aatcgagatc	ttatagatat	agttatgtt	agcgttgcatt	3060
aatattttgt	ttttagaaagaa	tttttataag	gttttttgc	gaatgatttt	gtgttttagt	3120
taggagagg	agggtttttt	ttgatttcgt	tttggagttt	tttaaagtat	ttaaattatt	3180
tgatggggat	aaatggagag	gatagatgag	ggagtagggt	ggagcgtttt	agtagaaatgt	3240
tttttattta	gaattcggtt	ttattttgtt	gttagtaagg	atgtgggtt	aagaattaag	3300
tttaggggtt	tataggaaaa	agttaaaggg	ggaggggtgg	gaatttaagt	ttattnittt	3360
tttaaagtat	ttaaagggttt	tttggatgga	gaagagtatt	ggagtaaaaa	tttttagata	3420
aattttattt	gggatagtgg	gtattttgc	cggtttagta	aaaataaatg	gtgtgggtt	3480
tggaaaatga	gggttggagg	ttgtgaataa	agtagtggat	gtgtttgtt	agtatattaa	3540
cgggaagaag	tatttagatg	ggaggagtat	tagggtagg	agaaatgtt	gatagatttt	3600
agtgttaggg	taagaaggaa	gattattttt	ttttagaaat	aggagggtt	taggtatgtt	3660
gttaattttgt	ttttgtatgt	gttttgagtt	tttattttat	aatgagaaag	tttggttttt	3720
ttttttttt	tggatgattt	aggattttgc	gttggggatg	tagtattttt	atttttagtt	3780
ttttttttt	tggatgatgaa	ttttttattt	tttatttata	aaatagattt	ggatttagagg	3840
tattgtatag	tttttttagg	attttaaagg	aggaaagagt	ttttttttt	tttttaaagt	3900
tgtttttttt	aagaggattt	taatagttat	tttagtcgg	tgtatagtag	gattatggaa	3960
ttttttttt	gtattatagg	gattttattt	ttattnattt	attgttata	aaaatttgat	4020
gtttttttt	tgagatagag	tttcgtttt	tttttaggtt	tggagttgt	ttgtgcgtt	4080
ttggttttt	gtattttttgc	ttttttgggt	ttaagtaatt	ttttttttt	tttttttaag	4140
tagtgggtt	tatagggtttt	tgttattata	attggtttaat	ttttttgtatt	tttagtcgag	4200
acggggtttt	attattttgg	ttaggttgcgt	tttgcatttt	tgattttat	tttattttat	4260
ttcggttttt	taaagtgttgc	ggattaaagg	tgtgagttat	tgtattttgt	ttaaaatttga	4320
tgtttttttt	ttttttttta	atataataat	tggattttt	tagttttta	tttttttttt	4380
ttttttttt	ttttttttga	gatagagttt	tgtttttta	tttaggttgg	aatgtatgtt	4440
tttagtttgc	atttattgtt	attttttttgc	tttgggttta	agtatatttt	ttgttttagt	4500
ttttttttt	tttgggatata	taggtatata	ttattnatgtt	tagataattt	ttttgtattt	4560
ttagtataga	cggggtttttgc	ttatgttgcgt	tttggtagttt	tcgaattttt	gttttttaagt	4620
gatttttttgc	tttttttttttgc	ttaaaatgtt	gagattatag	gtatgatgtt	ttaagtttag	4680
ttttttttt	tttttttttttgc	atagagttttt	attttgttat	ttaggttgg	gtgttagtgc	4740
acgatttttgc	tttattgttgc	tttttttttttgc	tcggttgcgt	tgatttagtt	tttttaagtat	4800
ttgggattat	agttatataat	tattatgttgc	ggttaatttttgc	tgtatgtttt	gttagagatag	4860
ggtttttattt	tgttttttttgc	gttgcatttttgc	aatttttgcatt	tgtaaatgtt	ttattngttt	4920
tggttttttt	aagtatttgc	atagagtttttgc	tggttttttttgc	tggttttttttgc	tttttttttttgc	4980
ttttgagata	gagtttttttgc	ttgttatttttgc	ggttggagtttgc	tagtgcgttgc	atttttttttttgc	5040
attgtatattt	ttgttttttttgc	ggtttaagtgc	attttttttttgc	tttatttttttgc	taagtagtttgc	5100
ggattatagg	tgtgtatttttgc	cgtggtttagt	tttttttttttgc	aattggttag	tttttttttttgc	5160

tttttttatt tttttatagt ggaaaatgg ttaggattga ttgatatgaa gataagttt 5220
ggggtttata ttttaattttaa tttttgtatt taagtttgg gttaagattt tggcggttg 5280
agtatttattt attttgtaa gaattttgtaa aaattttattt tgaagtatta ttataattt 5340
tattttttt atttaaataaa ggattttcg tttatttttt ttaggtatat tgagttttat 5400
agttttgtt tttttttttt ggtgtttagg tttgggtttt tgagtttggt gtttatattt 5460
atggtatttg gtatatagtt ttgcataat gggatattt aggaggttc gagatattt 5520
atagtttgg gtttagtaattt tggattttt tttttatattt ttaggtatt ttataattt 5580
gtttttttt tttttgtggg taaagtgttt ttgaatgttt atggttaaa ataagattt 5640
tttttttattt attttaaat ttttttttag atttattttt gaggaggaa atagaattt 5700
ttatattttt gtatgtggg ataggttga atagggaa ggtgagggt tagtgggtt 5760
tatataaggag tgttagatggg ggagtaggt tttttttgtt ttttaagtt ttttaaataa 5820
tattttttaa ttttggcga gaggagtag gagtattcgaa acgcggaaat cgagggtta gtttaatttgcgt 5880
tttagttata gttggataat ttccgggtta gtttattat aagttatata gttgtttttt 6000
tcgtgtttaa tttgtttgtg atagaaatta aggggtttc ggtatttagt atttaggcgg 6060
tggaatcggtt gtttacgta cggtttcg ggttaggttt cggtaggtat tcgcggggag 6120
ttacgttagtt aggagggtgg ggtgtttat cgatttagga cgcggtaacg gatcgggggag 6180
ggcggaggtt tagcgatcg ttttttttc gttcgtcggtt atttttgtt ttttattttgg 6240
ttcggcgcg gtttgcgagt tagcgagggtt cgcgcgggtga agtattgtt gatgttgcag 6300
ttcaggtttt tttgggtgtaa ttagtgcgtt ttcgtcggtt ttttagttt ggcgcgttcgt 6360
gaaggcggtt tcgtttcggtt agtgcgttacg cgtgttagt tgccgtgcgt 6420
agtgcgttaat ttcgtttcg gtcgcgtgcg tgcgtgtacg cgtgttagt tgccgtgcgt 6480
ttcgggttag agtgcgcgtc gtaatcgtaa gattgaaacg tagatcgacg gatgttgcgt 6540
tttgggtttt tttgggttagga acgtcggggc ggggatacgt acgttgcgtt ttaggaatg 6600
atttatctgt ttcggagttt tatttataaa ttttattttat tataaggaaac gggggcggtt 6660
gttagcggttcc gggtaagcggtt ataagagtgg ttttgggtcg gaggcgaggg cgggaaggtg 6720
cgggaagtcg cgcgtgcgcgg agtttgggtt agtttgggtt cgggtcgtt tgtagcggtt 6780
ggagttttt cggagtcgtt aatttaggtt ttttttttag tttcgcgtt gatttagttt 6840
ttttgtgtcg tcgggaaatc ggttaatttga acgttttttgcg cgcgcgtat ttaggttagt 6900
ttcgagaatg tttgtattgt gtttgggtta ttttcgtttt ttttatacg ttcgggtttc 6960
gcgtttattt cgttcgtttc tgcgttgcgtt ggggtttt agtttaggtt tcgggttcg 7020
taatagttaa ggtagacgag cgcgcgttag cgttagtggt aggtgaattt gtaatttgcgt 7080
gagaggtttt gccgtgaggc ggaggagttt tagtgcggg aaatgttgcg gatgttgcag 7140
ggaagttttt gggagagggtt ggttatttttatttttgcgtt taggttttcgtt aggttcgatt tatttttagt 7200
ggttatttttatttttgcgtt cggattttaa ttttgcgtt ttttgcgtt gaaatcggtt 7260
cggaagggtt tagtagaga gtttgggtta atagttggat tttatcggtt tagtataaa 7320
ttttttttt ttttattttgtt aattaaaaaa ataataataaa aaaatcggtt tttgtttttt 7380
ttatttttagt tggagtgtaa tggcgcgatt tcggtttac gtaatttgcgtt tttttttgggt 7440
ttaagcgatt tttttgtttt agtttttgcgtt gtttttttgcgtt ttaggttgcgt ttaggttgcgt 7500
gtttagttaa tttttgtattt ttttagtagag acgggtttt attatgttagt ttaggttgcgt 7560
ttttaaattttt ttttttttttgcgtt tgatttattt gtttgcgtt ttttgcgtt ttttgcgtt 7620
ggtttgagtt atcgatattcg ttttttttttgcgtt gtttttttgcgtt gtttttttgcgtt 7680
tatttttttttgcgtt ttttttttttgcgtt ttttttttttgcgtt ttttttttttgcgtt 7740
tttatttttttgcgtt ttttttttttgcgtt ttttttttttgcgtt ttttttttttgcgtt 7800
tttttttttgcgtt ttttttttttgcgtt ttttttttttgcgtt ttttttttttgcgtt 7860
tttagcgatt ttttttttttgcgtt ttttttttttgcgtt ttttttttttgcgtt ttttttttttgcgtt 7920
tagtattttt ttttttttttgcgtt ttttttttttgcgtt ttttttttttgcgtt ttttttttttgcgtt 7980
tttatttttttgcgtt ttttttttttgcgtt ttttttttttgcgtt ttttttttttgcgtt 8040
acgatgaagt ttttttttttgcgtt ttttttttttgcgtt ttttttttttgcgtt ttttttttttgcgtt 8100
agatttacgg ttgaaatattt ttttttttttgcgtt ttttttttttgcgtt ttttttttttgcgtt 8160
tatttaggtt ttttttttttgcgtt ttttttttttgcgtt ttttttttttgcgtt ttttttttttgcgtt 8220
tagttttttt ttttttttttgcgtt ttttttttttgcgtt ttttttttttgcgtt ttttttttttgcgtt 8280
tagttttttt ttttttttttgcgtt ttttttttttgcgtt ttttttttttgcgtt ttttttttttgcgtt 8340
taaatatgtt ttttttttttgcgtt ttttttttttgcgtt ttttttttttgcgtt ttttttttttgcgtt 8400
cgttgcgtt ttttttttttgcgtt ttttttttttgcgtt ttttttttttgcgtt ttttttttttgcgtt 8460
attttgcgtt ttttttttttgcgtt ttttttttttgcgtt ttttttttttgcgtt ttttttttttgcgtt 8520
attttgcgtt ttttttttttgcgtt ttttttttttgcgtt ttttttttttgcgtt ttttttttttgcgtt 8580
tattttgcgtt ttttttttttgcgtt ttttttttttgcgtt ttttttttttgcgtt ttttttttttgcgtt 8640
tagttttttt ttttttttttgcgtt ttttttttttgcgtt ttttttttttgcgtt ttttttttttgcgtt 8700
gggattatag gtatgagttt ttttttttttgcgtt ttttttttttgcgtt ttttttttttgcgtt 8760
attttgcgtt ttttttttttgcgtt ttttttttttgcgtt ttttttttttgcgtt ttttttttttgcgtt 8820
atgtatataat agatggaa ttttttttttgcgtt ttttttttttgcgtt ttttttttttgcgtt 8880
atgtttaattt tagattttat ttttttttttgcgtt ttttttttttgcgtt ttttttttttgcgtt 8940

<210> 15
<211> 11001
<212> DNA

<213> Artificial Sequence

<220>

<223> chemically treated genomic DNA (Homo sapiens)

<400> 15

ttttagattt	tagaaattt	ggagcggtt	gagcgagaaa	atagaggtaa	gtggtaggt	60
attgttaagt	attagttta	gtatgttt	agtttttt	agtaggattt	gcgggttag	120
gcgcgaaggt	aaggttt	gaaatggtag	ggagggtt	ggggatgtag	gaggtatgga	180
tgtgggtgg	gtgtttt	tttttagggt	tagtttagatt	ttttgattt	tttttaggt	240
gggtttagat	ttataggtt	gatgtgtt	aggtagtgg	tttagacgg	ttcgttgg	300
tttattttag	tgttagaggtt	tttaagcgtt	tttacgtat	ttagaatgag	ttgttattgtt	360
gttaggtgagg	gtatttt	attttggatt	tttaagttt	attttata	tttttatatg	420
tattgttatt	tttaatattt	atttgtt	agggagtgtt	aagttaa	ttgggaaaag	480
tatggaaaga	tttgtt	ggtagtt	ggtgatagag	ttaaatgagg	tttgtatgt	540
ttgagggtcg	attattt	ttaagggat	ttaatttagaa	tgtatttt	aattttaaga	600
ttacggttt	gttttgcg	gagttt	ttcgtatgt	gagagt	cgggcgtt	660
agttgttgat	cgattttt	tttttatt	ttaagtgaag	ttcgcagatt	ttttgtttt	720
tttagtgggt	aggtaagt	tgttgtt	gtaaatcgga	tttaggagg	tagggtcg	780
tgtggggatt	ttttttt	agtatagtaa	agttggttt	tagaaatacg	ggtattt	840
cgtgggttt	tgcggtcgtc	gtcgttgtt	tcgttccggg	tgggtgtga	ggaggggacg	900
aaggaggaa	ggaagggtt	ggcgggggg	ttttgcgag	agcgcgtt	gttcgttt	960
cgggtttat	agttttgtt	tttaggttt	tattgcgcgg	ttttttt	tttttttcg	1020

tcgttttagtt tgatgtttgg gggaggcggtt gaagtcgggg ttcgttttgtt ggtttcgttc 1080
ggttcgcgtt tggtagcggtt taaaggtagc gaagtcggg ttatgcggg ttatgcggg 1140
ggagtttgag ttatgttgcgtt tgccggaggtt ggtattcgtt gggcgcggtt ggaagggtcg 1200
tattcgttgcgtt gacgttgcgtt acgttgcgtt tattcgttgcgtt ggtatcgtt gtaattttat 1260
acggtagttt gtttttggcgtt gtgggtatcg ttttagtgcgtt gcccgggtcg ttacgtatac 1320
gtgggtcgat ttttggcgtt attttatcg gggcggtcg cgtaaagggtt tggtagcg 1380
gcgtgagtag tgggttgcgtt cggttacgtt acgttgcgtt ggtatcgtt ggtatcgtt 1440
tgcgttgcgtt ttaagtcgtt gtagaggggg tcggcgggg tagtttgcgtt ggtatcgtt 1500
cgtttattttc gttttatcggtt tgaagactgcgtt gcgaaatgg ttatgttgcgtt gtcgttgcgtt 1560
attcgttattt gggttataga tgatgttgcgtt tttttttttt gtcgttgcgtt 1620
ttaagttttt tattttttaaa atgttttgcgtt ttttttgcgtt aaagggttgcgtt 1680
tttcggagtt tattttttttaaa ggtttttttt tttttttttt tttttttttt tttttttttt 1740
tttttaggggtt aagggttgcgtt attttttatcg ggggggggtt tggaaaaattt tagaattttt 1800
ggtgggtttt ttgttaagtagt ggggggggtt ggggggggtt ttagttaatataa tttttttttt 1860
atttagtggaa ttagatgttgcgtt aaatatgttgcgtt gtagttatattt attttagtgcgtt 1920
ttttggaaat cgtagtgcgtt taaagggttgcgtt tttttttttt gtagatattt gttggaaat 1980
tttaggggtt tttttagtgcgtt ttttttgcgtt gttttttttt tttttttttt tttttttttt 2040
aattgttgggg agtggatattt aggtatttgcgtt aaatttttaaa aattttttaaa attttttttaa 2100
tatggagttt ggggttgcgtt ttattttttt gttttttttt ggaattttgcgtt gatggatattt 2160
gttttaggtt tggtagtgcgtt tggagatattt tttttttttt gttttttttt gttttttttt 2220
tagttgggggg ggggttgcgtt ttgttgcgtt gttttttttt gttttttttt gttttttttt 2280
gtgggttgcgtt ttgttgcgtt tagttttgcgtt gaaaggcggtt gcccgggtt gttttttttt 2340
taggagttttaa agattttttt ggtttttttt gttttttttt gttttttttt gttttttttt 2400
aaaaatgttgcgtt taggtttttt ggggggggtt tttttttttt gttttttttt gttttttttt 2460
gggagaattt ggggggggtt tttttttttt ggggggggtt tttttttttt gttttttttt 2520
tttttagttt ggcgtatagtt tgagattttt tttttttttt ggggggggtt tttttttttt 2580
taaggttggg atattgttgcgtt gttttttttt ggggggggtt tttttttttt gttttttttt 2640
aggatgttgcgtt ggggttgcgtt attttttttt ggggggggtt tttttttttt gttttttttt 2700
ggttttttttt tttttttttt ggggggggtt tttttttttt gttttttttt gttttttttt 2760
gttaagttgcgtt taggtttttt ggggggggtt tttttttttt gttttttttt gttttttttt 2820
cgttttttttt atattttttt ggggggggtt tttttttttt gttttttttt gttttttttt 2880
tagtggatattt gtcgttgcgtt tgggttgcgtt gttttttttt gttttttttt gttttttttt 2940
attttagtggatattt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt 3000
gttaggatattt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt 3060
agtaagttttaa aaatgttgcgtt ggggggggtt tttttttttt gttttttttt gttttttttt 3120
ggtagtgcgtt agatcgttgcgtt ggggggggtt tttttttttt gttttttttt gttttttttt 3180
ttgggttgcgtt tgggttgcgtt ggggggggtt tttttttttt gttttttttt gttttttttt 3240
ggtttttttt ggggggggtt tttttttttt ggggggggtt tttttttttt gttttttttt 3300
gttttagttt tttttttttt ggggggggtt tttttttttt gttttttttt gttttttttt 3360
tgcgttgcgtt tgggttgcgtt ggggggggtt tttttttttt gttttttttt gttttttttt 3420
atttttagtggatattt gttttttttt gttttttttt gttttttttt gttttttttt 3480
aaatataaaa attttttttt gttttttttt gttttttttt gttttttttt gttttttttt 3540
tgaggttgcgtt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt 3600
atttttagtggatattt gttttttttt gttttttttt gttttttttt gttttttttt 3660
tggttaatggatattt gttttttttt gttttttttt gttttttttt gttttttttt 3720
ttttttttt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt 3780
gcgttagtgcgtt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt 3840
ggttttttttt tttttttttt gttttttttt gttttttttt gttttttttt gttttttttt 3900
cgttttttttt tttttttttt gttttttttt gttttttttt gttttttttt gttttttttt 3960
gttcgttgcgtt tttttttttt gttttttttt gttttttttt gttttttttt gttttttttt 4020
ggatacgttgcgtt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt 4080
tatagttgcgtt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt 4140
cgatgttgcgtt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt 4200
tgcgttgcgtt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt 4260
tttcgttgcgtt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt 4320
tggtttttttt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt 4380
ggagtttgcgtt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt 4440
ttttttttt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt 4500
gcgttgcgtt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt 4560
tcggggcggtt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt 4620
ggggcggtt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt 4680
ttgttagttaa gaggatttgcgtt attttttttt gttttttttt gttttttttt gttttttttt 4740
agttcgttgcgtt tttttttttt gttttttttt gttttttttt gttttttttt gttttttttt 4800

aaatattatg ttatagtgat ttttttatt atgtgtgaga tatggagaat tggtttaag	8640
tattatttg ttatgggtg gttggattat tgatgtgtat ttttttatt ttttttatt	8700
ttgtgtggg ttatggttc gtgtcggggt agaggagaaa aatgggttgc tttttttagg	8760
ataaattttt attttaattt aatttaggggt tggtgattag aatgtgtaaat tgaggtgtg	8820
tttattgtat tttttttt tttgagatcg agtttgcgtt ttgtgtttt ggttggagt	8880
cgatggtacg attttagttt attgtattt ttgtgtttt tttttttcg agtttgcgtt	8940
ttagttttt taagtagttt ggattatagg tttttttttt tttttttcg agtttgcgtt	9000
tttttagtag agacgggggt tttttatgtt ggtttagttt tttttttttt tttttttttt	9060
gggttattat tcgtttcggt tttttaaagt tagttgtttt ttgtgtttt tttttttttt	9120
tagttgtttt ttgtttttt tggtttgaag tttttttttt tttttttttt tttttttttt	9180
tgtgtgtata cgataatagt ttattgtat tttttttttt tttttttttt tttttttttt	9240
attttagttt tttgaatagt tgggattata tttttttttt tttttttttt tttttttttt	9300
ttttttttt ttagtagaga tgagggtttt tttttttttt tttttttttt tttttttttt	9360
gaggattaaag tgattttttt attttagttt tttttttttt tttttttttt tttttttttt	9420
attatattta gtttattttt attttaatgt tttttttttt tttttttttt tttttttttt	9480
tttgggtttt gtttatgtgt ttttagttt tttttttttt tttttttttt tttttttttt	9540
tttagtgttg aggttttagg taggttagtag tttttttttt tttttttttt tttttttttt	9600
atttatttag agtatgtaaa attaggagta tttttttttt tttttttttt tttttttttt	9660
tatatgtata ttagggatag ggggttaaag gtagtttagt tttttttttt tttttttttt	9720
ttatttttt gagaagttt gggtttttta agggtttttgc gtttatgttgc tttttttttt	9780
taggacgagt ttgtggagt gtagtttttgc gtttatgttgc tttttttttt tttttttttt	9840
attaaggagt ataatgtta gattaatagt aatttttttgc gtttatgttgc tttttttttt	9900
tttaggaagg gggcgtgggg aggagtaggt attttttttgc gtttatgttgc tttttttttt	9960
tataatttgag gttatttttgc gtggcgtaa gtagtaattt gtttatgttgc tttttttttt	10020
taagtagatt gatatttttgc ttggaaatttta ttattaaagggt gtttatgttgc tttttttttt	10080
gaataaggac gttttttata tagtttttgc tttaggttttgc tttaggttttgc tttttttttt	10140
ttttgtgttt ttttagtaaga agtttttttgc tttaggttttgc tttaggttttgc tttttttttt	10200
gggtataagt gttaggcgtc gtttttttgc tttaggttttgc tttaggttttgc tttttttttt	10260
gtatgtgttgc ttacgtataa gggtaatgttgc agtttttttgc tttaggttttgc tttttttttt	10320
ggtggtggat gattttcgta agttttgttgc tttaggttttgc tttaggttttgc tttttttttt	10380
tgggtttttt attttattttt gttttatgttgc agggtaatgttgc tttaggttttgc tttttttttt	10440
gggggttggat agtttttttgc tttaggttttgc tttaggttttgc tttttttttt tttttttttt	10500
agttgttggta ttaggttttgc tttaggttttgc tttaggttttgc tttttttttt tttttttttt	10560
tttttagtttgc tttaggttttgc tttaggttttgc tttaggttttgc tttttttttt tttttttttt	10620
tagtttttttgc tttaggttttgc tttaggttttgc tttaggttttgc tttttttttt tttttttttt	10680
aggaaattgttgc ttggaaagata agttttgttgc tttaggttttgc tttttttttt tttttttttt	10740
ttaaaatgttgc ttggaaatgttgc tttaggttttgc tttttttttt tttttttttt tttttttttt	10800
aagaattgttgc ttgggttttttgc tttaggttttgc tttttttttt tttttttttt tttttttttt	10860
tttattttat gatatgaggttgc ttggaaatgttgc tttaggttttgc tttttttttt tttttttttt	10920
aaggatttttgc ttgggttttttgc tttaggttttgc tttttttttt tttttttttt tttttttttt	10980
attggggat atttgatttttgc tttaggttttgc tttaggttttgc tttttttttt tttttttttt	11001

<210> 16
<211> 3501

<212> DNA

<213> Art i

11. Artificial sequence

220

223

223) Chemically treated genomic DNA (*Homo sapiens*)

<400> 16

gtgggggttgg taggggtgtt	gttttggtat agtttgggt	ttggtagtgg tgggtgggt	60
atgggttaag agttgttatt	gttgtgggga ggggagttt	gttgttggg attgttaggt	120
atgggttgg ggggtttgtg	gtttaggagg ggaatgggt	tgggtgggt agtagtgggt	180
aggggagttt aggggttgg	tttgggtttt gttgttggat	ttgggggtt tgaggaagag	240
ttgtgagttg aggggttggg	gttgggttat tttttttgtt	ttgtttgttag ttggaaaatt	300
tttttttaag ttgggggtgg	tggagttttt ggggagaagg	gttggggggaa gttgtggagg	360
gaggtgttgg gttgtgtgt	gttagggtta gtttgaggtt	ggatgtggg tgggtgttag	420
gtttgggtta gggttgttagt	tgggtgtgtg ttgtgtttgt	ttgggggtttt gttttttttt	480
ttttttggga gtgtgtggt	tttttttttt tttttatttt	ttttttgttt tagttttttt	540
ttttgatata atgttttttt	tgtgtgggt ttgggttttt	tgttttgtttt gttatggtag	600
ttgttgtttt ttttttttgt	gtgggtgttg ttgggggttt	gattgagggt tqaactttt	660

720-800

tggtagggt ggttttaggg	tgggtatgt gtttttttt	tttgtattat ttttttaat	720
tgggtaatt tttttgagg	tggaggtgt tggtttttg	ttttttttt ttttatttg	780
gttaaagttt ttttttga	atgattttt ttgaagtgg	tatttattt aaattgggt	840
attgtttta aaagggttat	tgttttga tagttttt	tttggaaagt ttagtattt	900
gttaggtgtt ttgggtgtg	taggtgtt tggttttt	tttattgtg gtgtttatt	960
ttttgtttt tttttgtt	tgggtgggtt ggttgggtt	tttattttag agggtagtt	1020
gtttttgtt ggttttagg	ttgttagggtt gatttttt	tttagttgag ggaaggggaa	1080
gtggagggga gaagtgtgg	gttggggta ggtggtagg	gtgtgtatg gtttttattt	1140
gtttgggtgtg ttttttga	ggagagtgtg ttgggttagat	gtgttggat atgtggagg	1200
tgtttggta ttttaggtag	ttgttgtgt agttaataaa	ttagtgtatt aagggtttt	1260
tgtgtgatgt gattattgtg	gtgtagaatg tttttttt	tgtgtataag aatgtgttgg	1320
tggtagtagt tgtttattt	aagtttttgg tgggtatga	taatttgtt aatttggatt	1380
atgatatgtt gagtttgg	gtgtttgtt tgggttgg	tttattttat attgggtt	1440
tggtgatgg ttagaggtg	gttgggtt tgggtgtt	tttgggggtt gagttgagtt	1500
tgggtgtgtt gttgtgtt	gttagttatt ttagatattt	tgattttgtg gtgtgtgt	1560
agaaatgtt taagtgtat	ggtaagtatt gttatttgt	gggtgggtt ggtgggtt	1620
gtggtagatgt gtttatgtt	tgggtgggtt ggggtttgt	gttggatgt ttggttattt	1680
aggtttggta ttttttta	gttgggtttt tgggttgg	tgtgtggag ttgttttgg	1740
gttttagaggt tgggttaat	atgtattgtg ttgagttgt	tgtgtggga ttgggttgg	1800
ttgttgtatt ttgtgtttt	gagtgtgtt gttttttt	ttgtgggtt gatttggta	1860
agaagagtt gttgggttt	gtgggttag agtgggtt	gttgaggt gatgtttt	1920
tgtgttttga tagttttt	agtgtgtt ttgtgttta	taaggagtt tttttgtt	1980
tgtgtgtt gttgtgtt	ttttttaga agtggagga	gtttgtattt tttttgtt	2040
tattttgg tggtaggtt	agtttggat tttagttttt	tgggtttt gatgggttta	2100
gttttttttta ttgtggatg	aagtatgagt tgggtttgg	tagttatgtt gatgagttgg	2160
gttgggagtg tgggtttt	agttaggtt gtgaagagt	tgggtggat gtgggtt	2220
tgtttgggg gttttgtt	ggtttgggt tgggttgt	ttattttgtt agtttggatg	2280
gttttgggtt ggggtgtat	gggtatgatt ataagagtag	tagtggagat attggtagta	2340
gtgaggattt tagttgtt	ggtaggttatt ttgagggta	ttatgtttt tatttggtt	2400
atggtagattt tgagagttt	gtgtataatt ttagtgtgt	tattttgtt ggttaagggtt	2460
tttttagttt tgagtagtt	aatgtgtatg tggaggtta	tgtggaggag gaggaagtgt	2520
tgtatggtag gtttgggtg	gttgaagtgg ttgttgggt	ttgtggtttta ggggttttt	2580
ttggaggtgg tggggataag	ttgttgggg tttgggtgg	tttggagag ttgttgtgt	2640
tttattgtt tgggtgtgt	gataagagtt ataaggattt	gtttatgtt tggtagtatt	2700
agaagatgtt ttgggttatt	tggtttattt tagtattat	ttgtggaaag aagtttatgt	2760
agtgtggat tatgtgtt	tatgtgtta gttatttgg	tttaagttt ttgtgtgt	2820
atgtgtgtt tatgtggtt	atgtgttagt attgtttat	ggagtatatg tgtatttatt	2880
tgggtgagaa gttttatgt	tgttaggtgt gtgggtgtaa	gtttgtatag taatgttaatt	2940
ttattagttt tatgaaagat	tatgtgttgg ggggtgtgg	ttgtgtggtt ggggtgttgg	3000
tgggtttggg ggggtttt	gggtttttt gtttgtatgg	taagggttaag ttgttatttt	3060
ttgaggggtt ttttgggt	gtttgttttta tgggtgagta	gttgagttt aagtagtagg	3120
ataaggtgt tgggtgtt	ttgttgggtt agattatgt	ttttttgtt gattttaagg	3180
tgggtgttga gagttttat	ttgttgggtt agttatgtt	tgagttgggt tttagtttt	3240
ataaggtgt tgggtgtt	agttaggggt tttatttgg	gtttgggtt gatgggttga	3300
ttattgattt tttttttt	atttagagtg tttttgtt	gtttgtttt tttgttgg	3360
gtgggtttgg tttgtattt	agggaggtgtt ggggtgtt	tgtaggggtt attgtgtttt	3420
ggataattgt agtgggttta	tagtgggtgtt tttattttt	gttgggttta ttgggtttt	3480
ttgttttgg ttttagttt	ggtgggttta ttgggtttt	tttgggtttt g	3501

<210> 17

<211> 3501

<212> DNA

<213> Artificial Sequence

<220>

<223> chemically treated genomic DNA (Homo sapiens)

<400> 17

ttgagtttaag gtatgaagt	gtgagggttag gtgaggtgt	tgaggggtgg agttgttatt	60
gtgggtatgt tgggtgtt	ttgggtatag tgggtttgt	gtgttggttt tgggttttt	120
tgggggtgtt gttagggtt	tgttagtagt atagagtgg	ttggtgaggg gtgttttagg	180
tgggagagaa atgggtatgt	gtttgggtgt	tgtaggtgt gtttaggtgt	240

ttagtatttt	ggtgttttg	ttggggttga	ggtttagttt	ggttgtgaat	ttggtagtg	300
ggtagaggtt	tttagtgtt	attttgggt	tgtgttagaa	gtgtgtgg	tgtgttagta	360
gtttgggtgt	ggtgttttg	tttigtgtt	ttaggtttag	ttgttgg	gtgaggtgag	420
ttatagtaaa	gatgttttg	gggaagtgt	gttgtttt	gtgttggg	ttggggatgt	480
tggggagttt	tttaagttt	gttagtgtt	tggttgg	ggttgtttt	tttatgggt	540
gtatttttat	gtgggtgatg	agggtgtt	gttgtgtgaa	tttgtgtt	tatattgt	600
attttaggg	tttttgg	gagtggatgt	gtatgtttt	tgtgagg	tattgggtg	660
tgaattgtat	gttgtatgt	ttgtatgt	agggttgag	gtttaggt	ttgtgtatgt	720
ggtgtgttat	gttttatgt	tgtgt	tttttggta	gtgggtat	ggtaggggt	780
gggttagta	gtgtgtttt	ttgtgtgtt	gtagtggt	tgggtttt	tagttttgt	840
tgtatgtatgt	gtagtggt	gtttagt	gtttttttag	gttatttga	gtttgggtga	900
ttttgttttt	gtttagtttta	aaagggggtt	tttaggttggt	gtttagt	gttattttgg	960
ttgttttggt	ttttagt	agtgttttt	ttttttttat	gtgagttt	atgtgtgt	1020
ttagttgttt	agagttgggg	aagttttgt	tgtatggaa	gtatatgtat	agggtgttat	1080
tgaagttttt	gggttggta	taggttaggt	gtgggtatgg	gtagttttt	agggtgggt	1140
taggtgggtt	gggggttttg	ttgttattgg	ttttttgtt	gttgggtttt	tagttgtt	1200
tgttgggtt	tgtgtgggt	ttgtttaggt	tgttagggta	gtgtgggt	gtgttaggt	1260
tgagtggggg	tttttgggt	gagatgg	ttttttatt	atgtttttt	tagttttgt	1320
tggggggagtt	gtgttttgg	tttagttgt	tgttata	attaggttt	gtttgggtt	1380
ttattttagt	atagaggaga	ttagttgt	tgggtgggt	gggggtttt	gtttgggt	1440
tgttgggtt	gttgtgaaat	gggttgaag	gtgggtgggt	tttttttagt	ttttggaaagg	1500
gtagtgggtgg	tagtgtatgt	agggtgag	gtgggttttt	gtagtggt	gggtgggt	1560
tgggaggggtt	gtttgggtgt	gggggtag	tgtgttttagt	tagtgtt	tttgggtgt	1620
tggagtttgg	tgggtttttt	ttggataggt	ttagttata	aagagggag	tagtgggt	1680
ttgaggata	gagtgtgg	gttgggttgg	gtttgtatgt	gtatagttt	gtgttagt	1740
tgtttaggt	gggttttgg	ttttaggt	gtttgtgtt	ttttaggt	tagtatttt	1800
ttgggtatgg	gttaggtt	tggatgtt	gtgtgggtt	ttttaggtt	ttgggtgggt	1860
gattataggg	tgttaggt	ttgttgg	tgttgg	ttttaggt	tagtatttt	1920
tgtgggtttt	gagggtttt	ttgtatag	ttaggtt	ggggattt	aggtagtt	1980
tgggtgttag	tatgtgtt	agggttgg	tagttttgg	gtttaggtt	gtgggttag	2040
ttttttttgt	ttttagt	agggttgg	ttagatgaa	gtttagt	ttttagt	2100
tgggtgggtt	tattatgtt	tgggttagt	ttagatgtt	gtttagt	ttttaggt	2160
tgaggttagt	gttgggtt	gttagt	ttttagt	gtttagt	ttttaggt	2220
ttatgtatgt	tatgtgtat	aagaagttt	tgggtgtt	gtttagt	ttagtagt	2280
gttgggttga	gtgggtgggt	gttttattt	tgttagt	ttttgttta	gtatatttt	2340
ttgtggggat	atatattgtt	tgggtgag	tgtgtgtt	tttgggtt	ttgggtttt	2400
tttggtattt	tttttttttta	ttttttttt	tttagt	gtgggggtat	tagttttgt	2460
gttgggtat	tggtaagga	ttgggtt	tttgggtt	gagtttagt	ttggttgg	2520
ggatttaggag	aaggagttag	aggtagt	tgtgtgtt	aggggaggtt	agggtgggtt	2580
gtatgttttta	gggtatttgg	ttgggtgtt	gggttttga	gaagaaaatt	gttaggtgt	2640
agtgtttttt	ttggagatag	ttatttatt	taagtaaaat	gtttagtttta	gaaaaagtt	2700
tttaggggtt	agaattttat	ttaagtag	agaaagggag	ttgaggaaatt	agtgttttt	2760
gtttgggag	aagtgtttt	agttggg	agtatgtt	aggagggag	tgtgtgtt	2820
gtttgggtt	tgtttgg	gggggtgtt	aattttgtt	tgggttgg	gtgggtgtt	2880
tgtggggagt	ggaggttagt	gttgggtt	tgggttagt	gtgaaggtt	gtttgggtt	2940
ggggaggggt	ttatatttgg	gttaggtt	gaggttagaa	gtagtggtt	gggaggggg	3000
agttatgtat	tttttaggg	agggaggg	tagtttttt	gttgggtat	gtgtatagtt	3060
ggttgtgtt	ttgatttgg	tttgg	atttgttt	tgggttgg	ttgggttttta	3120
tatgtgtgg	tttgggttt	tttttgg	ttttttgtt	ttttttttt	ttgaaattt	3180
gttgggttta	atttgggaa	aagttttta	attgtat	gggtggagg	agtgtgtt	3240
ttttaggtt	ttgggtt	gtttttttt	gtgggttttta	aatttgg	tagttttgg	3300
agttgatgtt	ttaggtttt	tgggtt	ttgggtttt	gattttgtt	ttttttgtt	3360
ttgtgggggtt	ttgtgggttt	ttatgtgtt	tttgggtgg	ttgggtttttt	ttttttgtt	3420
tgggtgtat	ttaggtga	tgttttattt	gtgtgtt	gttttgag	tgtgttaggg	3480
tagtgggtt	gttagttt	t				3501

<210> 18

<211> 2501

<212> DNA

<213> Artificial Sequence

<220>

<223> chemically treated genomic DNA (Homo sapiens)

<400> 18

tttttatagt	gtaaaatgtgt	ttttattatt	ttttggagta	attttattta	aaattgtttt	60
tagtataaaa	tttaaatatt	taaatatgtat	tttgggtt	ttgttttgt	ggttttattt	120
ttttttttt	taaatttagt	tagttttgt	gttggta	atgtttttt	ttttttag	180
gggttgttat	tttaggtttt	ggttttttt	tagaaagttt	ttttttttt	tttttagtgg	240
ggataggggt	tgtttattt	gatattatta	gttattttat	atataatgg	tataagttt	300
ggttgtattt	ttattgaaag	tttattttt	gatttgagt	agtttgagga	ttttattaa	360
attaggaga	tgtttagtaa	atgtgattt	aattatgatt	gttttaata	tataaatgtt	420
agattattt	ggaatattt	ttaaaatgtt	ttttttttt	gagattttt	tttgggaggt	480
aagtagtggg	ggtttaggt	tttggattt	gatagtttt	tgatgtttt	atgtagaagt	540
gttagggata	ttatattgtat	aaattttat	tatttttaag	ggggattttt	tttttaggg	600
gttattttt	gaagttttt	aaggataggg	gttgtatgtt	gttttttag	gttagtaatt	660
aaattttagaa	aatgttttatt	gagtgaatga	tgaatgata	ggtgaataga	tgaatgtaa	720
gtgttgagg	aattttttt	ttatataatgt	tttagtagtt	ttiatgtttt	tttagttag	780
aaatggttt	tggaaaggtaa	gttttttagt	gagttggagtt	attttaattt	atattttttt	840
gatatttaag	ggagttgtgt	gttttgggtt	tatttttttta	ttagaaattt	gtaagttatt	900
gatttttgg	ttgtttttgt	tattttttgt	ttttttttgt	ttttagttt	gtgttagtgg	960
gttttggtt	tttgggtgt	tgttggta	gttttttattt	atgggtttat	tgttgagggt	1020
tgatgggtgg	gtggattttgg	ttattgggt	gggggttaggt	gagttatgt	aggttggagg	1080
ttgtgtttt	tgttgggtgt	tagttgggt	ttttttttgg	gttggatata	gtgttagtgg	1140
gtagttgagg	ttattttgtt	gaggtgggtt	ggaggggaat	ggttattttt	gaggttattgt	1200
atttttttag	gaggaaagag	ttggaaatat	ttgttttttt	aagtaggtat	agttgtttt	1260
tttttagtat	tttgggtgtgg	gttttttaag	gttttgggtt	agaggagagg	ttaggttggg	1320
ttgttgattt	taaaatttggg	tgaaagtttt	ttttgattttt	tattttgtgg	tattgattgt	1380
tattttttt	gtaatttaatt	ttttagattt	tttgggttagt	tttttaaagg	attgaaaagt	1440
tgtgagggg	gggggttgg	attttttttt	tgaagtgtat	agatgttagt	ttttgaaaag	1500
ttattttgg	gttttagtgg	tgtttttttt	tgttgaaga	tttaagttt	gtgagaggat	1560
tttttttaaa	gaggggtttt	gataagagtt	ttttttgtt	ggagtttgt	tgtttagtaa	1620
gttataattt	gtttttgaaa	tttattggag	tttggtaga	gttgttaat	ttaaatgtgt	1680
atagggggtt	ggtgtatgtat	ggagaaagaa	aatgggagta	ggatgggtat	atttgaggaa	1740
ttggagagtt	gagaattttt	aagtggatgt	gttagtggga	aagttgttt	tatttttagga	1800
gtggtaaaat	ggaaaattgt	tatgtgaat	agtttatttt	tttaagttat	aaaaattaa	1860
aataaattat	ttatattaaat	atagatgttg	tgttagtggaa	ttttatattt	gtttttattt	1920
agtgggtgt	ttttgtattt	tttaagtgta	gggattttga	tattatgtat	ttttgatttt	1980
ttattggtag	tattttatatt	ttggaaaggt	tttaatgtat	gaatttttg	agtttataat	2040
taaatgttat	aaatttggaaat	tttggtaattt	aatttttattt	tattttata	tttgtattga	2100
taaaatgtgtt	ttttatgttg	tttttttagaa	aatgtttttt	gtgttgatga	atagtttaat	2160
attttatatt	tataatgttt	tggttattttt	tgtatggta	tgtatttggg	tgttagttata	2220
tttttttaat	gttttttagga	aaatattttt	tttatttttt	gtttttattt	taaataatgt	2280
attttataat	gtttgggtgtt	ttaaattttt	ttttagatgtt	tttggataat	ttttatgttag	2340
gagggtttag	gattatattt	taagatgttt	ttgttattttt	taaggagatt	ttttttttt	2400
ggggtttataat	ttgaaaattta	ttaaggata	gggattgttt	ttttgatata	tatttagtata	2460
tttatatatt	gtatgttagta	tattttatatt	tagtattttt			2501

<210> 19

<211> 2501

<212> DNA

<213> Artificial Sequence

<220>

<223> chemically treated genomic DNA (Homo sapiens)

<400> 19

attgagtatt	gggtaaaat	gtattgtata	ttatgtgtaa	gtatgttaat	gggtttaaa	60
gaagtagttt	ttattttga	atgatttttta	gatatagttt	ttgaaaagga	agtttttttt	120
agtgtatggta	aaaatgtttt	agaatgtat	tttggattt	ttgttatgtaa	aatttttttt	180
gagttgttaa	aaaagattta	aaatattaaag	tgttgtaaa	tatattttt	ataataaaag	240
taaagtgtaa	ataaaaatgtt	tttttttttt	tattagaaag	gtatgattat	attttttttt	300
atgtttatgt	agagataatt	agatgtttat	gggtataaaa	tatgttggta	tttatttttt	360
ttgaaaatgt	tttttggaaag	gtatgtataag	aagtttatttt	attaatataat	atatgaaaatgt	420

atataggaaat taattgtatag aatttttagtt tgtaatgttt aataatataat ttaaaaataatt	480
tatgttattag ggtttttta ggtataaggt attatttagtg gagaattaaa ggtgtataat	540
gttaagattt ttgttatttg aggttataga gtttatttt tggtgagaaa ttaatgtaaa	600
attttattgt atagtatata tgggttatg aatggtttg ttaattttt tgtattttaa	660
aaaatggggt tattttatata aataattttt tattttgtt tttttgaaat ataggttaatt	720
tttttattgg ttggtttattt ttggaatttt ttgtttttt gttttttaga tgtgtttatt	780
tttattttat tttttttttt tattatatgt ttgattttt tggttattt agtttataat	840
ttttgttaag attttagtgg attttgagaa tagattgtg tttgttaagt atataaattt	900
taatgggaa gggtttttat tagatgtttt ttttaaagaa ggtttttta tgaatttaaaa	960
attttatgt agagggaaat aaatattgaa tgattgaatg attttttagg agttgatatt	1020
tttgtgtttt aggggggtgaa tttagtttt tggttttttg ggttttttag ttttttaaaa	1080
gattaggtaa agatthaaga gagttatattg taggaagagt aataattgt gtttataagat	1140
aaagggttagg gagaattttt attttagttt gtaatttagta gtttagttt gttttttttt	1200
tttagtagga ttttggaaag tttatattgg ggtgttggg agaagtgggt tgtatttgtt	1260
tgagagatta ggtgtttttt gttttttttt ttttaagaga tgggttggg ttgtatgtt	1320
tatttttttt ttattttat tagtgggtt attttagttt tggttgggt tggtatgtt	1380
tttggaaaaga gtagtttagtt gtgttttagt aaggggtgtg gtttttaattt tttgtatgtt	1440
tatgtttttt tgggttgggtt attagtatta ttgtttgtt gaatttttagt ggtgagttt	1500
tgaataaggt ttgtatgtat atatataatga ataagtagag ttgttggatg ttgatttgtt	1560
gataggagga ggtggggaaat ggtgggggtg ggttgggggtt tagtgggtt tgattttt	1620
gttaggaagat gagtgttagag tgggttgggtt ttttggaaattt ttggaaatg tagttaagag	1680
tgattttatt tgggttggaa ttttgggtt aggggttattt tgggttgggtt gaagtaatgg	1740
gagttgttag gatttgttga gaagaatagt taatttgata ttttgggtt atttatttt	1800
ttgttggttt atttttattt taataatgtt ttttgggtt tagtgggtt ttttagagaaa	1860
tagtattgttgg ttttttatttt tgagggtttt tagagatag ttttggaa ggaaagttt	1920
tttttagggat ggttaaagatt tgtagtggta ataattttt ttttttata tggtaatattt	1980
aggggattgt taaaatgttag agttttggat ttttattgtt tttttttttt aatagaattt	2040
taaggggtaa aaatattttg ataagtgttt ttaatgtt ttgttgggt atgttgagaa	2100
tagttatagt ttaatataat ttttattgtt atttttttagt ttttggatagg atttttaagt	2160
tattttaggt tagatggtaa attttaata atgggtgtat ttagattttt gattaatgtt	2220
tgttaagttag ttaatgggtt taaaataat agattttt ttttgggttggg agaaagagga	2280
aaaattttt gaaggaggat taggatttaa agtgggtattt ttttggatagg aagaagggta	2340
ttataggtag tataatattt agttaggttt ggggagaaag aggttaaagt tataaaagta	2400
aagtttagtaa gattatgttt agatgtttga attttgggtt gaaaatgggtt ttaagttagga	2460
tttatttttaa qagtgggtttt aatataat ttttggaa a..	2501

<210> 20

<211> 2470

<212> DNA

<213> Artificial Sequence

<220>

<223> chemically treated genomic DNA (Homo sapiens)

<400> 20

aaagatgatt	aaaagtttcaa	ttgttttattt	gaagagtta	tttttttattt	ttttaataaa	60
agggtatttt	tagtagttt	tgtttatttt	gttattttgg	ttttttttgt	ggttgttaa	120
ggttataatt	tttgtgtttt	agtaaattttg	tgtatgttt	tttttttttt	tgttattatt	180
ttttttttta	ttttgtttta	ttattttgat	gtaaaattat	ttgttaattt	tatttgaat	240
gagaaatttt	aaggtttata	ttatttaaat	tttgttagat	tttttttttt	gttatatgg	300
ttataatgtg	ttgggtattt	ttagatttgt	ttattaaaaaa	gatgtaaaat	aaaataatga	360
ttatttttgt	ggattttttt	tttatttttg	agatgtttt	tttgggtgt	ttattttttt	420
atttttgtt	tattgattag	aggaggggtt	ttaattatgg	gtgaatttta	tattttattg	480
aagaggttat	gttataatgt	tatttttata	atataattta	tattttatata	gtatttttat	540
tttttagata	ttttttttta	ttaattttaa	taatattatt	gtaagttatg	ttgaagtaga	600
ttgttaagtgt	ttatttataaa	attgtgaat	gaattaaaaat	gaaagggtaa	agattaaatt	660
atgatttaggt	ttgaaattaa	tatataagat	ttaattttt	ttaattaaag	atttttgttag	720
gtgatttttg	ttttaggat	tttttttttt	tttagatgt	tattggattg	tatttaggtt	780
attgttagatt	ttagttgttg	tagaattaat	tagatthaag	atgagtttt	tgattttttt	840
ttgttagagtt	tttaattgt	tgaattttaa	tattgttg	attagttatg	gttataattt	900
gtttgtttta	tttgtgttaa	tggattttat	attatagagg	tattttttta	atgttaagat	960
gtttaagtat	tgttaagtgt	taaatttattt	aatattttt	agttattaag	taattaagat	1020

aggtaggatt ttatttgttt taaaatgatt tgattnaat taaaagaga atgtggattt 1080
 tttgaatttt atttgttiaa tttaatata attttagta ttttataatt ttttttaaag 1140
 ttttttatt tggattttt ttgtatttt tttgttttt ttttttttt ttagttataa 1200
 taattgttag atttgtttt atttttttt gatagtttt attttaagg ttatttattt 1260
 ttttaggtt tttttgggtt ttagtttag tatagttagat tttaagatata tatagtttat 1320
 agtatagtt attatagttt atttttgaa taaatgtat tgaattttat gtttagtaatt 1380
 ttatatttattt taaaaggtt taaagttttt atttatgtt tttttttatg 1440
 ttatatttgt taaatgattt ttttttaatg atattttaga attttagaat tattttatta 1500
 tggaggatgt gtaagattttt ttttttattt aataaaaagt gtgaaatgga atatgttaatt 1560
 ttatatttattt tttttgggtt taaaatttt ttagattttt ataaaattttt gaaataaaaat 1620
 agtatttattt atataaataa atttttattt taatttattt ttttaagttt tttttgttaag 1680
 aatgggtaaa atattttaa aattttgaag aaatttattt ttgatagaaa gtttaatttt 1740
 tttgtgagaa ggttaatgtt ttagatata attaaagttt tttttttt ttttaattttt 1800
 tttatatttga attaagattt tattttttt tttttttt tttttttt tttttttt tttttttt 1860
 tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt 1920
 tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt 1980
 tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt 2040
 tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt 2100
 tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt 2160
 tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt 2220
 tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt 2280
 tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt 2340
 tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt 2400
 tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt 2460
 tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt 2470

<210> 21

<211> 2470

<212> DNA

<213> Artificial Sequence

<220>

<223> chemically treated genomic DNA (Homo sapiens)

<400> 21

ttagttttt tgaatttat agaaaatttt gtttagtat agtgatgtt tatttggttt 60
 ttttttttta attttaaaaa gaattaagaa ttaatttagttt attggagttt tatattttattt 120
 ttttttatattt gatttttga atgaattttaa tattttttat taaaatattttt aatgttaat 180
 ttttgtttaa aagagtttattt atattttgtt ttaattttaa atatattttt aagtaaagtg 240
 ttttatttttta agtttataag agggatattt gaataaaaaat ggataaaat tattttttttt 300
 ttatagttttt gatatttttta tatttagatgt ttttagttttt agttttgtt gatgatttgg 360
 attattttttt agttttgtt gaagatttga gttttttattt ttttagtttta tttttttt 420
 taataatttttga ttatatttttta ttgttagttt tttttttt tttttttt tttttttt 480
 aaaggattttt gaaatttttattt attttttttt ttagtggttt ttttttttta aagaaagggg 540
 taaaggaaat aaaaatttttta agatgtttaa gaagaattttt gtttaatattttt tagttttttt 600
 ttttttttta atatttttttta agtagttttt ttttttttta tttttttt tttttttt 660
 ttaagataaa ttttttttta atagaagaga gaattttttt tttttttt tttttttt 720
 ttttttttta ttttttttta gtaataattttt tttttttt tttttttt tttttttt 780
 ttttttttta ttttttttta aatatttttta tttttttt tttttttt tttttttt 840
 tagtaatattt ttttttttta ttttttttta tttttttt tttttttt tttttttt 900
 ttttttttta ttttttttta tttttttt tttttttt tttttttt tttttttt 960
 ggattaatgtt gattttatattt tttttttt tttttttt tttttttt tttttttt 1020
 atatttttttta tggtaaaata gttttttt gttttttt tttttttt tttttttt 1080
 ataaaatggta tatgttggat agtattttaaat gaagatttttta agttttttt gatggagat 1140
 ggttaataaag aatttttttta atttttttta tttttttt tttttttt tttttttt 1200
 agttttatgtt atgttataatg tggttttttt gttttttt tttttttt tttttttt 1260
 tttttttttaa gatggatgtt tttttttt tttttttt tttttttt tttttttt 1320
 tttttttttaa gatggatgtt tttttttt tttttttt tttttttt tttttttt 1380
 ggttaagagga tttttttttaa gatggatgtt tttttttt tttttttt tttttttt 1440
 aatttttttttaa gatggatgtt tttttttt tttttttt tttttttt tttttttt 1500
 atattttttttaa gatggatgtt tttttttt tttttttt tttttttt tttttttt 1560
 taaggttagat agtttttttaa gatggatgtt tttttttt tttttttt tttttttt 1620

gattttatta aaggaaatta ggggatttat ttagattta gtagttta taatggtag	1680
aatttatagt aaatttggta taatttaatg atatttgggg aggaagggga gttttgttag	1740
tagggattat ttataaaaagt ttgtgttg aaaaaatttg gttttgttg ttaattttag	1800
gtttggttat gatttaattt ttgtttttt atttaattt attttataat ttgtaaatga	1860
atatttataa ttgttttaa tataatttt agtgatatta ttaggattaa taaaaaaagg	1920
tatgttaaaa ataaaaagtat tatgttaaatg taagtttat tatgaaaata tatatgtat	1980
ataattttt tagtaagata tagggttat ttatgtttaa gattttttt ttgattaatg	2040
ggtaaggggt gaagaagtaa ttagttaaa ggagatattt taaaataaa gaaaaaattt	2100
ataggatgtg ttattttttt gttttatatt ttttaataa gtaggttgaa aatattttag	2160
tatattataa attatgtat agaggtagg atttgataga atttgaataa tggatattt	2220
aaaattttt attttaataa aaattaatag gtaattttt attaaataaa taaaataaaa	2280
taagagaaaa ggttagtaata gagaaaaaaa tggatgtta taagtttatt gagatata	2340
agttataattt ttatataattt ataaaaagag ttggatgggt aagatgatgaa gagattgtt	2400
aaagtatttt ttattatagg aataaaaaaa ttaattttt agatgatgaa taaaattttt	2460
aatttatttt	2470

<210> 22

<211> 7001

<212> DNA

<213> Artificial Sequence

<220>

<223> chemically treated genomic DNA (Homo sapiens)

<400> 22.

aatgtaatgg aaaaagagag attgttaaagt tagaagggtt aggaattgtt ttttggattag	60
gtgtggaaagg taagggaaa ttatgtttt aagaagatag tgagattta atttgggtgg	120
ttggagagat agtgtatgtt ggtatagata tggggagtt gagaggaaa ttatgtttg	180
gaatgggtat ttatatttgta ataagttgt aatgtttgtt agattgttgg aaaagtgggg	240
ttggagatattt atttaatggta ggagtttagt taatttttattt ttttttttattt ttgagagat	300
tagtaagttt tgggtggaaat gtgtgtgtt agtaggagag ggttagggagg gaagttttaaga	360
gagttggggag tttgagtgtaa gttttttttaa aaggttagaaag aggaaatgtt gtgttagtata	420
gtatattttt ttattttatgtt ttatataattt tagggataaag gtttatttaag atgatgttgg	480
aagagaatgt tggagagaaa gtggtaaga aaattttttt tattttaattt ttgggtttaa	540
ttttgattgtt aagtttttgta ataattaaag tttgtgagga gatagttat ttttttattt	600
tttttatgtt aatagtgaat aattgtatgtt tttttttttt tttttttttt tttttttttt	660
ttttttttt tttttttttt aatattttt gttttttttt ggattttttt agatgtatggg	720
tggttattgt tgattttatag gaggattat tggattttat aaaggtaat agttttttt	780
ttaatattttt attttatattt agtattttt ttaatatttg attatggaga gagttttttt	840
gtgtttaaat attgttaatattt tgggggtttt ttaatatttgaaaatata tttgtatgt	900
gttatttttta atatttttattt gttttttttt tttttttttt tattttttttt aagatgttattt	960
tataaaattttt ttatgttaattt tatagtgttt taggtttaga gattttttt tttttttttt	1020
gtgatttagag ttatgttaataa tttaagggtgg tgattttatgtt ttgttaataa agttttttt	1080
gggtgttatg tggggggaa ttgtgtgtt ggttattttttaa gggttattttt agtattgtt	1140
gttagtattt tgggtgagag aatagtgtt aaggtggta agaggtggat ttatgttaat	1200
gttattggaa aatgagagat ttgtttttttaa attatgttta gttttttttt aagttttaaa	1260
attagtttaa aataaaggta ttatgtttta tttttttttt atatttttagg ttttttataaa	1320
tatgtattttt ttatgttttta atagaaagta gttttttttt aatgtttttttaa aggtttttt	1380
gggtttttttt aatgtttttttaa aggtttttttaa tttttttttt gttttttttt aatgtttttt	1440
ttaaaatattt tattttttttt tttttttttt tttttttttt tttttttttt tttttttttt	1500
gttttagagat tgggggtttttaa ttgtttttttt tttttttttt tttttttttt tttttttttt	1560
ttttttttttt aattttttttt tttttttttt tttttttttt tttttttttt tttttttttt	1620
attttatattt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	1680
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	1740
gtttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	1800
gttggggtaa aggggtgggg tttttttttt tttttttttt tttttttttt tttttttttt	1860
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	1920
tgtgttagtag tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	1980
tgtttttttttaa attttttttt tttttttttt tttttttttt tttttttttt tttttttttt	2040
ttatataattt agttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	2100
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	2160
aggtttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt	2220
tggtttagtgt ttgtttttttt tttttttttt tttttttttt tttttttttt tttttttttt	

tgtttttttt ttttttttta ggattttag	gattttttgt	gttatttgt	tataatttgg	2280
tagtttata ttttttaaga	gttttatgaa	gtttttttg	tatgtttttt	2340
ttgaaaattt	aaagtgtat	ttatggaaat	taaatttattt	2400
gtaatgat	ttgggtataa	agggaaatat	tttgatgt	2460
ttatttgtt	ataatttata	gttatttata	ttaatgtgt	2520
gtatattgtt	taataatgg	ttattttgt	aagaattaga	2580
aaatagttaa	aaatgttaatt	tttagtaata	gtaagttgg	2640
attttggtag	atatttgtt	gggtgttgg	tatgttaatt	2700
gtatttagt	tttaggtt	gtatgaaagg	aagtttattt	2760
attatagat	tatgatata	tttatttattt	ttaatgtat	2820
tatataatata	tatataatata	tatatgtgt	tgtgtatgt	2880
aatttagtta	aaaattttt	tttatttgtt	tttatttgg	2940
tagtttaagt	gaattgagaa	gattgagtt	taggataaa	3000
attttaaaa	tttggtagt	ggattagatt	gataatgtaa	3060
tttggtagt	gaggtatgt	ttggatgaa	aagtttata	3120
gttttggtag	tataatttaat	ttgtggaaagg	tatgtatattt	3180
gtttttttga	attattttt	atatgagaat	tttaatggg	3240
ttaatataaa	tatataagtt	aggtttagag	aatttttagaa	3300
attttgggag	tatttgttag	aggaagaaat	tgaggttttg	3360
gtaaaatgt	agttttttt	atatgtat	tttgaatttt	3420
tttttggtag	gtttttttt	ttgttaataa	tagtgggtt	3480
tgtatattt	attttattt	tttatttgg	gttatagtgt	3540
tatgtatata	ttatgtattt	tttagttaatg	agggttattt	3600
aatagagata	tatttgagtt	ttgtatgggg	tatataaggt	3660
tttttggatt	ttttttttgt	gtttatttta	agtttagttt	3720
gattttttgt	ttttttttgt	ttttgggtt	atttttagta	3780
aagtaaagta	aagtttaggg	ttttgggtt	tttatttag	3840
gagtgtatgt	taagttatgt	ttttgggtt	tagtgtatgt	3900
ttgtatgt	tatgtatgt	ttttgggtt	tttttagat	3960
gttggggag	gggtttttgt	ttttgggtt	ttttttttat	4020
tggatttgt	ggttttttgg	ttttgggtt	gttgggttgg	4080
gttgggttgt	ttttaatttt	tttttttt	tttttttt	4140
ttttttttgt	tgtggggata	tttttttt	tttttttt	4200
ttttttatat	taaagtattt	tttttttt	tttttttt	4260
agtttttggaa	tttggtag	tttttttt	tttttttt	4320
tggatagtag	taagtttgg	tttttttt	tttttttt	4380
ttgtgggtt	ttgtatgt	tttttttt	tttttttt	4440
ttgaggtt	gggtttttgt	tttttttt	tttttttt	4500
tttttggattt	gttggatgtt	tttttttt	tttttttt	4560
atgggtatgt	gggtttttat	tttttttt	tttttttt	4620
ttgggttttt	gggtttttat	tttttttt	tttttttt	4680
gtttttttgt	gtatgtgt	tttttttt	tttttttt	4740
ggtttttgt	gtatgtgt	tttttttt	tttttttt	4800
aaatgtattt	tttattttt	tttttttt	tttttttt	4860
ttaataaaat	atatgttgg	tttttttt	tttttttt	4920
tttaggttaa	taaatatgg	tttttttt	tttttttt	4980
aaagttgggg	gttggggag	tttttttt	tttttttt	5040
ttttgtttaa	tgttttttt	tttttttt	tttttttt	5100
agttatgat	atgatttttt	tttttttt	tttttttt	5160
ttttagttt	gggttttttag	tttttttt	tttttttt	5220
ttgggtttagt	ttgtgttgg	tttttttt	tttttttt	5280
taggttttt	gtgagttttaa	tttttttt	tttttttt	5340
ttgttagttt	agtatgtatgt	tttttttt	tttttttt	5400
tttagtttagg	ttttgttttt	tttttttt	tttttttt	5460
gagattattt	tgtgatttta	tttttttt	tttttttt	5520
ataagaattt	tttttttttt	tttttttt	tttttttt	5580
tttggttttt	gtttttttgt	tttttttt	tttttttt	5640
gtgaatattt	tttttaggtgg	tttttttt	tttttttt	5700
agggtgttat	atgggtgggt	tttttttt	tttttttt	5760
ttgggttttt	tatatttttt	tttttttt	tttttttt	5820
tttttaggaa	tatttatagt	tttttttt	tttttttt	5880
attgaaggggt	agattttgggg	tttttttt	tttttttt	5940
	ggtatttagt	gtgtat	tttttttt	6000

gagtattta tagttatgta gatthaagtt gtttttattt	aaaagataaa taatgaataa	6060
aattttaaa ggttggata ttttaaatta attttattt	tttaattt gggtaaaat	6120
agagaaaaag gatttttttt gtttattttt ttttttttaa	atggaagaat aaagtatagt	6180
gattaagtt aatttatata aatatttaaa attgttgat	gtgaaggaaag gtattggat	6240
gatgtgaatt ttataattttt atgtggatt ttagaaatta	ttttttttt tatttaattt	6300
ttagttttt tattgtaaat taatgttggt gaatttaat	gggtattaaat gagattgtt	6360
tttggtagat tatttattgt tttgttaata attataaagt	gaatttggtt aaatataagag	6420
gggattgtat tttatttaaa attgtttattt attttagtga	taagtggat tagtgaataa	6480
tgttttattt tatattttttt gtattatag atatttaat	taattttagaa taataaaaaaa	6540
agagataagg aatttaaaaaa ttaaaaaaaa aatttgata	aatgggattt tgtgtggaaa	6600
tttagttta gaatgatttt tttgtgtt tattttttgg	attatttttt tttttttgtt	6660
agaattttgt ttgttattat ttagtaagga aaagaagtat	ttatgttaagt tttttatatg	6720
gatagatattt atttagtatt ttttttttt tagttttttt	gtttaaatga ttttgggtat	6780
aaaggaaagg attgattggg ttttttttagg aaattttaaag	tttttttaagt agtttttaaa	6840
agttttgggg ttgaaagttag tttttttaaa ttgtttgtt	tgatttagag ggttatgaat	6900
ttagtttagt gagtttagaa tattttttaa aaggattaaa	atggaaagga atataataga	6960
aaatattaga gtgtatggta ttttgtaagg ataagtttg t		7001

<210> 23

<211> 7001

<212> DNA

<213> Artificial Sequence

<220>

<223> chemically treated genomic DNA (Homo sapiens)

<400> 23

ataaaaattta tttttatgaa atattatgta ttttgatatt ttttattata tttttttttta		60
tttttagttt tttaaaaat atttttagatt tattaaattt agtttatgtat tttttgggtt		120
atgataagta gtttggaaat attgtttta gttttaaaat ttttgagaat tatttaagaa		180
atttaaagg ttttaaaaaga gtttaattaa tttttttttt tatttttaga gttatttaag		240
tagaaaaattt gagaggggaa aaatattaaa taatattttgt ttatatgaag aatttggata		300
gatgtttttt ttttttggtg gataataata ggtagaattt taataaaaga gggaaagataa		360
tttgggaaat aaaatatagg aaaaattattt taaaatttga atttttatattt agagttttat		420
ttgtgttaat ttttttttta atttttaagt tttttgtttt ttttttttattt atttttaagag		480
tgtttgaata ttatgttaatg tagaaagtgt aagatagggtt attttatattt gatatttattt		540
attattggga tgatgaataa ttttgaataa gatgtgattt tttttgtatt tgatttagtt		600
tattttgtaa ttatttagtaa ggttagtaat aatttattaa ggagtagttt tatttagttt		660
tatttgaatt tagtagtattt aatttgaat aaaaagaattt gggaaatattt agggaaagaaa		720
atgggttttg gagtttattt taaggttatg gaatttataat tatttttagt ttttttttta		780
tattaagttag ttttaaatgt tttgtggaaat tagatttaat tttttttttt ttttttttattt ttaaattttaaa		840
tttaaaaaaaa aaaagggtggg tagaagaaat tttttttttt ttttttttattt ttaaattttaaa		900
ataagtaaaa ttaatttgaa atatgttaat ttttaaaatgt ttttttttattt gttttttttt		960
tgagtaaaa tagtttggat ttgtgtggttt gttttttttt ttaaggtgtt		1020
tgaagatgta tattgaatattt tttttagaattt tttttttttttag tttttttttt ggtttttttt		1080
tatttttagttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt		1140
tggttttagg tttataaggtt agaaagatattt agggatattt gttttttttt tagtgtatag		1200
ttggggaaatg ttttaattttg gatttagttt tttttttttt tttttttttt tttttttttt		1260
tggggatattt ttgtttttgtt gttttttttt tttttttttt tttttttttt tttttttttt		1320
ttttttgtttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt		1380
aaaatgggag ggagaggaga gggagaaaga ataaattttt tagggaaaaaa attttttttt		1440
aggatataata attttttttt tttttttttt tttttttttt tttttttttt tttttttttt		1500
tgtttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt		1560
tattttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt		1620
gggttggata gttttttttt tttttttttt tttttttttt tttttttttt tttttttttt		1680
tgtttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt		1740
agttatattttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt		1800
tattttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt		1860
gggttggatagg aattttttttt tttttttttt tttttttttt tttttttttt tttttttttt		1920
agtttagatg aaaggaaattt tttttttttt tttttttttt tttttttttt tttttttttt		1980
aattttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt		2040
tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt		2100

ttgtttttt	tatggatgg	aagtgggtgg	agagtatgtt	tttttagtt	gtttggtag	2160
agaatttgat	tttgaatgt	gtgtgggttg	tatgtagaat	tttgggttg	ggttgtgt	2220
tttgggtttt	ttgtgtgtat	tttgggttg	tgtgtttgt	ggtttttgt	gttttttagg	2280
ttttttttt	ttttttttt	ttttttttt	tttgggtgg	tgtgggtgg	attttgcgtt	2340
gtgggtgtgg	tgtgggtatt	tgtagaatgt	tgggggttg	gtttgtgt	ttgtgttagt	2400
gttgggtttt	tttttaggt	agtagggat	ttgtgggttg	tgggggtgt	ggaaagggtgt	2460
tagttgtgtt	ggtgggtgt	gtagtattag	tgggttgga	gatatgtgt	tgagtgggg	2520
gaaattttt	aggtgttgg	agttgaatgt	tgtagttta	gatttgggt	ttagggag	2580
gttgggttg	ttgttagattt	gtgtgttg	ggtgggttg	gtgtgtgt	ttaggtgt	2640
gttttgggg	tagttgtata	ttgtgggtt	gttgggttg	agttatattt	tgttaggg	2700
ttgttttagg	gggattttgt	gttgtggat	gtttagggt	tttagttgt	ttttttggat	2760
ttgatgtagt	agggttattt	tagatgttt	ggtgtggagg	gttatggta	tggtttgtgg	2820
ttgtgggtag	ggttagattt	gtgtttgt	aggtagaaag	gtttagaaat	ttgtgggtt	2880
tttggaaaaa	gagtagatgtt	tgaggttaga	ggtagatgt	tgtatgttt	gttgatatgt	2940
gagttttgt	tttgggttg	tttgggagt	ttgtgggtt	ggtgaagtt	gtgtattgt	3000
tgggagtaag	tgtagttta	ggatgaatgt	ttttgttag	ttttgggtt	tttgggttt	3060
taatttaag	tattggttt	ttgagttat	atgtattata	aagggttgg	aggatggta	3120
gggattgtt	ttttgtttt	atattggtt	aaatattatt	ttaggtataa	tttgatttgg	3180
agtgatttt	aagagtagtt	ttttgaatt	ttattttatt	ttgtgttg	tttggataga	3240
ggtttagttt	tatggtagg	gggtgggggt	gtatgaggat	ttgttaaagg	tggttttaggg	3300
aagattgggt	ttaaaataaa	tgtaaagat	ggattaggg	gttgggtttt	tttaatgtgt	3360
tgtttttagt	gtttgtttt	agattttgt	atattttgt	ttgtttttt	tttgggttg	3420
ttttttttt	ttgttggta	gaaatatgt	gtgtgtat	aggatgattt	tggggaggt	3480
tatattgtaa	tttagatagg	gtagatagaa	tgggtgtgt	ggttgtat	gtagtttagt	3540
atagatagt	atatttagt	gttggggaa	ttgatagggg	gtatttgagg	gaaagggggt	3600
ggagatttt	ggtataatata	taggaagagt	tgtatgtt	tattaggaga	atgtatattt	3660
ttaggattt	agttttttt	tttgtaaaat	ggtttttaaag	tagatagatt	tttttataat	3720
tttttagat	tttttttagtt	tgattgtgt	gtttagtt	gattatagta	ttgttatttgg	3780
tttttattag	aattttttagt	tgaaggatga	tttagaaaaa	ttttgggtt	gggtgtat	3840
gggtgtttt	tttttttata	ggttggat	gtaattaaa	ttttggaaa	ttgaatataa	3900
aatgtgattt	ttttatattt	aatataattt	taggtat	attaaagttt	ttgttattt	3960
gttatattgt	tgggttgggt	tagttatag	atttttaaa	tgtattttg	tatgtttt	4020
tttttagttt	ataatttgc	ttttttgtt	tattttgg	aggatatgt	gaattaaata	4080
tttagatgaa	aaataaaatag	aaaaaagttt	ttaattgt	taaaagttt	atatgtat	4140
gtatataat	atataatata	atgtgtat	atataatata	atataatata	atataatata	4200
aggagataaa	aaataggt	agtattat	gttggataaa	ttttggat	tttataattt	4260
tgaataaaatt	ttttttgtt	tagttataa	gattttgata	taattattaa	tattttgtt	4320
taattgttat	tttaaaatatt	taatagagta	ttttagtga	tgtttatgt	ttattttaaat	4380
gttaagttt	ttgttattaa	gagttatatt	ttttagtatt	ttatattaag	tatataattt	4440
atthaatttt	tataaaaata	gattttgtt	ggataatat	taaatgtat	tgaagttaa	4500
attgagttt	gtattatgt	tttagatatt	tttagaaata	aagggttaaa	aatatattag	4560
gtgttattgt	gatattttt	tttaggtt	gtaattatt	ttttttaaag	taatttttta	4620
tagatgattt	aatttttata	aatttatttt	ttaattttta	aatgttttt	taaaatataat	4680
gtaaaaagta	tttttaggg	ttttttaaaa	atgtgaattt	gttaaattat	atgtaaatgg	4740
tataaaagaat	tttataagtt	ttgaaagaaa	aaggagat	atataattt	ttatggagaa	4800
tagtaatttt	tattttttt	tttagatata	gatatttagt	agaaaggtt	tttgggtttt	4860
taaaatgtt	aagttataga	gagagaaatt	aaaataagt	tattttgtt	gattaagaat	4920
gttttttag	aaatgtttt	tgggttgt	gaagttaaag	gttggagag	tgagaaggaa	4980
ggaaggaatg	tgtttgtat	tgtgaggtt	ttagtgtgt	aatttaggt	agagagtgt	5040
tggatgttt	tgtgtgttg	atggtagga	tttgggaat	agtttaggt	taggttattt	5100
ggtagttttt	tttggtagat	atgtatttt	gttattgtat	agtgtggat	gaatgttagt	5160
ggggagtgt	ggggagattt	ttgtttgtt	atagggat	gtgtgtata	tttagagaaa	5220
gttgttattt	gggagagaaa	tttagtttt	tttgggtt	tttgggagg	ttggaaagta	5280
ttttatgttt	tttgggtt	ttttaagtaa	gaggaaaaat	agtttgg	tgaattata	5340
ttttatgttt	aaaatagaat	gttagttaa	agtgtatgg	tattaattt	ataaaatagg	5400
atatgggtt	tttttttgaa	ggaaatataat	tttataataa	aagttttt	ggatataatgt	5460
ggattaaatg	ttttatttgg	tttagtttt	agttttgaa	tagaggtt	tttatgtttt	5520
tgattgtatt	agggaaattag	attttgcatt	aaatgtttt	gtatttttag	gtgtgtttt	5580
tagttgtat	gtaaatatttt	tttattttgt	taattaaatt	tataaatttt	tttatgtata	5640
gttttagttt	tttgggtt	taaatatgt	aaaaatatgt	attattaaaa	gtttaggtata	5700
tgaatataag	ataaaaggtag	atattttgt	tttaaaattgt	ttttaggttt	ttgagttgt	5760
ttgattgtt	tttggaaatgt	ggtttttat	tttttagtgg	tgtttatatg	gatttatttt	5820
ttgattattt	tttaattat	ttttttggat	atagtattaa	tatgtat	tgaggtgtt	5880

ttagagtgtt tatgtttagg gttttaggat atatgatatt	taatggaggt tttgttgtta	5940
gatattagtt attatttgg atattaaatg atttaatta	taatgtttagg agtggttggt	6000
tttgggtttt gggatattat gtagttattg agagattt	gagtgggttt ttagatttagt	6060
ataaaaaaga aatagaaagt tataaaaatg ttaatgatgt	tattatgtaa atatatgttt	6120
ttgtgtttt aaagattttt agtattgtag tggtttagta	taggagagtt tttttatag	6180
tttagtattga aaataaaat tggatataaa taaatattga	aaagaaagat ttttattttt	6240
tgttgggtat agtgggtttt tttgttaggtt aataatggtt	atttatgttt tagatttagt	6300
ttagaaaaaa gtaagagtat ttagggaggg aggagagagg	aatagggaa aggagaagga	6360
aaggaaaggg gatttgtat ttttttattat tgatatagg	agaataagaa gtttagttgt	6420
ttttttatag gttttagttt ttagagatt tataattaa	gttagtttaa gaagtttagt	6480
aaaggttagt ttttaatta tttttttt agtattttt	tttaaattta ttttggtgag	6540
ttttgtttt gggtttggg agtatgggtg ggaaagtata	ttgtgtttagt ttgatttttt	6600
ttttttgtt ttggtaaaaa ttttattttt gtttttagtt	tttttgggtt ttttttttat	6660
ttttttgtt tggatataa ttttttagtt gtgattttt	gttttttta ggtgaagaag	6720
ggtaaagatt gattttgggtt ttttggtaa tttttttta	gttttatttt ttttagtgggt	6780
tgttgggtat tttttttttt tttttttttt tttttttttt	ttttttttt tttttttttt	6840
taattttttt tttttttttt tttttttttt tttttttttt	ttttttttt tttttttttt	6900
attttttttt ttgagggttg atttttttt gttttttata	tttaatttaag agtaatttt	6960
taagttttttt agttttataa tttttttttt tttattgtat	t	7001

<210> 24

<211> 11001

<212> DNA

<213> Artificial Sequence

<220>

<223> chemically treated genomic DNA (Homo sapiens)

<400> 24

ttaagttaga tttttttaa ttatttggg ataggttagg	tatatttga gtttaatttt	60
attttatagg ttaatattt tggagttaga aagtttttag	gtaaaaagtt tgaaggggt	120
ttttttatgt tattagatgg atttttgtat ttttagaaga	ttttttatat taggaaagat	180
taaaagtatta aggttaattt ttttggttt ttggataat	tttaggtttt ggtatgagtg	240
gtttggaaat ttttggttt gttataatgt ttatataattt	ttggaaattgt ttgttaggg	300
ttgtttttt gtaataattt ttttttaagt tttattgtag	ttatagttta ttagttttgt	360
tttagtataa ttaagaaatt aagaattatg tattatgtt	tattttttta gagttatttt	420
tttttaggat aaagtttagg gttttgtat tgggtttgt	taggagttgt agttgttaggg	480
tttggttattt atttaatagt ttttgttaat atattgtgaa	ggggaaatgaa tgatttagaga	540
tagggtagt ttttttagtt ttgtatgtt aggtgtatgt	gtatataattt ttatataaggg	600
ttgtgggggt tatttattat taagaatttt tttttttttt	tgtgtttaa gagttgtaaat	660
tttgggtgtg atagatatag taggtgtttt atagttttt	tttaatgtat ttatgtgtt	720
ttgtgttttga tatttgggtt ttgtttttggg tttttttttt	ttggtaggtt aaaggaagtg	780
ttttttttggg agggatataga gatagggtgt atttttttta	tattttgtaa ggagggtgg	840
gtgtaaagat tttttttttt ttaaagaaat agagaaatta	gttgaattttt gatgaagttt	900
gttgagatgt tagttttttt ggggttagt tgggtatgtt	ttttttttttt tttttttttt	960
ttaaagataa ttttagttgt gattttttga gtattaggt	ttttttttttt tttttttttt	1020
ttttttatgtt ttttttttga gtagttattt tattaagttt	ttttttttttt tttttttttt	1080
ttgggttattt ttttttttga tttttttttt aatttttagtt	ttttttttttt tttttttttt	1140
ttttttataa gttttttttt gtaagatggg tttagtataaa	ttttttttttt tttttttttt	1200
tagggttttt ttgaaaaatg atatagttgg tttttttttt	ttttttttttt tttttttttt	1260
ttttttttttt atgtatataat tttttttttt gatttttttt	ttttttttttt tttttttttt	1320
ttttttttttt tttttttttt tttttttttt tttttttttt	ttttttttttt tttttttttt	1380
ttttttttttt tttttttttt tttttttttt tttttttttt	ttttttttttt tttttttttt	1440
ttttttttttt tttttttttt tttttttttt tttttttttt	ttttttttttt tttttttttt	1500
ttttttttttt tttttttttt tttttttttt tttttttttt	ttttttttttt tttttttttt	1560
ttttttttttt tttttttttt tttttttttt tttttttttt	ttttttttttt tttttttttt	1620
ttttttttttt tttttttttt tttttttttt tttttttttt	ttttttttttt tttttttttt	1680
ttttttttttt tttttttttt tttttttttt tttttttttt	ttttttttttt tttttttttt	1740
ttttttttttt tttttttttt tttttttttt tttttttttt	ttttttttttt tttttttttt	1800
ttttttttttt tttttttttt tttttttttt tttttttttt	ttttttttttt tttttttttt	1860
ttttttttttt tttttttttt tttttttttt tttttttttt	ttttttttttt tttttttttt	1920
ttttttttttt tttttttttt tttttttttt tttttttttt	ttttttttttt tttttttttt	1980

aaattttgtt	tttattaaaa	atataaaatt	agttaggtgt	ggtgttat	gtttgtatt	2040
tttagtttatt	aggagggttga	ggtaggagaa	ttgtttaaat	ttggggaggtg	gaggttgttag	2100
tgaattgaga	ttgtgttatt	gtattttagt	ttgggttaata	agagtaaaat	ttgggtttaa	2160
aaaaaaaaaa	aatttagtaaa	attatatttt	aattgtat	tttgatata	gtattttagt	2220
tgagttggag	tgaggggtt	tttggagaa	ggtagttt	ttttttttt	tgttttgta	2280
tggggttat	atttattgt	gggtgagagg	agtggagagt	ggtgtat	atagtttag	2340
ttttagtgg	atagagttagt	atttggagtt	agttttt	tttttatata	tagtgagaaa	2400
aattattgt	atatgtat	taattttgt	ttaagtgt	taaaagtag	tttaggtta	2460
gttttaatt	tgttagaggt	atataggtag	ttttttgg	gtttttgt	ttttttgt	2520
ttgtttggag	atttggttt	aagatttt	ttttttgt	gatgaagttt	tatttttgt	2580
tttaggttgt	agtgttagtgg	ttggatttt	gttattgt	agttttgtt	tttgggttta	2640
agtgat	ttgtttt	tttttgagta	tttgggatta	taggtgt	ttataataat	2700
atttggtaa	ttttttt	tttagtagag	atggatttt	attatattgg	ttaggttggt	2760
tttgaattt	tgat	tgat	tttttttt	ttttttttt	ttaaagtgt	2820
ggtgtgaatt	attttagtt	atttagagat	tttaattt	attatttatt	tttatttttta	2880
tttagggatt	ggat	tttgggtt	tttgggtt	tttattgtat	tagttttt	2940
attgat	ttttttt	ttttttt	tttattgt	tagttttt	tttgggtt	3000
gttagata	ttttagttag	aatgtgagtg	ttatagat	agttaaat	agtgttgatt	3060
aatattttgt	ttttagaagaa	tttttataag	ttttttgt	gaatgattt	gtttagtt	3120
taggagat	agggtttt	ttgat	tttggagtt	ttttaagt	ttaaatttatt	3180
tgatgggat	aaatggagag	gatagat	ggagtaggt	ggagtgtt	atagaatgt	3240
tttttattt	gaatttgg	ttat	tttagtaagg	atgtgggtt	aagaat	3300
tttagggtt	tat	agtaaagg	ggaggggtt	gaatttaa	tttattttt	3360
ttttaagt	ttaaagg	tttggat	gaagagat	ggagtaaa	ttttagtata	3420
aattttatt	gggat	gtat	ttggtagt	aaaataat	gtgtgggtt	3480
tggaaaat	gggttgg	ttgtgata	agtagtgat	gtttagttt	atatattaa	3540
tggaaaga	tat	ggaggat	tagggtag	agaaat	gatagattt	3600
agtgttagg	taa	gattt	ttttaga	aggaggtt	taggtgt	3660
gttaattt	tttgg	ttttag	tttattt	aatgaga	tttgggtt	3720
ttttttt	tggat	aggat	ggtgggt	tagtattt	atttttagt	3780
ttttttt	tggat	ttttt	tttggat	ttttagt	aaatagattt	3840
tattgtata	tttttt	ttttt	tttggat	ttttttt	ggatttaggg	3900
tggttgg	aagg	taat	tttagt	ttttttt	tttttaaagt	3960

ttttttttt	gtattat	gattt	ttat	attgttata	aaaattgtat	4020
ttttttttt	tgagat	ttt	ttttag	ttggagtgt	ttgtgtatt	4080
ttgggttatt	gtat	ttttt	tttgg	ttaagt	ttttttta	4140
tagtggat	tat	ttttt	tttgg	ttttgt	ttaggtg	4200
atggggttt	attt	tttgg	tttgg	tgat	tttattt	4260
tttggtttt	taa	tttgg	tttgg	tttgg	tgtttagt	4320
ttttttttt	ttttttt	ttttttt	ttttttt	ttttttt	ttttttttt	4380
ttttttttt	ttttttt	ttttttt	ttttttt	ttttttt	ttttttttt	4440
tttagtttt	attt	tttgg	tttgg	tttgg	aatgtgtt	4500
ttttttttt	ttttttt	ttttttt	ttttttt	ttttttt	ttttttttt	4560
tttagtata	ttttttt	ttttttt	ttttttt	ttttttt	ttttttttt	4620
gatttgg	ttttttt	ttttttt	ttttttt	ttttttt	ttttttttt	4680
ttttttttt	ttttttt	ttttttt	ttttttt	ttttttt	ttttttttt	4740
atgat	ttttt	ttttt	ttttt	ttttt	ttttttttt	4800
ttgggattt	attt	ttttt	ttttt	ttttt	ttttttttt	4860
gttttattt	ttttt	ttttt	ttttt	ttttt	ttttttttt	4920
ttgttattt	ttttt	ttttt	ttttt	ttttt	ttttttttt	4980
tttttattt	ttttt	ttttt	ttttt	ttttt	ttttttttt	5040
tttttattt	ttttt	ttttt	ttttt	ttttt	ttttttttt	5100
tttttattt	ttttt	ttttt	ttttt	ttttt	ttttttttt	5160
ggatttattt	ttttt	ttttt	ttttt	ttttt	ttttttttt	5220
tttttattt	ttttt	ttttt	ttttt	ttttt	ttttttttt	5280
tttttattt	ttttt	ttttt	ttttt	ttttt	ttttttttt	5340
tttttattt	ttttt	ttttt	ttttt	ttttt	ttttttttt	5400
tttttattt	ttttt	ttttt	ttttt	ttttt	ttttttttt	5460
tttttattt	ttttt	ttttt	ttttt	ttttt	ttttttttt	5520
tttttattt	ttttt	ttttt	ttttt	ttttt	ttttttttt	5580
tttttattt	ttttt	ttttt	ttttt	ttttt	ttttttttt	5640
tttttattt	ttttt	ttttt	ttttt	ttttt	ttttttttt	5700

ttatattttt	gtagttggtg	ataggtaga	atagggaa	ggtaggggtt	tagttggttt	5760
tatataggag	tgtagatgga	ggagtaggat	tttttttgt	tttttaagtt	tttttaata	5820
tatttttaa	tttttggta	ggatttttt	ttttttat	tttttttag	tttttttaag	5880
gagggagtag	gagtatttga	atgtggaaat	tgaggtgtt	gtttaaattt	tttgggtgg	5940
tttagttata	gttgataat	gtttggttt	gttttattat	aagttatata	gttggttttt	6000
ttgtgtttaa	tttgggtgt	atagaaatta	agggggttt	ggtatttagt	attaggtgg	6060
tggaaattggg	gtttatgt	tggtttgg	ggttagttt	tggtaggt	ttgtggggag	6120
ttatgttagt	aggagggtgg	gttggttt	tgatttagga	tgtggtaat	gattggggag	6180
ggtggagtt	tagtattgt	tttttttt	gttgggtgt	atttttgt	ttttatgttgg	6240
tttgggtgt	gtttgtgagt	tagtaggtt	tgtgtggta	agtattgtt	gagttttgag	6300
tttgagttt	tttgggtgt	gtagttattt	tttgggtgt	gttttaggt	tattttggaa	6360
gaagggtttt	ttgtttgtt	tataggta	tttgggtgt	tttagtttt	gtgtgtttgt	6420
agttgttaat	tattttttt	gttgggtgt	tgtgtgtat	tgtgttagt	tgtgtgtgt	6480
tttgggttag	agttgtgtt	taattgtta	gattgaaat	tagattgtt	ggatttttagt	6540
tttggtttat	tgggttagga	atgtgggtt	ggggatatgt	atgtttgtt	tttaggaat	6600
attttattgt	tttggagttt	tatttata	tatagggaaat	gggggtgggt	6660	
gttagtgtt	gggtaagtgt	ataagagtgg	tttttgggtt	gaggtgaggg	tgggaaggtg	6720
tgggaagtgt	gtgtgtgtgg	agtttgggtt	agtttgggtt	tgggttgg	tgtgtgggt	6780
ggagttattt	tggagttgg	aatttagttt	tttttttag	ttttgtgt	gaatttagttt	6840
tttgggtgt	ttggaaattt	ggttaattt	atgtttttt	tgtgtgtat	ttaggttagtt	6900
tttgagaat	tttggattgt	gtttgttta	ttttgtttt	ttttagatgt	tttgggtttt	6960
gtgtttattt	tggtgtgtt	ttgttttatt	gtgggtttt	agtttaggtt	ttgggggttt	7020
taatagtta	ggtagatgag	tgtgtgttag	ttgttagtgg	aggtgaattt	gtatatttga	7080
gagaggtttt	gtgggtgaggt	ggaggagttt	tagttgggg	aatgtttt	gagattgaag	7140
ggaagttttt	gggagagggt	tgtgtttgt	tagttttgt	agtttgatt	tattttagt	7200
ggttattttt	tattttat	tggattttt	tgtgtttat	ttgggtgtt	gaaaatttgg	7260
tggaaaggta	tagtagaga	gtttgttta	atagttggat	tttattgtt	tagtataaa	7320
ttttttttt	ttttatttgg	aattaaaaaa	ataataataa	aaaattgtt	tttgggtttt	7380
ttattttagt	tggagtgtaa	tgggtgtatt	ttgtgttatt	gtatattt	ttttttgggt	7440
ttaagtgtt	ttttgtttt	agtttttga	gtatttagga	ttatagggtt	ttgttattat	7500
tttagttaa	ttttgttatt	tttagtagag	atgggtttt	attatgtt	ttaggtgtt	7560
ttaaaatttt	tgatttttag	tgatttattt	gttttgggtt	tttaaagtgt	tgggattata	7620
gttttgagtt	attgtattt	gtttttattt	ggaatgtat	atggaatata	tttggttatt	7680
tatttgaagg	aaaaattttaa	tatttttaat	ttatgtttt	ttgtgtt	ttattttgtt	7740
ttatttttt	tagattaaga	tattttttt	tatattttt	aattttt	ttttttttt	7800
ttttttattt	attttagtta	gttttggtt	tttttttagg	aaattgttt	ggatagggtt	7860
tttagtatt	tgtgtattat	taaatggaaat	tttagtggttt	attttttatt	tttatttttt	7920
tagtattatt	tgaagtttgt	ttttttgtat	tttttaggggt	tatattttt	tagtttttt	7980
tttattttt	gtagttttt	tttagttttt	tttagtagattt	tgatthaatt	tttataatttt	8040
atgatgaat	ttgggtttag	ttttgattat	ttggttgggt	tgtttataatt	tatttggttt	8100
agatttatgg	ttgaatattt	gatthaattt	tttagatttt	atttttgtt	tttagtatttt	8160
tatttaggtt	ttaaaagat	gttttaagt	aatatggta	aaatttaatt	tttttttttt	8220
tagttttt	gttatattt	tttagttttt	ttttgttagt	aaaaatggtt	ataggtttt	8280
tagttattgg	agataaaaat	ttaaatttat	tttgattttt	ttttttgttt	ttattttta	8340
taaaatgtt	taaatttttt	gttttttat	ttttaggtt	attttattt	tttttggaa	8400
tgttgaat	tttttagttt	gtttttttt	ttttttttt	ttttttttag	atagatgtt	8460
attttgggt	taaggttgaa	gggttagtgg	atgattttgg	tttattgtaa	tttttggttt	8520
ttgtgtttaa	gtatatttt	tatttttagt	tttgagta	ttgggattat	aggtatttt	8580
tattatgtt	ggtttatttt	tttttatttt	tttagtagata	tgagggttta	ttatgtgtt	8640
taggtgtt	ttgaattttt	gattttagt	gatttattt	tttttggttt	ttgaagtgtt	8700
gggattatag	gtatgat	ttgtgttgg	tttttggttt	atttttgt	ttttgttata	8760
attttgggt	tttttagtt	gaatttgt	tgtttttt	tattggat	gagggttttt	8820
atgtatata	agatttggga	tattttat	ttataagtt	ttaaataggt	tagtagtag	8880
atgttaatt	tagattttat	gttataataa	tttggggagt	ttttaaaatt	tattgtat	8940
tagggtttat	tttttagtagt	tgatthaata	gtttgtgtt	gggatttag	ttaggggaa	9000
ggattgtaaa	agtattttt	gtgattttag	ttgggtgtt	tttagggag	agtaatttt	9060
gtttgttgg	gattttttag	ggtgtagaag	gattgttgg	tgtgtggtt	tgtgtatatt	9120
tttagtattt	atttatttgg	ttagaaaagg	gttgggttta	aataaagatt	taataaaaatt	9180
tttgggttta	gggggtttat	taaagggtttt	aaattttttt	aggtttttt	ttataggtt	9240
taattttttt	ttatattttaa	gtttttggag	gggggttat	gtgttgaga	agaggtaagt	9300
ttgggaagat	ggattttttag	gatgttaggt	ataaattttt	tttaagaag	gtttaaggtt	9360
tttaaagat	aagaaaattt	aaatttagt	attttataat	ataagtagtt	attttggttt	9420
atttgggtt	tagatatgag	tggagtgta	taagggataa	attattttt	tgtattttt	9480

agtatgggg	tgaaagtaat	ggattttagtt	tttgggagtt	gtttttgtt	atttttttt	9540
ttgtgattt	ttttgtgtt	ttttgtgtt	ttttttgtt	ttttgttaggt	9600	
gtgtgggtt	attatttat	tgttatgtt	aggtttttgt	gtatgtat	9660	
ttgttataga	ggttgtatta	tgtgtgtgt	gtgggtttt	tgggttggaa	9720	
ttggtaggaa	ttagttgtt	tgtgggtt	tatgtgtgt	tttgtgtat	9780	
ttggtatgtt	ttagttgggt	gtggttttt	ttatgtgtt	taggggtgt	9840	
agtttaatga	gtttaggtt	ttttgatat	gttgggtgg	gtttgtt	9900	
gggtgttagt	aagtgtgggt	tgggtgggt	tatagggtgg	ttttgtt	9960	
tttaggattt	agatgggt	gtgggaagga	gttgggaga	gttgtgtat	10020	
gtgtaggat	tgtgggggtt	gaaggtgggg	ttgggtgtgt	ttttgttagag	10080	
tttggttttt	ttttttttt	ttgtttttt	tttatatttt	attttggat	10140	
ttgtgattgt	aaagtattat	gtggagat	ttgtgtttt	ggaggttagt	10200	
tagaggaaga	gggtttttat	atttggttt	gtttttttt	gtttgtttt	10260	
atatttgggtt	tatttattgg	gtggggtag	aagtttttag	tttttattt	10320	
gagggagattt	gtttagtagt	tttattgtt	gtttgtttt	ttattgtgga	10380	
ttggtagagg	ttggattgt	attttgggt	ttaggggtgt	attttgggt	10440	
gtatgggtgg	ttgggtttt	gtatttttta	gtattttttag	tttgggtt	10500	
taggatataa	gtttttttat	gttttttta	gttgggttatt	ttgttatttt	10560	
ttgggtattt	ggatggtaat	gtatgtgggg	gatgtgggag	taggttttag	10620	
tttttaggata	tttttattt	tagtaatatt	atttattttt	gtattgtgag	10680	
aagttttgtt	attttagttaa	gtatagtggg	gttgggtttt	agttattgtt	10740	
tttagttgtt	ggtttttagt	tatttggggg	aaagtttagga	agttttgatt	10800	
ggtgggggtt	tttttattt	atttatgtt	tttggatattt	tttgggttattt	10860	
ttataggttt	tattttgtt	tttggatgtt	tagttttgt	tttgggggtt	10920	
ttggaggtgg	tgtttggtaa	ttgtttgtt	tttgggtttt	tttagttgtt	10980	
ttagattttt	gggattttaga	a			11001	

<210> 25

<211> 11001

<212> DNA

<213> Artificial Sequence

<220>

<223> chemically treated genomic DNA (Homo sapiens)

<400> 25

tttagattt	tggaaattt	ggagtgggt	gagtggaaaa	atagaggtaa	gtggtaggt	60
attgttaat	tttttttta	gtatgtttt	agtttttt	agtaggattt	gtgggttag	120
gtgtgaaggt	aagggtt	gaaatggtag	ggagggtt	ggggatgt	gaggtatgg	180
tgtgggtgg	gtgtttt	tttttaggt	taggtattt	tttttattt	tttttttagt	240
gggtttagat	ttataggtt	gtatgttt	agtagtgg	tttaggtgg	ttttgtt	300
tttattttag	tgttaggtt	tttaagtgtt	gtttagat	tttagatgt	ttgttatttt	360
gttaggtttag	gtatttt	attttggatt	tttaagtttt	attttat	tttttatat	420
tattgttatt	tttaatattt	atttggttt	agggtgtt	aagttaagta	ttgggaaaag	480
tatggaaaga	tttggtttt	gttagttt	gtttagat	ttaaatgagg	ttgttagtt	540
ttgagggtt	attattttat	tttaagggat	ttatttat	tgtatttt	aattttaa	600
ttatggttt	gtttttgtt	gagtttt	tttggatgt	gagatgt	ttgggtgtt	660
agttgtttag	tgatttttt	ttttttt	ttaagtgtt	gtttgagatt	ttttgtttt	720
tttagtgggt	aggttaatgt	tttggttt	gttaattt	tttaggggt	taggtt	780
tgtggggatt	ttttttttt	agtatgtt	agttgtttt	tagaaatat	gttattttt	840
tgtgggttt	tgtgggtt	gttgggtt	tttgggtt	ttgggtgt	ttggggat	900
aaggaggaa	ggaagggtt	gttgggggg	gttgggt	agtgtttt	ttttgtttt	960
tgggtttat	agttttt	tttaggttt	tattgtgt	ttttttt	ttttttttt	1020
ttgttttagt	tggatttt	gggagggtt	gaagtgggg	tttgggtt	gtttttgtt	1080
ggtttgttt	tgttaggtt	taaagttagt	gaagtatgg	tttaattt	ttatgttgg	1140
ggagttttag	tttattgt	tgtgggtt	gttgggtt	gggtgtgt	gaaagggtt	1200
tatttgggt	gagtgtt	atgtgtgt	tattgtgt	gttattgt	gtatgtt	1260
atggtagtt	gtttttgtt	gtgggtt	tttttagtt	gtgggtttt	ttatgtt	1320
gtgggtgt	ttttgtgt	attttattt	gggtgtgt	tgtaaagg	tgttagt	1380
gtgtgat	ttttgtgt	tttttattt	gggtgtgt	gttagtaagg	gttagt	1440
ttgtgtgg	ttaagtgt	gtagaggggg	ttgggtgggg	tagttttga	ggatttaggt	1500
tgttatttt	tttttattt	tgaagagt	gtgaaaatgg	tttattttt	tttattttt	1560

atttgtatggggttataga tgagtagagg tgggttggta tatgtaaaaa tatgttgatt 1620
ttaagttttt tatttttaaa atgttttggg ttttttttagaa aagggtttg tgggtttaggt 1680
tttggagtt tatttttttta ggtttgttt tttttaaata tttatgattt ttttttagaaat 1740
ttttaggggtg aagggaaattt attattttatg ggagggagtt tggaaaaattt tagaattttt 1800
ggtgggtttt ttgttaaagt gatgtttgtt gagttttat ttagttaataa tttttttttg 1860
attttagtgaat ttagatgtta aatatgtat gtagttatat atttagtagt tttttttgtat 1920
ttttggaaat tggtagtaag taaagggtgtt ttttttttgg gtagatatta gttggaaatta 1980
ttaggggtgt tttatagtt ttttttttta gttggattt tattttagat ttgttgaaattt 2040
aattgttggg agtggatttt aggtattatg aaattttaaa aatttttaaatttattgtaa 2100
tatggagttt ggggttagta ttattttttt ggtttattta ggaattttgtg gatggatgt 2160
gttttaggtt tgggtgtgt tggagattttt tttttttgtt ataagaggat attataaaattt 2220
tagttggggg ggtataaag ttgtataga atgtaaagaa tgaataaggg gttgagtgt 2280
gtgggttatg tttgttaattt tagtattttg gaagggtggag gtgggtggat tattttaggt 2340
taggagtttta agatttagttt ggttaatatg gtggaaattttt atgttttattt aaaaataaaaa 2400
aaaaatgagt taggtgttagt ggtgggttt tggtaattttt gttattttggg aggttgaggt 2460
gggagaattt tttgaatataa ggaggtggag gttgagtgt gttgagattt ttttattttt 2520
tttttagttt ggtgatagag tggattttgg ttttaaaaaaa aaaaaaaaagaa 2580
taaggttggg atattgttagt gttttaaag agaaataaaag tagttatgga gataagaagt 2640
aggatgattt ggtatgtttt attagaggta gagataaggg agaaattaaa gataagttt 2700
ggttttttgtt ttttagtaattt gggagtttag tggtaattttt ttttggtaaag aggaagtttgg 2760
gtaagtgtag tagtgagggtt gaagaaaagg gaatttaattt tttggtttagt ttatttga 2820
tgggttttagt atatttttagt gaaggatttgg gtatggagga ttttagttgtt gggtttaggt 2880
tagtggtttta gttgtggattt tgggttagat gaatgttagat agatttaggtt agtggatttgg 2940
attgagtttta gattttattt gtagatatttgg aagtttaggtt agaatttgtt aaggagtttga 3000
gttaggagttg tagggggtagt gaggaaaattt gggaggtgt agttttttggg agttaaaggg 3060
agtaagttt aaatgtatgtt gagggggtgtt gatggagaa tggaaatattt gattttattt 3120
ggtagtatata agattgttga ggattttgtt tgggttagtt ttttggagga agaggtaat 3180
ttgggttggag tggtagagg ggaggtgaa ggtgaaggat tagagtgtat agagatttagt 3240
gtttgggtt gaggggagta gagataggta ataattatag ggtagatgtt ggttaaaggt 3300
gttttagttt ttttttaagt aaatgggttagt atgttttttata tttttttttt tagtgaaggg 3360
ttgggtgtgg tggtaattt gtttagttt agatttttgg aaggttgagg tgggtggattt 3420
attttaggtt aggagtttga gtttagtttgg tggtaatatttgg tggatttttttaaa 3480
aaatataaaa attagttggg tttgtgttgg ggtttttgtt attttaggtt ttttaggaggt 3540
tgaggttagaa gaattttttgg aattttggag tggaggttttgg tttgttagtttgg aattttgttt 3600
attgtatattt agttttgggtt ataaaatgaa gatgttagttt tttgtgttgg ttttttttaat 3660
tggtaatagag gaaaggggaa gttttgttgg aggtgataga gatttaatttgg ttttaggtt 3720
ttttttgtt gttgtttttt gttttttttt tagatgtttt ggttttttaat attagagttt 3780
gtgttagtagt gtggagttat tttttttttttagt gttttttttttagt gttttttttttagt 3840
ggttttttt tttttttttttagt gttttttttttagt gttttttttttagt gttttttttttagt 3900
tgggtttttttagt tttttttttttagt gttttttttttagt gttttttttttagt gttttttttttagt 3960
gtttttttttttagt tttttttttttagt gttttttttttagt gttttttttttagt gttttttttttagt 4020
ggatataat gttgttagt gttttttttttagt gttttttttttagt gttttttttttagt gttttttttttagt 4080
tatagtgtat gttttttttttagt gttttttttttagt gttttttttttagt gttttttttttagt 4140
tgatttttttagt gttgtataga ggggtttttttagt gttttttttttagt gttttttttttagt 4200
tgggtttttttagt gtaatgtttttagt gttttttttttagt gttttttttttagt gttttttttttagt 4260
ttttgtatgtat gttttttttttagt gttttttttttagt gttttttttttagt gttttttttttagt 4320
tgggtttttttagt gttgtttttttagt gttttttttttagt gttttttttttagt gttttttttttagt 4380
ggagtttttttagt agtggatgtt gttttttttttagt gttttttttttagt gttttttttttagt 4440
ttttttttttagt gttttttttttagt gttttttttttagt gttttttttttagt gttttttttttagt 4500
gtgggtgtttttagt gttttttttttagt gttttttttttagt gttttttttttagt gttttttttttagt 4560
ttgggtgtttttagt gttttttttttagt gttttttttttagt gttttttttttagt gttttttttttagt 4620
gggttgggtttttagt gttttttttttagt gttttttttttagt gttttttttttagt gttttttttttagt 4680
ttgttagttaa gaggattttgg atttggagtt tttttttttttagt gttttttttttagt gttttttttttagt 4740
agttttgttagg ttgtgtttggg attaggtggg agtttaggggg tttttttttttagt gttttttttttagt 4800
agtgggtttttagt ggagtttttttagt tttttttttttagt gttttttttttagt gttttttttttagt 4860
ttttttttttagt ttgttagttttttagt gttttttttttagt gttttttttttagt gttttttttttagt 4920
gtgtgttaaa tttttttttttagt atttttttttttagt gttttttttttagt gttttttttttagt 4980
ttatagatag tttttttttttagt gaaaatgtt gttttttttttagt gttttttttttagt gttttttttttagt 5040
tatttttttagt tttttttttttagt gttttttttttagt gttttttttttagt gttttttttttagt 5100
tttgaatgtt tttttttttttagt tttttttttttagt gttttttttttagt gttttttttttagt 5160
tttggtaggtt tttttttttttagt gttttttttttagt gttttttttttagt gttttttttttagt 5220
ttttttttttagt atttttttttttagt gggatgtt gttttttttttagt gttttttttttagt 5280
ttatttttttagt gttttttttttagt gttttttttttagt gttttttttttagt gttttttttttagt 5340

- 39 -

gatttggaa tagataggaa agaagtttg tttggatta taagtattta ggagtattt	5400
atttataffa agggggaaag ttagattata aaatgtttaa agaggtggaa aaagagattt	5460
aggttataa tttaggattt taaggtgtt tgaattttt tagtatttt tattatttgg	5520
gaattgtgtg ttagatgtt ttgggtgtat tattaggtt agagaattt taggttat	5580
tagaaaaaag aaataggat tgcgaatttt agtatgtttt gtagaaatgg ggtggaaatt	5640
tttatttaag taaaagaaagt ggagttgtga gtatgtttt agataaaattt ttataaaatt	5700
ttttataaaa tgggtgtgt ttagatgtt aaaattttt tagtattttt ggggtgtaaagg	5760
gttgagtga gttagattt ttgggtttgt tttatgtt gttagttt agttattttt	5820
tattgtgaa aggtggaaa attataagat attaatttaat tgaaaaggag gtttagttat	5880
ggaggtgtat atttgaatt ttagttattt gggagggtga ggtagaagga ttattttgaat	5940
ttgggaggtt gaggtgttag ttagttaaga ttgtgttattt gtatttttagt ttgagtgtata	6000
gagttagatt ttgtttaaa aatagaaaag gaagtttaagt atgggtttt atatttttaa	6060
tgttaatgtt ttgggaggtt aaggttagt gattattttt aatttagaat ttgaggttag	6120
tttggtaat atgtgaaat tttattttt ttaatataat aaaaattttt taggtatgtt	6180
ggtgtgtat ttagtattttt gttatttttgg agattgaattt atttaatttggaggtt	6240
gtttagtga gttaaagattt tttatgtt gttatgtt tttatgtt ggtgataggg tgagggtttt	6300
ttttaaaaaaa aagaaagaag gttgggtttt gtagttttttagt tttgtattt tagtattttt	6360
ggaggttaag gtaggtat tattttagt taaggtttt agattgtta gtttaatata	6420
gtaaaattttt gttgttattt aaaaataaa aaaaattttt gttatgtt gttgtgttt	6480
gtaattttttag ttattttggaa gtttaggtt gtaggtttttagt ttgaatttttagt aagatagagg	6540
ttgttagttag tttagattttt gttattttttagt tttagtttgg atgagagat aagattttt	6600
tttaaaaaaaaaaaa aaaaagaaaga ataggaggtt gagaagttt aagttatata	6660
tttaaaaaaaaaaaa agaaaaaaaat attgttttta gtttaggtt agtggttt attttttaatt	6720
tttagtattttt gggaaagtttga ggtgggttga ttatgtttagt aggagttttaa gattttttt	6780
gttaaaaatgg tgaaattttt gtttattaa aatataaaa aatttagttt tagtgggtgtt	6840
aggtattttt aatttttagt atttggggg ttagaagtttga gattttttt aatttagggag	6900
gttagagattt taatgttta agattgttattt attgttattt agttttggaaa atagagttag	6960
atttttgtttt aaaaaaaaaaa ttatttttagt ttatgtttaa tagttagt ggggtgggtt	7020
ttttatgtgt tagaagggaa attttatgtt tttgtgtt gttattttttagt gatgtgtttt	7080
gaaattttttt tttatgtt gttttttggaa atagaaaaaa aatttttttt ttttttagaa	7140
tttttggaaagg gttgtgtat gtttttaattt taagtttgg ttttagtga agataggag	7200
gtttatttttta agaagggaaag gggttgaaa ttaggttattt gtatttttagt tttaggtttt	7260
tgggttattt aggaagggaa gaaggatgtt gttttttttagt tttaggttag gagtttagag	7320
ttattataag aataagttttag tattttttt gttttttttt tttttttttagt aaaaatgt	7380
ttttttttttt gttttgtt taggttttgg tttttttttt tttttttttt tagtattttt	7440
ttattttttgtt attttttttt gttttgtt tagaataaaata tattttatgtt ttatttttata	7500
gttttttagttt ttatgtt ggggttata ttatgtttagt ttattttttttagt gataaggtt	7560
tttattttttt ttagtaaggtt ttgttattttt gttttttttt tagtgggtttt tttttttttt	7620
gagattttttt gatattttggg gaagaaaatgtt agttttttt tttttttttt tttttttttt	7680
ttttttttttt aagggtttggg ttttagttt tagttttata ttttttttttgg ttgtagaata	7740
gtgtgggtt ttgggtttagt agttttttttagt taaaatgtt tttttttttttagt tttttttttt	7800
ttttttttttt tttttttttttagt agatggttttaa agtggttttagt gggatttttagt ggtggagtt	7860
gggagaattt tgggtttttttagt gggtttagtta taagattttt ttataggaaa ttttttttttgg	7920
atttttttgg gataaaagtat tgggttagt ttagtttagt tttttttttttagt atttttgtat	7980
ttaatttttagg gtttattttga ttttaatagg aagttttttttagt gatgttagtgg gtttaaggaa	8040
gtttttggaga agaaagttgg ttttagttttagt tgggtttttttagt gttttttttttagt ttatgtttagt	8100
ggtaagaattt tagttttttttagt atgaggtttgg ggtttttttttagt ttatgtttagt aattttttttgg	8160
ttgggtatgt tgggtttttttagt ttgtttaatggt gttttttttttagt ggggtttagt taggtggatt	8220
atttgggtt aggagttttaa gattaattttt gttttttttttagt tttttttttttagt tttttttttttagt	8280
aaatataaaa attttttttttagt tttttttttttagt gttttttttttagt gttttttttttagt tttttttttttagt	8340
gtttttttttttagt gttttttttttagt gttttttttttagt tttttttttttagt tttttttttttagt	8400
gttattttttttagt tttttttttttagt gttttttttttagt tttttttttttagt tttttttttttagt	8460
ttgggtttaaaa tttttttttttagt gttttttttttagt tttttttttttagt tttttttttttagt	8520
tattttttttttagt agatttttttagt tttttttttttagt tttttttttttagt tttttttttttagt	8580
aaatattttat tttttttttttagt tttttttttttagt tttttttttttagt tttttttttttagt	8640
tattttttttttagt tttttttttttagt tttttttttttagt tttttttttttagt tttttttttttagt	8700
ttgttagtggg ttatgtttagt gttttttttttagt tttttttttttagt tttttttttttagt	8760
ataaaattttt attttaattttttagt tttttttttttagt tttttttttttagt tttttttttttagt	8820
ttttttttttttagt tttttttttttagt tttttttttttagt tttttttttttagt tttttttttttagt	8880
tgatgtgtat atttttttttttagt tttttttttttagt tttttttttttagt tttttttttttagt	8940
tttagttttttttagt taagtttttttagt tttttttttttagt tttttttttttagt tttttttttttagt	9000
ttttttttttttagt agatggggttttagt tttttttttttagt tttttttttttagt tttttttttttagt	9060
gttgattttttagt ttgttttttttagt tttttttttttagt tttttttttttagt tttttttttttagt	9120

tagttgttt ttgtttttt g	tggtttgaag tagggtttta	tttagtttt taggttggag	9180
tgtgtgata tgataatagt	ttattgtagt tgtaatttt	tgggtttaaa tgattttttt	9240
attttagttt tttgaatagt	tgggattata ggtatattat	tatatttggt taattttttt	9300
ttttttttt ttagtagaga	tgaggtttt ttatgttgtt	taagtgggtt ttaaattttt	9360
gaggattaag tgattttttt	attttagttt tttaaaatgt	tgggattgta gatgtgagtt	9420
attatattta gtttgatttt	atttaaatg agatttttt	tttagagttt ttagttgtt	9480
tttggttttt ggttatgtgt	ttttagttgt	gtggatttt taaggttata	9540
tttagtgtt aggttttagg	taggttagtag agagaagtta	aatgattttg ttttttttt	9600
atttatttag agtatgtaaa	attaggagta gtgtgggtt	taggtgggtt attagttatg	9660
tatatgtata ttagggatag	ggggtaaaag gtatgtttt	tttaaagatt gtttagagg	9720
ttatttttt gagaagttt	gggttttta agggtttgt	gtttatgtt gtttattttt	9780
taggatgagt ttgtggagt	ggagatattt gattttttt	aagttgagat tgatgagaag	9840
attaaggagt ataatgtta	gattaatagt aatttttttta	tgatgttggt gagttgattt	9900
tttaggaagg ggggtgtggg	aggagtaggt atttagttt	gtgttgata tttagagggt	9960
tataatttag gttattttgg	gtgggtgtaa gtagtaattt	gtgtatattt agtttagttt	10020
taagtagatt gatattttat	ttggaatttttattaaaggt	ttggttttt tatttttttta	10080
gaataaggat ggtttttata	taggttttat taaggttttag	ttgaagttgg tttgttttgt	10140
ttttagtgtt ttagtaaga	agttattttt ttttaggtt	gttgggtgg gtttaggatg	10200
gggtataagt gttaggtgtt	gtatttttt ttattttgtt	aaggatgtt gtaagtattt	10260
gtatgtgtt ttatgtataa	gggtatgtga agtattttag	gttttgggtt gaaagttttt	10320
gggtgtggat gattttgtt	agtttgatt ttttaggtt	gttgagtgta atggtaagg	10380
ttggttttttt attttatttt	gtttatgtt aggtatata	tgtatgtatt tgatgtatgt	10440
gggggtgagt agttggttt	gtttttgatt attattttt	ttttatagtg tattttgtgg	10500
agttgttga tgatgagtag	ttttgtgtt tttgtttttt	ggtaggggtt agtgataagg	10560
ttttgagtt tgtttgaag	aaaaatgatt ttggggaggt	gaatgtgagt atatagttt	10620
tagttttt gttgttatta	gataggattt atgggttgtt	gttatagtaa gggttggagg	10680
aggaatttgtt tggaagata	agttttgtaa aatagttta	ggagtgtata ggtattgtaa	10740
ttaaagtaaa ggttttttaga	ttatttatgt taaagtttag	ggttgtttta agaagttagg	10800
aagaatttgtt ttgggtttt	gatttttttt ggtgtggaaa	atttttggat gatgtaggag	10860
tttatttaat gatatgagga	ggttttttt agattttttta	tttggaaagt tttggttttt	10920
aaggatttag gtttggtggag	tgaaattaga tttagaatat	gtttgatttg ttataggtta	10980
attggggaat atttgatttg	g		11001